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ABSTRACT
ADRs are a major complication of drug therapy and are one of the main causes of 
attrition in drug development. Bioactivation of drugs to CRMs is believed to be a 
crucial step in the development of many direct and immune-mediated ADRs. FS, a 
furan containing diuretic drug, has been shown to produce massive hepatic necrosis 
in mice through bioactivation of the furan ring to a reactive epoxide intermediate. A 
thiophene analogue of FS (TPA) has been synthesized in order to compare the 
heterocyclic moieties in the same biological environment. NVP, used for the 
treatment of HIV-1 infection, can cause skin reactions and hepatotoxicity, which are 
thought to be mediated through CRM formation and subsequent induction of the 
immune system. FS, TPA and NVP can be used to assess current systems used to 
investigate the potential hazard of a drug.
Substitution of the furan ring in FS to a thiophene ring (TPA) improved the 
potency towards the pharmacological target; the Na172C17K+ co-transport system in 
the thick ascending limb of the loop of Henle. It was found that TPA was three times 
more potent than FS, with IC50 values of 17 pM and 50 pM respectively. TPA 
displayed an improved safety profile in vivo in terms of serum ALT activity levels 
compared to FS (237.3 and 4441.4 U/L respectively, 1.21 mmol/kg i.p. for 24 hours). 
Evidence for the bioactivation of TPA, was provided through studies in rat and 
mouse liver microsomes. Neither FS nor TPA elicited hepatotoxicity or depleted 
hepatic GSH levels in the rat in vivo.
The disposition of FS and TPA were found to be similar in the mouse; 
however, the plasma AUC increased supraproportionally (~240-fold to 4300-fold) as 
the dose was increased from 3/5 to 400 mg/kg orally in the mouse and rat suggesting 
that, in both species, clearance for both compounds becomes saturated at high oral 
doses. The toxicokinetic studies reported highlight that the liver exposure in the 
mouse was twice that in the rat (1.12 mmol/kg i.p.), with free liver AUC values at 
243 and 128 pg.h/ml respectively. It was also observed, an i.p. dose of FS induced 
hepatotoxicity in male mice, yet, at the same dose, orally administered FS failed to 
do so. Oral administration of FS in the mouse resulted in significantly reduced 
plasma and liver exposure compared to i.p. administration.
NVP was tested in in vitro and in vivo systems for a toxicological end-point; 
NVP failed to induce cytotoxicity in both male Wistar and female Brown Norway rat 
hepatocytes, however, a NVP-induced skin rash developed over 3 weeks of daily 
NVP treatment in female Brown Norway rats. Urinary metabolites were quantified 
by mass spectrometry on day 7, 14 and 21 of the study; however, no time-dependant 
trend in any NVP metabolite was observed. No evidence of liver injury or elevation 
in serum HMGB-1 was observed. It is shown, in the work presented, that 12-OH 
NVP is a substrate for bioactivation; 12-OH NVP was administered to male Wistar 
rats and only Ml was identified in the bile. Following administration of NVP to male 
Wistar rats, both Ml and M2 were identified in the bile.
The work presented here has shown that the development of an assessment 
framework that encompasses all aspects of drug disposition and metabolism, and 
their relationship with bioactivation and toxicity, would be a valuable tool in drug 
development. The construction of a decision tree that can be populated with 
quantitative data could be used in the assessment of NCEs and highlight properties 
that require optimisation. Outcomes of changes or interventions to a new therapy 
could then be measured quantitatively and mechanisms defined. A caveat to this
ix
framework would stipulate that the model systems employed would have to be 
carefully selected to best represent the clinical situation. This work highlights the 
need for improved preclinical hazard assessment and understanding of animal 
models. Development of more informative and translational biomarkers would allow 
better clinical hazard identification, as well as improving survivability of NCE 
during the drug development process.
x
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Chapter 1: General Introduction
1.1 INTRODUCTION
Adverse drugs reactions (ADRs) are a major cause of drug attrition and are a huge 
burden on healthcare systems. In the US, ADRs rank between the 4th and 6th leading 
cause of death (Lazarou et al.y 1998). The majority of ADRs are predictable, and 
become apparent during preclinical and clinical toxicity assessment (Olson et aL, 
2000), and those that manifest in the human population, are commonly as a result of 
a prescribing error or through drug-drug interactions (Winterstein et aL, 2002). 
Unlike these ‘predictable’ types of ADRs, idiosyncratic ADRs are rarer but are more 
likely to be fatal (Edwards and Aronson, 2000). Idiosyncratic ADRs are often 
detected only when the offending drug has been released into the wider population 
following regulatory approval. Idiosyncratic ADRs are generally immune mediated 
(Uetrecht, 2009) and include hepatotoxicity, severe cutaneous reactions, anaphylaxis 
and blood dyscrasias (Park et al, 2000).
The work of James and Elizabeth Miller provided the first evidence of drug 
metabolism leading to the formation of reactive metabolites that can bind covalently 
to protein and ultimately result in toxicity (Miller, 1970, Miller, 1994). This concept 
is now well established, and there is a wealth of evidence to suggest that drug 
metabolism to a reactive metabolite (bioactivation) is the initiating step in a number 
of direct and immune-mediated toxicities (Park et aL, 2005, Kalgutkar and Soglia, 
2005). A common mechanism for the detoxification of reactive metabolites occurs 
via glutathione (GSH) conjugation (Williams et aL, 2002). The identification of drug 
metabolite-GSH adducts in a preclinical setting is sometimes treated as a hazard 
signal as it is indicative of reactive metabolite formation (Gan et aL, 2009, Reese et 
aL, 2010), conversely it could be argued that identification of a GSH adduct is an 
indication of an effective detoxification system. Idiosyncratic ADRs are not 
reproducible in preclinical species, and so, much focus has been on the development 
of surrogate endpoints of toxicity (biomarkers; either biological or chemical), animal 
models and improved understanding of structure-activity relationships of drugs.
A list of chemical moieties frequently associated with drug bioactivation and 
subsequent toxicity (structural alerts) has been compiled (Kalgutkar et aL, 2005). 
One approach to improving a drugs safety profile would be to avoid incorporating 
these structural alerts altogether; however, these moieties often are key to the
3
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pharmacology of the drug. In addition, the presence of a structural alert does not 
automatically result in a toxic compound; not all drugs that contain a structural alert 
are bioactivated and not all bioactivated drugs are toxic (Kalgutkar and Soglia, 
2005). The structure-activity relationships are, therefore, not straight forward.
Five-membered aromatic heterocyclic rings are widely distributed in nature and they 
are often incorporated into new chemical entities during drug design to increase 
pharmacological selectivity and potency (Dalvie et aL, 2002). Furan and thiophene 
rings are examples of heterocycles with one heteroatom. These chemical moieties 
have been used safely and effectively in some therapeutic agents, but there are 
examples of drugs containing a thiophene ring have been withdrawn from the market 
due to ADRs, and examples of furan containing compounds that can cause toxicity in 
humans and laboratory animals (Kalgutkar and Soglia, 2005). Structure-toxicity 
relationship investigations revealed that these moieties can be sites of bioactivation 
and ultimately result in the toxicity of the compounds. Furosemide (FS), a furan 
containing diuretic drug, has been shown to produce massive hepatic centrilobular 
necrosis in mice by a mechanism independent of its diuretic action (Mitchell et al., 
1974). Toxicity has been shown to be caused through bioactivation of the furan ring 
to a reactive epoxide intermediate (Mitchell et al, 1974, Mitchell et al., 1976, Wirth 
et al, 1976, Williams et al, 2007).
Although furosemide is safe in man, its tendency to cause severe liver necrosis in 
mice along with other hazard signals, including covalent binding to microsomal 
protein and adduct fonnation with trapping reagents, would mean that the drug may 
not have survived the development process today. However, furosemide provides a 
useful tool for the investigation of the mechanisms of drug-induced hepatotoxicity in 
mice. The research conducted in this thesis aims to assess whether replacing the 
toxicophore (furan ring) in furosemide with a thiophene ring would alter the toxicity 
profile while maintaining its pharmacological activity, and to investigate the 
structure-activity relationships of the two moieties in the same chemical 
environment.
Currently, there are few systems to investigate a drugs propensity to be bioactivated, 
and even fewer systems to examine the biological effects of drug bioactivation. 
Urinary mercapturates (breakdown products of GSH-adducts) have been used as
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markers of bioactivation to reactive metabolites in in vitro and in vivo systems 
(Seutter Berlage et al, 1977). More recently, in the light of improved bioanalytical 
techniques, drug mercapturates have been used in the quantitative assessment of 
bioactivation in humans (Staack and Hopfgartner, 2007, Ma et a!., 2008). 
Assessment of the degree of covalent binding to protein is also frequently used in in 
vitro and animal studies, as an indicator of a drugs potential to cause toxicity. Animal 
models of idiosyncratic ADRs are highly desired, however, only very few are 
established (Roth et al., 2003, Shenton et ai, 2003; Shenton et al, 2004) and the 
relevance of these models to the human reaction remains unclear. An animal model 
of an idiosyncratic ADR which displays similar characteristics of the human reaction 
with a measurable, biological or chemical, endpoint would be highly beneficial, as 
extrapolations could easily be made to the clinic. With better animal models, a 
greater understanding of the mechanisms of ADRs would be elucidated and would 
improve drug survival during development and help implement safe and effective 
drug use in the clinic.
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used 
in developing countries for the treatment of HIV-1 infection. NVP is associated with 
clinically restrictive side effects; NVP-induced skin reactions and hepatotoxicity are 
thought to be mediated through reactive metabolite formation and subsequent 
induction of the immune system. Uetrecht and colleagues have characterised 
extensively a dose-dependent model of NVP-induced skin rash in female Brown 
Noiway rats that resembles the idiosyncratic cutaneous reaction seen in humans 
(Shenton et al, 2003, Shenton et al, 2004) and appears to be immune mediated 
(Shenton et al, 2005). Chen et al. (2008) have proposed that the skin rash produced 
in female Brown Noiway rats by NVP and 12-hydroxy NVP (12-OH NVP) may be 
due to NVP quinone methide formed through dissociation of 12-OH NVP sulphonate 
in the skin.
The work presented in this thesis uses furosemide and NVP to investigate the 
relationship between chemical structure, bioactivation and toxicity, and examine 
systems currently used to detect reactive metabolite formation and/or toxicity. More 
specifically, phannacokinetics, covalent binding and thioether adduct detection are 
explored, and the information they can provide regarding the potential toxicity of a 
drug molecule using these two drugs is examined.
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1.2 ADVERSE DRUG REACTIONS
ADRs are defined as a response to a drug that is noxious, unintended or undesired 
occurring at doses normally used for the prevention, diagnosis or treatment of disease 
(Edwards and Aronson, 2000). ADRs can differ in terms of mechanism, severity, 
clinical presentation and the target organ(s) affected. Despite intensive investigation 
in the fields of chemical toxicology and molecular biology, ADRs remain a major 
complication of drug therapy (Lazarou et a!., 1998, Phmohamed et al, 2004). ADRs 
account for 6% of hospital admissions in the UK, and of this fraction there is a 2% 
mortality rate (Piimohamed et al, 2004). ADRs present a major problem to the 
pharmaceutical industry; drug attrition rates are at their highest with the overall 
success rate for approval of a new chemical entity (NCE) at just 11% (Kola and 
Landis, 2004). Of the NCEs that fail to make regulatory approval, 62% of attrition 
occurs at phase II clinical trials (Kola and Landis, 2004). During the period of 1975 
to 2000 over 10% of newly approved drugs in the US were withdrawn or given 
black-box waruings (Lasser et ai, 2002). NCEs failing so late in development mean 
the costs, in terms of financial and time investment, are huge (Kola and Landis, 
2004). In 1991 poor pharmacokinetic and bioavailability profiles of NCEs 
contributed to a total of 40% of attrition. In 2000 this had been reduced to 10%, 
however, lack of efficacy and safety issues became, and remain, the most common 
reasons for drug failure, each contributing to 30% of drug attrition (Kola and Landis, 
2004).
1.2.1 Classification of ADRs
ADRs are described as either on-target or off-target (referred to as idiosyncratic 
throughout) reactions. On-target reactions can be predicted from the known primary 
or secondary pharmacology of the drug and often represent an exaggeration of the 
pharmacological effect of the drug (e.g. hypotension with antihypertensives and 
hemorrhage with anticoagulants); either the parent drug or an active metabolite is 
usually the offending species. They show simple and clear dose-response 
relationships and, therefore, can usually be avoided by dose reduction and are only 
rarely life-threatening (Testa and Kramer, 2009). In contrast, idiosyncratic ADRs are 
those that do not exhibit simple dose-response relationships and cannot be predicted
6
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from knowledge of the basic pharmacology of the drug. Host-dependent factors are 
important in predisposition of these reactions and therefore, they are only observed in 
veiy low numbers of patients (Uetrecht, 2008). The exact mechanisms of 
idiosyncratic ADRs are unclear; however it is believed that many idiosyncratic 
reactions are initiated by reactive metabolites (Uetrecht, 2008, Smith and Obach, 
2006)), which bind covalently to cellular macromolecules and either cause direct cell 
damage or trigger an immune response leading to cell death (Uetrecht, 2006, 
Williams and Park, 2003, Guengerich, 2006).
1.3 PHARMACOKINETICS AND BIOTRANSFORMATION IN ADRS
1.3.1 Absorption, distribution, metabolism and excretion (ADME)
The concentration and length of time (duration) that a drug is in the circulation can 
be a major determinant on whether a therapeutic effect, or indeed a toxic effect, will 
be achieved. Pharmacokinetics (PK) is the study of the time course of a drug in the 
body, where parameters of absorption, distribution, metabolism and excretion 
(ADME) can be described quantitatively. The PK of a drug will depend on its 
physicochemical characteristics, the route of administration (ROA) and the 
individual. PK studies in pre-clinical models and in clinical trials inform dose 
selection, to achieve safe and effective drug therapy. If exposure to a drug is 
increased to a level that exceeds the therapeutic window (a range of doses at which 
an effective balance of efficacy and minimal adverse events is achieved) then the 
subject could experience an ADR. Increased exposure to a drug may be the result of 
poor dose selection, increased absorption, DDIs or impaired excretion of the drug 
from the body.
The dose of a drug and how frequently it is administered will have a major impact on 
the therapeutic and/or toxicological outcome of therapy. An active surveillance of 
outpatient adverse drug events has shown that unintentional overdoses accounted for 
39% of total reported adverse events and 73% of those that required hospitalization 
(Budnitz et al., 2005). Another retrospective study reported that poor dose selection 
contributed to 68% of preventable adverse drug events (Winterstein et al, 2002). The 
latter study also highlighted that these adverse events are often on-target ADRs;
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bleeding with warfarin or heparin overdose accounted for 32.2% of adverse events 
and hypoglycemic events with insulin overdose accounted for 14.2% of adverse 
events (Winterstein et al., 2002). Dose is also a critical factor in idiosyncratic ADRs; 
among US prescription medicines, a statistically significant relationship was 
observed between daily dose of oral medicines and reports of liver failure, liver 
transplantation and death caused by DILI (Lammert et a!., 2008). Examination of 
serious DILI cases reported to the Swedish Adverse Drug Reactions Advisory 
Committee (1970-2004) found that of 598 eligible Swedish DILI cases, 77% caused 
by drugs administered at > 50 mg/day (Lammert et a!,, 2008). However, genetics, 
disease state and environmental factors all play a role in idiosyncratic ADRs 
(Uetrecht, 2007) and are therefore much more complex and less well understood. In 
order for a drug compound to be a successful therapeutic agent, it has to reach the 
site of action (e.g. an enzyme or receptor) at an effective concentration; equally a 
toxic effect will only be achieved if the drug or di*ug metabolites reaches a certain 
concentration at the site of either a cellular macromolecule (can either be critical or 
non-critical).
Drugs that are administered orally have a number of barriers to contend with in order 
to enter the circulation, and how efficient they are at crossing these barriers, is 
related to the physicochemical properties of the drag molecule. Drags need to be 
soluble in the gut prior to absorption; they also need to be in an un-ionized state in 
order to diffuse through cellular biological membranes of the gastro-intestinal tract. 
Some drags undergo metabolism at the gut wall; those drags that are successfully 
absorbed by the gut may be subject to first-pass metabolism in the liver before 
entering the circulation. Therefore, after oral administration, the plasma levels of a 
drag may be a fraction of the initial dose. This is illustrated when different ROA 
result in differences in incidence and severity of ADRs with the same drag. A study 
set up to identify ADRs in relation to prescribing errors identified that incorrect ROA 
instructions accounted for 37.6% of total serious or severe errors (Lesar, 2006). 
Amodiaquine is an anti-malarial drag that has been associated with immune- 
mediated ADRs in the rat. A positive immune response was observed regardless of 
the ROA, but the magnitude of the response was in the order intraperitoneal 
administration (i.p-) > intramuscular administration (i.m.) > oral administration (p.o.) 
(Clarke et al, 1990). The anti-malarial artemisinin compounds display contradicting
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toxicity profiles between humans and laboratory animals. High doses of artemisinin 
compounds have been shown to cause specific neurotoxic effects on the brain stem in 
laboratory animals with prominent lesions primarily restricted to the pons and 
medulla yet have a good safety record in humans (Gordi and Lepist, 2004, Li et al, 
1998). A review highlighted that the differences in ROA are likely to account for the 
discrepancy; treatment with artemisin compounds in man is via an z.v. route, where 
the compounds have a short half life and are rapidly cleared from the system; in rats, 
the ROA is often i.m. and plasma concentration profiles revealed a prolonged 
apparent elimination half life due to pooling at the site of administration (Gordi and 
Lepist, 2004).
Drugs and their metabolites can be eliminated through a number of mechanisms but 
the primary routes of elimination are urinary clearance and hepatic clearance, which 
includes biliary excretion and metabolism. The degree and rate of drug clearance 
from the body will directly influence drug plasma concentration; rapid elimination 
will reduce the risk of toxicity but may also reduce the effectiveness of therapy. Most 
drugs have the physicochemical properties that allow for absorption through 
biological membranes into the circulation and to the site of action and are also, 
therefore, substrates for urinary elimination through glomular filtration and passive 
diffusion in the kidney. Drug-protein binding and urinary pH can affect these types 
of clearance mechanisms. Some drug molecules are eliminated via active transport in 
the kidney and can be subject to competitive inhibition.
Biliary excretion is one of the primary routes of drug elimination; polar drugs and 
metabolites, such as glucuronides and glutathione conjugates, can be excreted via the 
bile in an active process by efflux transport proteins (Lai, 2009). The size of 
compounds that can be excreted in this way, varies with species; humans have a 
higher molecular weight cut off (~ 500 Da) at the hepato-biliary plasma membrane 
than rodents or dog (300 - 400 Da). Inhibition of biliary excretion can lead to drug 
accumulation in the liver; work conducted by Spitznagle, et al (1977) indicated that 
satumtion of biliary excretion of furosemide, following a large dose of ftirosemide or 
pre-treatment with sulfobromophthalein, is closely associated with the appearance of 
liver necrosis in the mouse and of furosemide metabolites bound covalently to liver 
proteins. The anti-depressant nefazodone was withdrawn from the US market in
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2004, following withdrawal in Canada and Europe, due to incidences of 
hepatotoxicity. Nefazodone is predominantly excreted in the bile and there have been 
investigations into the inhibition of the Bile Salt Export Pump (BSEP), as a cause of 
nefazodone hepatotoxicity (Kostmbsky et erf., 2006). In sandwich cultured human 
hepatocytes, nefazodone caused a concentration dependent inhibition of taurocholic 
acid in canaliculi with an IC5o=14 pM (Kostmbsky et al., 2006).
1.3.2 Importance of drug biotransformation in ADRs
Drug metabolism generally renders drug molecules less reactive and increases their 
hydrophilicity, assisting the drug, and its metabolites, elimination from the body. 
Drug metabolism can also uncover more pharmacologically reactive groups (pro- 
drug). In some cases the enzymes that catalyze these reactions can render the drug 
more chemically reactive in a process known as bioactivation. These reactive 
metabolites are more often than not bioinactivated by mechanisms such as 
conjugation with glutathione (GSH); however if detoxication mechanisms are 
impaired (e.g. cellular GSH is depleted) these reactive metabolites are free to bind 
covalently to cellular macromolecules and elicit toxicity through a number of 
mechanisms (Figure 1.1).
Drugs can be metabolised in a number of organs in the body, such as the lung, liver, 
blood and skin. In each organ, the subset of enzymes differs and therefore the drug 
will be differentially metabolised throughout the body. The liver is the main organ of 
drug metabolism as the majority of enzymes are found here. Also, all orally 
administered drugs pass through the liver via the portal vein before reaching the 
systemic circulation and, as a result, the liver is a frequent target of drug-induced 
toxicity. In fact, 52% of all cases of acute liver failure in the US are attributed to 
ding-induced liver injury (DILI; Pelkonen and Raunio, 1997). DILI is the most 
frequent reason for the withdrawal of an approved drug from the market (Temple and 
Himmel, 2002).
Drug metabolism and bioactivation are catalysed by a range of enzymes that occur 
naturally in the body and have endogenous substrates. Examples of the type of 
reactions involved in ding metabolism include oxidation, reduction, hydrolysis,
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hydration, conjugation and condensation. Metabolism is divided into three phases. 
Phase I involves the addition of functional groups; if the resulting metabolites are 
sufficiently polar they can be readily excreted. If not, the metabolite can undergo a 
second reaction with an endogenous substrate to form a more polar conjugate. Phase 
II metabolism is usually thought of as a detoxication reaction and often involves 
conjugation reactions of the phase I metabolites rendering them less reactive and 
more easily eliminated. However, phase II metabolism can occur without phase I and 
can sometimes generate reactive species. Phase III metabolism can be thought of as 
the final step of elimination from the body.
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Figure 1.1: Schematic of drug bioactivation and possible targets and 
consequences. Toxicity may occur through accumulation of parent drug or, via 
metabolic activation, through formation of a reactive metabolite, which, if not 
detoxified, can effect covalent modification of biological macromolecules. The 
identity of the target macromolecule and the functional consequence of its 
modification will dictate the resulting toxicological response (Park el ai, 2005).
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1.3.2.1 Phase I drug metabolism
The cytochrome P450 mixed function oxidase system is the primary route for phase I 
reactions and is found, primarily, in the microsomal fraction of cells, i.e. the 
endoplasmic reticulum. They are responsible for 95% of phase 1 metabolism. This is 
a large superfamily of enzymes that are highly specific for endogenous substrates but 
are less specific for exogenous drugs and xenobiotics. There are around 40 
cytochrome P450 (CYPs) isomers in humans; those that are responsible for 
xenobiotic metabolism include CYP1, CYP2 and CYP3. CYPs will only accept 
drugs as substrates if they resemble the enzymes natural substrate; however, there is 
an overlap in substrate specificity between different isomers. All reactions mediated 
by CYPs require molecular oxygen, NADPH, NADPH-cytochrome P450 reductase 
and lipid. Reactions involve the initial insertion of a single oxygen atom which could 
then be followed by rearrangement or decomposition to the final metabolite. Other 
enzymes responsible for phase I drug metabolism include alcohol dehydrogenase, 
aldehyde dehydrogenase, xanthine oxidase, amine oxidases, aromatases and 
alkylhydrazine oxidase (Gibson and Skett, 2001). Table 1.1 summarizes the different 
reactions carried out by CYPs, their targets and their products
Reaction Transformation Targets
Aromatic hydroxylation Phenyl to phenol Carbon atoms of aromatic rings
Aliphatic hydroxylation Methyl to carbinol Linear carbon chains
Epoxidation Cyclic groups to epoxide Polycyclic compounds
Dealkylation (N, 0, and S) Removal of alkyl groups 
(intermediate hydroxyl)
Secondary and tertiary amines, 
alkoxy groups and alky 
substituted thiols.
Oxidative Deamination
Removal of amine groups, 
releasing ammonium ions and 
leaving a corresponding ketone.
Secondary amines in a 
CH3(CH3)-NH2 structure.
N-oxidation
Formation of N-oxides 
(sometimes forms 
hydroxylamines)
Amines, amides, imines, 
hydrazines and heterocyclic 
compounds.
S-oxidation Formation of S-oxides Thiol groups
Dehalogenation Dechlorination or debromination Halogen atoms
Alcohol oxidation Alcohol to aldehyde Alcohol groups
Table 1.1: Summary of phase I reactions listing the functional groups that are 
targets and the products of each reaction type.
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1.3.2.2 Phase II drug metabolism
Phase II reactions are sometimes referred to as the true detoxification pathway. A 
number of different enzymes catalyse these reactions and often require high energy 
co-factors (Table 1.2; Gibson and Skett, 2001). Glucuronide formation, GSH and 
sulphate conjugation are major routes of phase II conjugation reactions; however, 
GSH conjugation is arguable the most directly protective phase II reaction in terms 
of detoxification of reactive metabolites.
Reaction Enzyme Functional Group
Glucuronidation UDP-Glucuronoslytransferase
-OH
-COOH
-nh2
-SH
Glycosidation UDP-Glycosyltransferase
-OH
-COOH
-SH
Sulfation Sulfotransferase
-nh2
-so2nh2
-OH
Methylation Methyltransferase (SAM) -OH-nh2
Acetylation Acetyltransferase
-nh2
-so2nh2
-OH
Amino acid conjugation -COOH
Glutathione conjugation Glutathione-S-transferase Epoxide
Organic halide
Fatty acid conjugation -OH
Condensation Various
Table 1.2: Summary of phase II reactions listing the functional groups that are 
targets and the enzymes required for each reaction type.
1.3.2.3 Importance of GSH in cell protection
GSH is a major hepatocellular antioxidant due to its free thiol group and its relatively 
high abundance (approximately 10 mM in hepatocytes). It is a tripeptide, comprising 
of the amino acids cysteine, glutamate, and glycine. GSH is crucial for cell function 
and survival, and maintains the redox potential of the cell. GSH exists in either a 
reduced (GSH) or oxidised (GSSG) form and the change in the ratio between the two 
forms is directly reflective of intracellular redox alterations (Meister and Anderson, 
1983). GSH can undergo conjugation reactions with reactive metabolites, either
13
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through enzymatic catalysis by GSTs or spontaneously and thereby prevent the 
covalent binding of these products to cellular macromolecules and avoid cell injury. 
Reactive metabolites also introduce the threat of cellular oxidative stress; the 
formation of reactive metabolites through bioactivation of drugs can push the redox 
balance towards a more oxidative environment in the cell by stimulating 
overproduction of reactive oxygen species (ROS), introduction of electrophilic 
species and disruption of thiol status. ROS can cause cell damage through a number 
of mechanisms including lipid peroxidation, protein oxidation, DNA oxidation and 
mitochondrial damage (Boelsterli, 2003). The antioxidant role of GSH is to quench 
ROS and maintain the redox potential of the cell. GSH is also a hydrogen donor for 
glutathione peroxidise, the enzyme responsible for the conversion of H2O2 to water 
in parallel with catalase and is also involved in the repair of lipid peroxidation.
GSH synthesis is highly inducible upon conditions of oxidative stress and GSH 
depletion. Transcription factors controlling the expression of enzymes involved in 
GSH synthesis can be directly activated by electrophilic species that conjugate to 
GSH (Copple et al., 2008). Synthesis of GSH occurs in the cytosol through a two- 
step ATP consuming reaction (Figure 1.2). Initially, y-glutamylcysteine is 
synthesised through the condensation of cysteine and glutamate, a reaction catalysed 
by y-glutamylcysteinyl ligase. GSH synthetase then further catalyses the formation of 
GSH from y-glutamylcysteine and glycine (Meister, 1983, Yuan and Kaplowitz, 
2009). It is then utilised either as an enzyme co-substrate, or as a scavenger molecule 
in the presence of an oxidised substrate, resulting in the formation of GSSG. Under 
normal physiological conditions GSSG can then be recycled back to GSH by the 
enzyme GSH reductase (Figure 1.2; Yuan and Kaplowitz, 2009).
14
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Figure 1.2: Synthesis of GSH. (Adapted from DeLeve et ai, 1991) GSH is 
synthesised by a two-step ATP-dependent pathway, y-glutamylcysteine is formed 
from L-glutamate and cysteine, which is catalysed by y-GCL (1). Glycine is then 
added at the C-terminal of y-glutamylcysteine through the catalysis of GSH 
synthetase (2). Redox cycling between GSH and GSSG is mediated by GSH 
reductase and GSH peroxidise (DeLeve and Kaplowitz, 1991).
1.3.3 Relationship between structural alerts, bioactivation and ADRs
A number of chemical moieties frequently associated with bioactivation and 
subsequent toxicity have been identified (Kalgutkar et ai, 2005). However, the 
relationship between the presence of these so called ‘structural alerts’, their potential 
to be bioactivated and the downstream effects leading to ADRs, are poorly 
understood. In vitro and in vivo research using, clinically relevant, withdrawn or 
investigational compounds have aimed to provide an understanding of these 
connections.
Five-membered aromatic heterocyclic rings are widely distributed in nature and they 
are often incorporated into new chemical entities during drug design to increase 
pharmacological selectivity and potency (Dalvie et al., 2002). They are, therefore, an 
attractive replacement to structurally similar moieties during lead compound 
optimisation. Furan and thiophene rings are examples of heterocycles with one 
heteroatom. There are many examples where these moieties are used in effective 
therapeutic agents. However, therapeutic agents containing a thiophene ring have
15
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been withdrawn from the market due to ADRs, and examples of furan containing 
compounds that can cause toxicity in humans and laboratory animals (Kalgutkar and 
Soglia, 2005). Structure-toxicity relationship investigations revealed that these 
moieties can be sites of bioactivation and ultimately result in the toxicity of the 
compounds.
1.3.3.1 Thiophene containing drugs
Like many drugs, thiophene containing compounds are metabolised by the 
cytochrome P450 mixed function oxidase system (Kalgutkar et al., 2005). The 
metabolic and bioactivation pathways of many of these drugs have been investigated 
and a picture is emerging of possible routes of metabolism a drug containing a 
thiophene moiety can take. Many examples of thiophene-containing compounds that 
have been associated with ADRs (Figure 1.3 A), have therapeutic dose ranges that 
are greater than or equal to 50 mg/day; of the examples of ‘safe’ thiophene- 
containing compounds (Figure 1.3 B), three are dosed at less than 50 mg/day, 
cefoxitin is dosed at many grams per day, however this antibiotic is not taken 
chronically.
Thiophenes can undergo P450 mediated hydroxylation to 2- and 5- 
hydroxythiophene, and oxidation to a reactive thiophene 5-oxide (Mansuy et al., 
1991, Dansette et al, 1992), proved by the identification of thiophene 5-oxide dimers 
in in vitro and in vivo studies of thiophene (Treiber et al, 1997). Also, a mercapturic 
acid conjugate of dihydrothiophene 5-oxide, resulting from a 1, 4-Michael-type 
addition of thiol on thiophene 5-oxide, was identified in the mine of rats treated with 
radiolabelled thiophene (Dansette et al, 1992).
16
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Figure 1.3: Structures of thiophene-based drugs that are associated with ADRs 
(A) and those that are not (B). Typical dose and ROA given where possible.
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Tienilic acid (TA) is a diuretic drug, which was released in the US in 1979 as an 
antihypertensive. In 1980, TA was withdrawn from the US market due to severe 
hepatotoxic secondary effects and renal toxicity (Zimmerman et ai, 1984). 1 in 
10,000 patients taking TA suffered from auto-immune hepatitis (Dansette et al, 
1991), an immune-mediated idiosyncratic ADR that was not predicted by animal 
model studies. Studies with TA have shown that it produces a TA 5-oxide in vivo 
(Treiber et al., 1997). This metabolite forms an adduct with CYP2C (the enzyme 
responsible for its formation) via an alkylation reaction (Lecoeur et al, 1994). The 
major product of TA metabolism is 5-hydroxy TA, formed from the hydroxylation of 
the C-5 position on the thiophene ring; however oxidised intermediates of this 
pathway have been shown to covalently bind to microsomal proteins (Dansette et al., 
1991b). 5-hydroxy-TA is thought to be formed from TA 5-oxide in the presence of 
NADPH and molecular oxygen (Belghazi et al, 2001). Studies using electrospray 
ionization mass spectrometric analysis have deduced that the reactive intermediate 
could be an epoxide or a TA 5-oxide (Koenigs et al, 1999), although the formation 
of a TA 5-oxide is more widely supported (Mansuy et al, 1991a, Dansette et al, 
1992, Lopez-Garcia et al, 1994).
Suprofen is a thiophene containing NS AID, which, within a short time after its 
release, displayed severe adverse effects associated with renal toxicity. Within 40 
minutes to 8 hours of administration, patients suffered from flank pain and renal 
failure normally associated with chronic dosing of NSAIDs (Hart et al, 1987). 
Although some studies suggested that a glucuronic acid conjugate mediated the 
nephrotoxicity observed with suprofen (Mori et al, 1985, Smith and Liu, 1993), the 
fact that both TA and suprofen mediate the same renal toxicity symptoms and the 
confirmation of the CYP 2C isoform family is present in the kidney, suggests they 
might share the same bioactivation pathway (Kalgutkar et al, 2005). Like TA, 
suprofen has been shown to be a CYP 2C9 inhibitor (O'Donnell et al, 2003) and one 
of its major metabolites is 5-hydroxy suprofen (Mori et al, 1984). Similar to reports 
by Koenigs et al, (1999), O’Donnell (2003) observed evidence for the formation of a 
reactive epoxide intermediate, by the addition of semicarbazide, affording a y- 
thioketo a,|3-unsturated aldehyde open ring structure. It could be deduced that either 
the epoxide or the y-thioketo a,p-unsturated aldehyde is responsible for the covalent 
binding and subsequent inactivation of CYP 2C9. Incubations of suprofen with
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NADPH and semicarbazide, trapped a pyridazine derivative (O'Donnell et a}., 2003). 
This provided more direct evidence of an epoxide intennediate, as a pathway could 
then be suggested involving the initial epoxidation of the thiophene ring followed by 
spontaneous ring opening affording a reactive y-thioketo-a,p-unsaturated aldehyde 
(O'Donnell et al., 2003). Subsequent condensation of the aldehyde with 
semicarbazide would lead to the pyridazine adduct.
Although tienilic acid and suprofen have been shown to undergo similar 
bioactivation, the target organs of the primary toxicities they induce differ. It is clear 
that bioactivation plays a crucial role in the development of toxicity of these drugs. 
However, other major factors, that determine individual susceptibility of toxicity and 
the target organ, are unknown.
There are a number of other thiophene-containing drugs that are believed to cause 
ADRs through bioactivation to a reactive metabolite. Ticlopidine, an antiplatelet 
drug, is a thienopyridine derivative containing a fused thiophene ring (Saltiel and 
Ward, 1987). Its clinical use is associated with a number of serious ADRs including 
neutropenia, aplastic anaemia, agranulocytosis and cholestatic jaundice (Yim et al, 
1997, Ochoa et aL, 1998, Symeonidis et al, 2002), However, a staicturally similar 
drug, clopidogrel (antiplatelet and antithrombotic drug) has only minimal adverse 
events associated with its use. Ticlopidine has been shown to undergo bioactivation 
to a reactive S-oxide in the liver, which acts as a mechanism based inhibitor of CYP 
enzymes (Liu and Uetrecht, 2000, Evans and Baillie, 2005). Additionally, a GSH 
adduct of the thiophene moiety has been identified in activated neutrophils in vitro, 
via formation of a reactive S-chloride intermediate (Figure 1.4; Evans and Baillie, 
2005). There is no evidence to suggest that clopidogrel undergoes bioactivation to 
reactive metabolites.
The clinical use of the 5-lipoxygenase inhibitor, zileuton, is limited due to liver 
toxicity which is believed to be caused by the formation of a reactive Yoxide 
intermediate following degradation to 2 acetylbenzothiophene (Joshi et al, 2004). 
Another example is methapyrilene; this Hi receptor anti-histamine was used as a 
sedative before it was withdrawn following evidence that it caused liver cancer in 
rats. Methapyrilene has been shown to cause liver toxicity in rats associated with
19
Chapter I: General Introduction
bioactivation of the thiophene ring to either a reactive S-oxide or epoxide (Figure 
1.5; Graham et al., 2008). Duloxetine is a serotonin-norepinephrine re-uptake 
inhibitor associated with liver toxicity. Recently duloxetine adducts have been 
identified in vitro, indicative of bioactivation (Gan et al., 2009, Wu e/ al., 2010).
Ticlopidine
oa
Ticlopidine-S-chloride
~T
oa
-HCL
V
R=\ / Cl
Chloroticlopidine
Dehydrogenated
ticlopidine
TiclopidineGSH
adduct
Figure 1.4: Peroxidase-catalysed metabolism of ticlopidine in neutropils. Taken 
from Dalvie et al. (2002).
Despite the extensive list of thiophene containing drugs that are associated with 
ADRs, there are a number of examples that are not. OS 1-930 is an investigational 
anticancer agent that undergoes bioactivation to an 5-oxide; however, studies have 
shown that it is relatively safe in pre-clinical models and in human volunteers 
(Medower et a/., 2008). Tiotropium, a bronchodilator used in the treatment of 
chronic obstructive pulmonary disease, contains two thiophene rings which 
contribute to the compounds remarkable affinity to muscarinic receptors (Disse et al., 
1993, Disse et al, 1999). The metabolism of tiotropium was described by in vitro
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studies; metabolites include a variety of glutathione conjugates after oxidation of the 
thiophene ring system (Price et ai, 2009). Tiotropium is used safely in the clinic and 
does not inhibit cytochrome P450 enzymes (Price et al., 2009). Similarly, indiplon, a 
hypnotic sedative that has yet to be released onto the market, and rivaroxaban, a oral 
anticoagulant, both contain a thiophene ring yet there is no evidence of bioactivation 
at the thiophene ring and clinical trials have shown the drugs to be well tolerated in 
humans (Roth et ai, 2007, Kubitza et ai, 2005a, Kubitza et ai, 2005b). The 
antibiotic cefoxitin is also used safely in humans (Lapointe et ai, 1994).
Figure 1.5: Alternative hypothetical pathways of bioactivation of MP to the
intermediate trapped as a glutathione conjugate: to MP S-oxide, an epoxide that 
reacts with GSH without opening of the thiophene ring, and an epoxide that 
undergoes concerted opening of the epoxide and thiophene rings to produce a g- 
thioketo-a, p-unsaturated aldehyde.
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1.3.3.2 Furan containing drugs
Furan is an important heterocycle found in drugs and also occurs in nature. Many 
naturally occurring furans have been found to be hepatotoxic and hepatocarcinogenic 
in preclinical species and humans (Dalvie et al., 2002). Furan is a liver toxicant and 
genotoxic in rats and mice, and studies with radiolabelled furan suggest the primary 
metabolite involves ring scission followed by oxidation. There are examples of furan 
containing compounds that have been investigated following reports of human 
toxicity and there are examples of furan containing drugs used safely in the clinic 
(Figure 1.6).
A
Ipomeanol Menthofuran TeucrinA
Figure 1.6: Structures of furan-based drugs that are associated with ADRs (A) 
and those that are used in humans relatively safely (B). * TA-1801 was used as a 
probe to detennine the metabolic fate of a fiiran ring and isn't associated with ADRs.
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Ipomeanol, a naturally occurring product of mould-damaged sweet potatoes (Boyd 
and Wilson, 1972), causes the development of potentially lethal pulmonary lesions in 
the rat (Dutcher and Boyd, 1979). Oxidative ring opening of the furan ring and 
irreversible protein binding of the corresponding substituted y-ketoenal is thought to 
be the pathway resulting in toxicity (Figure 1.7; Baer et a/., 2005). Menthofuran, the 
product of P450 catalysed oxidation of pulegone, is the proximate toxic responsible 
for hepatotoxicity (Moorthy et ai, 1989); the furan ring of menthofuran undergoes 
further oxidation to a y-ketoenal, which is well established as the ultimate toxin of 
pulegone (McClanahan et ai, 1989). The postulated general mechanism of furan 
mediated toxicity via oxidative ring opening of the furan ring to a a, (3-unsaturated 
dicarbonyl or a y-ketoacid proceeds via initial epoxidation to furan-2, 3-epoxide (Le 
Fur and Labaune, 1985). The 2, 3-epoxide directly rearranges to hydroxyfuran which 
predominately exists as the lactone tautomer; hydrolysis of the lactone affords the y- 
ketocarboxylic acid (Le Fur and Labaune, 1985). Alternately, ring opening of the 
furanoyl epoxide can also lead to the formation of y-ketoenal (Khojasteh-Bakht et 
ai, 1999).
Ipomeanol
Ipomeanol epoxide
Ipomean ol enedial
Figure 1.7: Proposed route of bioactivation of ipomeanol. Adapted from Baer et 
ai (2005)
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Kobayashi et al. (1987) suggested an alternative mechanism for furan ring opening 
using deuterated TA-1801, a hypolipidemic, as a probe. The C-0 bond in the furan 
ring is directly cleaved following transfer of oxygen from P450 to the substrate. TA- 
1801 is converted to the corresponding deuterated y-keto alcohol and nondeuterated 
y-keto acid metabolites (Kobayashi et al., 1987). These results have been explained 
by a pathway in which TA-1801 undergoes an oxidative ring opening to deuterated 
a, p-unsaturated aldehyde followed by an enzyme assisted reduction to the y-keto 
alcohol. Oxidation of this alcohol affords the nondeuterated y-ketocarboxylic acid. 
This mechanism argues against the formation of an epoxide intennediate. Evidence 
for the formation of the epoxide intermediate has been demonstrated by metabolism 
studies of R-(+)-pulegone and R-(+)-menthofuran by human liver P450s using 1802, 
H2180 and C-2 deuterium labelled menthofuran (Khojasteh-Bakht etal., 1999).
Ranitidine is metabolised to an A-oxide and an S-oxide by flavin containing 
monooxygenase (FMO), neither of which involve the furan ring (Chung et ah, 2000). 
Ranitidine is a histamine Hh-receptor antagonist that inhibits stomach acid 
production. It is commonly used in treatment of peptic ulcer disease and 
gastroesophageal reflux disease and it is well tolerated in humans (Brogden et ah, 
1982). The cephalosporin antibiotic cefuroxime is another example of a furan 
containing drug that is well tolerated in humans (Bucko et al, 2002).
Thiophene and furan ring substitutions for improved potency and toxicity 
profiles
Despite the safety concerns thiophenes and furans present, compounds that contain 
these moieties have been found to show nematocidal (Bakker et al, 1979), 
insecticidal (Iyengar et al, 1987), antibacterial (Matsuura et al, 1996), antifungal 
(Chan et al, 1975), antiviral (Hudson et al, 1989) and have antioxidant activity 
(Malmstrom et al, 2001). In fact, therapeutic agents containing thiophene and furan 
rings have motivated researchers in pharmaceutical chemistry so that it now appears 
that at least one of these heterocyclic compounds has been prepared for every 
important therapeutic compound containing a benzene nucleus (Meotti et al, 2003). 
A number of studies have been conducted where a potential structural liability in a 
lead compound, has been substituted for a structurally similar alternative and
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subsequently assessed for potency and safety. Often substitution for a thiophene or 
furan ring affords a compound that has comparable or improved potency for the 
target molecule and a comparable safety profile to the original compound (Hagen et 
al, 2001, Brendle et al., 2002).
1.4 TARGET ORGANS AND MECHANISMS OF ADRS
ADRs can mimic natural disease and nearly every organ in the body could 
potentially be a target (Park et al, 2000). Furthermore, one or more organs could be 
adversely affected by a single drug. Although the parent drug can mediate ADRs, 
there is a large amount of evidence to suggest that drug reactive metabolites are the 
offending species in many ADRs. Parent drug or reactive metabolites can mediate 
toxicity through a number of mechanisms and these can be described as either direct 
or immune-mediated.
1.4.1 Mechanisms of ADRS: direct toxicity
Direct toxicity is damage to cellular macromolecules that can result in cell death or 
loss or change in cell phenotype (Liebler and Guengerich, 2005). As previously 
mentioned, parent drug can be responsible for direct toxicity; however, more often 
than not, it is a reactive metabolite that is the culprit. Drug reactive metabolites are 
often electron deficient and therefore, electrophilic in nature, for example, epoxides 
and quinones. Reactive metabolites can bind covalently to cellular proteins, lipids 
and DNA, causing biochemical changes, changes or loss of protein function, GSH 
depletion, oxidative stress, redox changes and lipid peroxidation. These events may 
then directly affect normal functioning of cellular organelles which can ultimately 
lead to cell death (Liu and Kaplowitz, 2007).
The work of James and Elizabeth Miller provided the first evidence of metabolism to 
reactive metabolites and subsequent covalent binding during their research into the 
carcinogenicity of aminoazo dyes (Miller, 1970, Miller, 1994). In 1973, a series of 
papers from Brodie, Gillete and co-workers elucidated the relationship between 
acetaminophen (APAP) metabolism, covalent binding and hepatotoxicity (Mitchell et
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al., 1973a). At therapeutic doses, around 55% and 30% of renally excreted 
metabolites are as the glucuronide and sulphate conjugates, respectively (Howie et 
al., 1977). A small proportion of the therapeutic dose (5%) is bioactivated to the 
electrophilic intermediate Af-acetyl-p-benzoquinonimine (NAPQI; Dahlin et al., 
1984). NAPQI is readily detoxified by GSH conjugation and is excreted in the urine 
as a cysteine or mercapturate product (Mitchell et al., 1973b). In cases of overdose, 
low capacity sulphation pathways become saturated and a greater fraction of the dose 
undergoes glucuronidation and oxidation. Under these conditions, NAPQI 
accumulates and cellular stores of GSH become depleted due to the shift in NAPQI 
formation and GSH synthesis (Figure 1.8). NAPQI irreversible binding to critical 
proteins ensues (Mitchell et al, 1973a, Mitchell et al, 1973b, Jollow et al, 1973, 
Potter et al, 1973, Reid et al, 2005) resulting in necrotic cell death of hepatocytes 
through mitochondrial destruction (Donnelly et al, 1994). Necrotic cells release 
damage-associated molecular pattern (DAMP) molecules which are thought to alert 
the immune system to dying cells (Figure 1.8; Scaffidi et al, 2002, Kono and Rock, 
2008).
o
II
— C—CH -j
Innate immune response
+++
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injury
Figure 1.8: Bioactivation and toxicity of APAP. Schematic of the multi-step and 
multi-cellular processes involved in APAP-induced hepatotoxicity. Adapted from 
Kaplowitz, et al (2005).
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1.4.2 Mechanisms of ADRS: immune-mediated toxicity
Some immune-mediated toxicities can be classed as on-target ADRs if they, as 
described earlier, are an exaggeration of the primary pharmacology of the offending 
drug. For instance, the immunosuppressant corticosteroids can increase risk of 
infection (Uetrecht, 2009). The liver is the most frequently affected organ by 
idiosyncratic ADRs, but skin, kidney and blood are also common targets. 
Additionally, idiosyncratic ADRs can present as generalised hypersensitivity or 
anaphylaxis (Park el aL, 2011). Although there is a lack of solid evidence, the 
majority of idiosyncratic ADRs are thought to be immune-mediated, based on 
clinical characteristics. Some current hypotheses regarding the mechanisms of 
idiosyncratic inunune-mediated ADRs suggest that bioactivation of the parent drug 
to a reactive metabolite is the first step in the process, followed by binding to a native 
protein and causing an adaptive immune reaction towards the modified protein (Park 
and Kitteringham, 1990b). Although bioactivation is highly implicated in 
idiosyncratic ADRs, the situation is complicated by many other host factors, 
including genetics, disease state, sex and age, which will influence whether an ADR 
is experienced or not. Tienilic acid (TA), an antihypertensive, was withdrawn from 
the US market due to severe hepatotoxic secondary effects and renal toxicity 
(Zimmerman et aL, 1984). TA covalently binds to the enzyme that metabolises it, 
creating a neo-antigen that is recognized as foreign by the host. In patients suffering 
from TA-induced hepatitis, auto-antibodies called anti-liver kidney microsomal 
antibodies where detected in their serum (Homberg et aL, 1984).
There are currently three major hypotheses on the mechanism of immune-mediated 
toxicities that are considered when investigating these reactions (Figure 1.9). The 
hapten hypothesis proposes that when a reactive metabolite covalently binds to a 
protein, the protein is altered and so is seen as foreign by the host immune system 
and leads to an immune response (Park and Kitteringham, 1990b). The danger 
hypothesis theorizes that foreign proteins alone do not generate an immune response 
and that a second ‘danger signal’, possibly from stressed or damaged cells, is 
required to elicit an immune response (Matzinger, 2002). The pharmacological 
interaction (PI) hypothesis, unlike the previous two, suggests that bioactivation to a 
reactive metabolite is not essential to elicit an immune response; instead the drug 
molecule can bind directly to a receptor on an antigen presenting cell (Pichler, 2002).
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Chapter 1: General Introduction
1,4.3 Mechanisms of drug-induced liver injury
The liver is a frequent target of drug-induced toxicity; it is the main organ of drug 
metabolism and all orally administered drugs pass through the liver via the portal 
vein before reaching the systemic circulation. DILI has been linked to nearly 1000 
drugs (Zimmerman, 1999). Approximately, 1 in 100 patients develop DILI during 
hospitalization when admitted to a department of medicine (Meier et al, 2005). A 
prospective study, conducted over three years, in a region of France, determined that 
the incidence of DILI was 13.9 per 100,000 inhabitants (Sgro et aL, 2002). Most 
cases of DILI are idiosyncratic reactions (Kaplowitz, 2005, Bjornsson, 2010). In 
terms of individual drugs, DILI is, overall, fairly rare; it occurs in between 1 in 
10,000 to 1 in 100,000 (or less) of those exposed to a single drug (Bjornsson, 2010, 
Larrey, 2002). Clinical trials typically have around 10,000 patients and therefore 
incidences of idiosyncratic DILI are not likely to emerge until the post-marketing 
phase (Larrey, 2002).
DILI can simulate almost all forms of acute and chronic liver injuries; it can present 
as acute or chronic hepatocellular hepatitis, fibrosis or cirrhosis, cholestasis, 
steatosis, sinusoidal and hepatic artery or vein damage, but DILI usually resembles 
acute hepatitis, cholestasis or mixed hepatitis/cholestasis (Bjornsson, 2010, 
Kaplowitz, 2004, Holt and Ju, 2006). DILI is difficult to diagnose, clinicians rely on 
information such as, duration of latency to symptomatic presentation and the pattern 
of liver test abnormality to help make a diagnosis. Latency of idiosyncratic ADRs 
can give an indication as to the mechanism of the reaction; latency duration of 
around 1 to 8 weeks is common of most immune-mediated ADRs and those with a 
latency duration of up to 1 year are thought to be non-immune-mediated (Abboud 
and Kaplowitz, 2007, Pirmohamed et al, 2007). Immune-mediated idiosyncratic 
DILI often presents with fever, rash and eosinophilia (Abboud and Kaplowitz, 2007). 
Liver tests showing increase levels of serum alanine transaminase (ALT) and 
aspartate transaminase (AST) are indicative of hepatitis, whereas increases in serum 
alkaline phosphatise (AP) levels are indicative of cholestasis.
Hepatocellular death, via either apoptosis or necrosis, underlies the clinical 
manifestations of drug induced hepatitis. Apoptosis is a form of programmed cell 
death, where the cell undergoes a series of biochemical changes; the cell shrinks and
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condenses through disassembly of the cytoskeleton and nuclear envelope, and the 
nuclear DNA fragments (Alberts et ah, 2002). Caspases (cysteine-dependent 
aspartate specific proteases) are responsible for the disassembly of the cytoskeleton; 
initiator caspases undergo self-cleavage and initiate a cascade of caspase activation. 
Necrosis, on the other hand, is regarded as ‘uncontrolled’ cell death (Alberts et ah, 
2002); although there is increasing evidence to suggest that necrosis is just another 
kind of programmed cell death (Festjens et ah, 2006). Loss of membrane integrity 
occurs early in necrosis and cellular contents leak causing an inflammatory response 
(Kono and Rock, 2008).
Cholestasis is the blockage of bile flow from the liver to the duodenum. Damage to 
hepatocytes (especially on the canilicular membrane), inhibition of biliary 
transporters (or genetic defects altering function) or damage to bile ductules and bile 
ducts can inhibit bile flow and lead to intracellular accumulation of potentially 
harmful bile constituents and drug or drug metabolites, resulting in the development 
of cholestatic liver cell damage (Velayudham and Farrell, 2003, Pauli-Magnus and 
Meier, 2006). Drug-induced cholestasis can be either be ‘bland’, that is no indication 
of inflammation or necrosis, or be accompanied by bile duct injury and inflammation 
(Abboud and Kaplowitz, 2007). The majority of clinically overt cholestatic and 
mixed hepatitis/cholestatic reactions are associated with bile ductular injury and 
inflammation (Abboud and Kaplowitz, 2007). Numerous drugs which cause 
cholestatic DILI in man inhibit BSEP activity m vitro, therefore potent BSEP 
inhibition by marketed drugs is a potential risk factor for idiosyncratic cholestatic 
DILI in man (Thompson et al.,2Q\\)
1.4.4 Manifestations of drug-induced skin reactions
The skin is the most frequent target of immune-mediated ADRs; they affect 2-3% of 
hospitalised patients (Bigby et ah, 1986), however more severe skin reactions are 
much less frequent (Figure 1.10). ADRs affecting the skin can range from mild 
rashes to life-threatening conditions such as toxic epidermal necrolysis (TEN; Nigen 
et ah, 2003, Merk et a},, 2007). The most common drugs that cause ADRs associated 
with the skin include antibiotics, sulphonamides and quinolones, anticonvulsants and 
non-steroidal anti-inflammatorys (NSAIDS; Lerch and Pichler, 2004). The skin has
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the ability to bioactivate drugs; it contains both phase I and phase II drug 
metabolizing enzymes, including some of those found in the liver and additional 
isoforms that are not (Du et a/., 2006, Bergstrom et al., 2007). The skin is also 
immunologically functional, containing antigen presenting cells, Langerhan’s cells 
and dentritic cells (Park et al., 1998, Merk, 2009). Immune-mediated ADRs are 
therefore possible in the skin, based on the hypothesis that a drug will be bioactivated 
and bind to cellular proteins creating an antigen that the host will raise an immune 
response to.
A B
Figure 1.10: Examples of severe drug-induced skin reactions. Skin rashes caused 
by (A) abacavir and (B) sulphamethoxazole
95% of drug-induced skin reactions are exanthematous or maculopapular drug 
eruptions and tend to develop within 1 to 2 weeks of drug treatment (Uetrecht, 2009, 
Merk, 2009). Immunohistological examination of this type of lesion shows mild to 
moderate mononuclear cell infiltrate with some eosinophils (Lerch and Pichler, 
2004). T-cells predominate and most are activated and express human leukocyte 
antigen DR (major histocompatilibility complex (MHC) class II) (Lerch and Pichler, 
2004, Bronnimann and Yawalkar, 2005). Increased numbers of CD4+ and CD8+ T- 
cells containing the cytotoxic granule proteins, perforin and granzyme B are found in 
the dermo-epidermal junction or in the epidennis, along with signs of keratinocyte 
cell damage (Yawalkar et al., 2000). Granule proteins can induce cell death through
31
Chapter 1: General Introduction
pore formation on the target cell membrane. Various cytokines and chemokines are 
upregulated in these types of maculopapular drug reactions (Yawalkar et al., 2000, 
Posadas et al, 2000, Posadas et al, 2002, Hari et al, 1999).
More severe ADRs affecting the skin include Stevens-Johnson syndrome (SIS) and 
toxic epidermal necrolysis (TEN) and have mortality rates of 5% and 30% 
respectfully (Roujeau and Stern, 1994). Most cases of TEN are drug-induced (Park et 
al, 1998). In early stages, these more severe ADRs, resemble maculopapular 
emptions except patients complain of painful skin (Uetrecht, 2009). As these 
conditions progress mucus membranes are affected and blisters form followed by 
skin detachment. Histological examination of the skin of patients with TEN and SJS 
reveal mainly CD8+ T-cells, suggesting that apoptosis is initiated by cytotoxic T 
lymphocytes (Nassif et al, 2004, Greenberger, 2006). Keratinocytes in SJS and TEN 
express the apoptosis inducing Fas receptor and its ligand (Murata et al, 2008).
1.5 TOXICITY HAZARD AND RISK ASSESSMENT AND 
BIOMARKERS
It stands to reason that research into systems that can detect potential human hazard 
of NCEs has been of high priority, given the fact that many serious idiosyncratic 
ADRs are not observed until the diug is used by a much larger population. However, 
it remains that there are no accepted methods for the detection of idiosyncratic 
reactions in preclinincal or in vitro systems (Park et al, 2005). The two conventional 
methods for the detection of drug bioactivation in both academic and industrial 
settings are (1) identification of thioether adducts of drugs and (2) the detection of 
covalent binding of the drug to protein or DNA. Means of elucidating the 
downstream effects of bioactivation are currently rare; much hope has been placed 
on the development of biomarkers and animal models of disease and ADRs to 
improve the translatability of hazard potential throughout the development process 
and into the clinic.
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1.5.1 Toxicity hazard and risk assessment
In order to drive attrition to an earlier stage in the drug development process, early 
application of preclinical toxicity assessment has been implemented, making it 
possible to incorporate an assessment of structure-activity relationships (SARs) and 
toxicity issue management into drug design (Kramer et al., 2007, Stevens and Baker, 
2009). Preclinical safety testing is designed to assess the potential of NCEs to cause 
toxicity in humans and to determine the dose-limiting toxicity, and whether this 
toxicity is reversible and if it can be monitored clinically (Stevens and Baker, 2009). 
If an insight into the mechanisms of these toxicities can be gained from these studies, 
then rational extrapolations can be made to humans and potential risk can be 
evaluated (Stevens and Baker, 2009, Stevens, 2006).
In vitro toxicity assessment aims to identify any development-limiting toxicities; that 
is those with no acceptable margin of safety (Kramer et al, 2007). In vivo toxicity 
assessment identifies dose-limiting toxicities that, taken with other preclinical 
findings, are used to develop a margin of safety based on the ratio of the no observed 
adverse effect level by the predicted human efficacious dose (Kramer et al., 2007, 
Stevens and Baker, 2009). The standard regimen for preclinical toxicity assessment 
is conducted in at least two species (one rodent and one non-rodent) at doses many 
multiples of the intended dose in humans, for at least two weeks (Peters, 2005). 
NCEs are tested for indications of potential genetic toxicity, DDIs, adverse primary 
or secondary pharmacological effects and metabolite-mediated toxicity (Kramer et 
al, 2007). A retrospective analysis of concordance of preclinical toxicity data with 
human toxicity data revealed that 70% of human toxicities were predicted by 
preclinical animal studies in one or more species (Olson et al, 2000). Of the human 
toxicities analysed only 4 were considered to be idiosyncratic. The research did not 
highlight those preclinical studies that show toxicity in animals but may have been 
safe in human studies. Drugs registered before the introduction of extensive toxicity 
testing, may have shown hazard signals in preclinical toxicity assessments, but are 
used safely in humans. Although the predictability of human toxicity through 
preclinical toxicity assessment is good (70%; Olson et al, 2000), it remains that 30% 
of on-target toxicities are not predictable and, in addition, idiosyncratic ADRs are not 
reproducible in animal models.
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In light of the increasing evidence to suggest that reactive metabolite formation is an 
initiating factor in many on-target and idiosyncratic ADRs, the Food and Drug 
Administration (FDA) have recently released ‘Metabolites in Safety Testing (MIST)’ 
guidance in 2008 and ‘M3(R2) Nonclinical Safety Studies for the Conduct of Human 
Clinical Trials and Marketing Authorization for Pharmaceuticals’. These guidelines 
highlight the importance of the identification and quantification of drug metabolites 
across human and preclinical species. If a metabolite is identified in man that is 
produced disproportionately to that in a preclinical species, then the FDA MIST 
guidelines suggest further investigation into these metabolites is required (FDA, 
2008). That may be through toxicity assessment of a species that produces similar 
levels of the metabolite as the human or synthesising the metabolite and 
administering it directly. The guidelines also suggest that human metabolites that are 
formed at, or greater than, 10% of the parent drug systemic exposure at steady state, 
should be treated with concern (FDA, 2008). Identification of reactive metabolite by 
the use of chemical trapping reagents, such as GSH or cyanide, in microsomal 
incubations can provide infonnation on the structure of the reactive metabolite 
through analysis by tandem mass spectrometry (LC-MS/MS) and/or nuclear 
magnetic resonance (Evans et alf 2004).
Based on the wealth of evidence to suggest that many direct, and immune-mediated 
toxicities, are caused through reactive metabolite covalent binding to cellular 
macromolecules, research at Merck proposed a covalent binding threshold criteria in 
the safety aspect of dmg development (Evans et al, 2004). Using levels of covalent 
binding of known hepatotoxins to microsomal protein, an upper-level of accepted 
covalent binding was suggested, 50 pmol dmg equivalent per mg of protein (Evans et 
ah, 2004). In order to test this concept, 18 known hepatotoxic and non-hepatotoxic 
compounds were tested for levels of covalent binding in human liver microsomes 
(Obach et al., 2008). Of the 18 compounds tested, 14 demonstrated some extent of 
covalent binding; of the 4 that did not, 2 were hepatotoxins and 2 were non- 
hepatotoxins (Obach et ah, 2008). Recently covalent binding studies conducted in 
human hepatocytes have provided a means of discriminating between hepatotoxins 
and non-hepatotoxins by incorporating factors such as daily dose and intrinsic 
clearance (Bauman et ah, 2009; Nakayama et al., 2009). Microsomes have been the 
system of choice to study covalent binding of drugs, however recent studies suggest
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that human hepatocytes might provide a more clinically relevant, metabolically 
complete system (Bauman et aL, 2009; Nakayama et ah, 2009). Although the 
detection of a bioactivation process in vitro is relatively straightforward, the 
downstream consequences in vivo are poorly understood; the identities of 
macromolecular targets, to which bioactivated drugs bind and for which binding 
results in toxicity, have not been established and remain an area of active research 
(Obach et al., 2008).
1.5.2 Animal models of ADRs
There are very few animal models of idiosyncratic ADRs; in order for an animal 
model to be useful, the mechanism of toxicity must resemble the mechanism in 
humans (Shenton et al, 2004). The mechanisms of most ADRs in humans remain 
unknown, and therefore, the usefulness of animal models is based upon comparisons 
of certain characteristics of the reaction seen in humans (Shenton et al, 2004). An 
animal model also has to have a biological or chemical endpoint that can be 
measured and that is similar to the clinical appearance of the ADR (Shenton et al, 
2004). Most preclinical toxicity assessment is conducted in healthy animals; it may 
be that performing toxicity assessment in genetically modified animals or animal 
models of disease would more effectively highlight idiosyncratic ADRs.
1.5.3 Biomarkers
A biomarker is defined as ‘a characteristic that can be objectively measured as an 
indicator of normal biological processes, pathological processes or a 
pharmacological response to a therapeutic intervention’, by the National Institutes of 
Health (NIH) Biomarkers Definitions Working Group (Atkinson A.J. et al., 2001). 
Development of biomarkers aims to allow earlier and more robust measures of drug 
safety and efficacy to get safe and effective dings to the market (Colburn and Keefe, 
2003). In terms of ADRs, biomarkers that are predictive of a toxicological outcome 
and can be used from in vitro toxicity assays to ADR diagnosis and management in 
the clinic would be highly desirable.
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In light of the mechanisms implicated in the development of ADRs, a number of 
genetic, chemical and molecular markers could potentially be used in the assessment 
of drug safety. It is likely that a ‘biomarker panel’ would be used to describe or 
diagnose an ADR rather than a single biomarker (Colburn and Keefe, 2003). Ideally 
biomarkers would be: organ specific, reflect the type and degree of injury, predictive 
(i.e. show elevation compared to normal without irreversible tissue damage), non- or 
minimally-invasive (found in blood or urine), assayed rapidly, transferable and have 
a low baseline variability across the population (Antoine et al, 2009a). Novel 
biomarkers aim to improve drug discoveiy and development and drug safety through 
to the clinic, and should be used alongside the gold-standard biomarkers such as 
serum alanine transaminase (ALT) and aspartate transaminase (AST) for drug- 
induced hepatitis and serum alkaline phosphatase (AP) for drug-induced cholestasis 
(Table 1.3; Antoine et al., 2009a).
A common mechanism for the detoxification of reactive metabolite occurs via GSH 
conjugation (Williams et al, 2002, Williams and Naisbitt, 2002). The identification 
of drug metabolite-GSH adducts in a preclinical setting is sometimes treated as a 
hazard signal as it is indicative of reactive metabolite formation, conversely it could 
be argued that identification of a GSH adduct is an indication of an effective 
detoxification system. Human urinary mercapturates (breakdown products of GSH- 
adducts) have been used as biomarkers of human exposure to reactive species 
(Seutter Berlage et al, 1977). More recently, in the light of improved bioanalytical 
techniques, dmg-mercapturates have been used in the quantitative assessment of in 
vivo bioactivation. Some compounds can be metabolized to several GSH adducts 
(Amore et al, 1997, Madden et al, 1996, Bu et al, 2007, Rousu et al, 2009, Wang 
et al, 2009a), suggesting that careful analysis of a drugs metabolites is necessaiy to 
identify a thioether derivative suitable for use as a biomarker of metabolic activation. 
Amongst the human pharmaceuticals the mercapturate conjugates of APAP (Siegers 
et al, 1984), phenacetin (Veronese et al, 1985), felbamate (Dieckhaus et al, 2002) 
and valproic acid (Gopaul et al, 2003) have been used for the quantitative 
assessment of in vivo bioactivation.
Proteins released from apoptotic and necrotic cells have been used as biomarkers of 
drug-induced cell death (Antoine et al, 2009b). Keratins are intermediate filament 
proteins expressed by epithelial cells responsible for cell structure and integrity.
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During necrosis full length keratin-18 (K18) is released passively into the serum 
(Schutte et ah, 2004). In Fas-mediated apoptosis, phophorylation and cleavage of 
K18 occur during structural rearrangement and a ‘caspase-cleaved’ K18 accumulates 
in the blood over time (Schutte et al., 2004). Serum quantification of casapase- 
cleaved K18 and full length K18 have been used for markers of apoptosis and 
necrosis, respectively, during pharmacodynamic therapeutic drug monitoring in 
patients and animal models (Cummings et al, 2006).
High mobility group box protein 1 (HMGB-1) is a nuclear binding protein that has 
pro-inflammatory activity and targets toll-like receptors (TLR) and the receptor for 
advanced glycation end-products (RAGE) on target cells (Hori et al, 1995, Park et 
al., 2004). HMGB-1 is thought to have a role in alerting the innate immune system to 
dying cells (Scaffidi et ah, 2002, Kono and Rock, 2008), which will be a key 
determinant in the extent of tissue damage. Two forms of HMGB-1 exist; a hyper- 
acetylated fonn is released from activated innate immune cells and a hypo-acetylated 
form is passively released from necrotic cells (Scaffidi et ah, 2002). Anti-HMGB-1 
antibodies inhibit the inflammatory response associated with APAP hepatotoxicity 
and endotoxin lethality in vivo (Scaffidi et al., 2002, Wang et ah, 1999b,). An insight 
to the level of organ damage, the mechanism of cell death and the involvement of the 
innate immune system might be gained by the quantification of the molecular forms 
of both K18 and HMGB-1.
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Biomarker Established
/novel
Organ
specific
Mechanism
specific
Compartment Reference
Alanine amino­
transferase 1
(ALT1)
Established Yes - ALT1 No - Necrosis
(leakage)
Blood (Lindblom et al,,
2007)
Glutamate
dehydrogenase
(GLDH)
Established No Yes -
mitochondrial
damage
Blood (Carakostas et al.,
1986)
Sorbitol
dehydrogenase
(SDH)
Established Relatively No - Necrosis
(leakage)
Blood (Khayrollah et al.,
1982)
p -Hydroxy-cortisol Established Relatively Yes - CYP3A4
metabolism
Urine (Park and
Kitteringham,
1990a)
Drug mercapturate Established /
novel
Relatively Yes - potential
reactive metabolite
Urine (Wagner et al.,
2007)
Keratin 18 (K18)-
fragmented
Novel No
(epithelial
cells only)
Yes - apoptosis Blood (Cummings etal.,
2006)
Keratin 18 (K18)-
full length
Novel No
(epithelial
cells only)
Yes - necrosis Blood (Cummings etal.,
2006)
Ophthalmic acid Novel No Yes - oxidative
stress
Blood / urine (Soga et al., 2006)
High mobility
group box protein
1 (HMGB1)
Novel No Yes - necrosis and
inflammation
Blood (Scaffidi et al., 2002)
Cytochrome C Novel No Yes -
mitochondrial
damage
Blood / urine (Miller ef a/., 2008)
Serum F protein 
(HPD)
Novel Relatively No - Necrosis
(leakage)
Blood (Foster ef a/., 1989)
Arginase 1 Novel Relatively No - Necrosis
(leakage)
Blood (Ashamiss et al.,
2004)
Malate
dehydrogenase
Novel Relatively Yes -
mitochondrial
damage
Blood (Zleveefa/., 1985)
Purine nucleoside
phosphoryiase
(PNP)
Novel Relatively No - Necrosis
(leakage)
Blood (Ohuchi etal., 1995)
Micro RNAs
(miRNA)
Novel Yes -
depending
on coded
protein
No- potential Blood (Wang ef a/.. 2009b)
Paraoxonase1
(PON-1)
Novel Relatively Yes - liver function Blood (Meneses-Lorente et
al., 2004)
Table 1.3: Summary of established and novel biomarkers to DILI with organ or 
mechanism specificity for non-invasive assessment not routinely used as part of a 
standard clinical liver function test. Taken from Antoine et al. (2009).
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1.6 FUROSEMIDE INDUCED HEPATOTOXICITY
Furoseraide (FS; 4-choloro-N-furfuryl-5-sulphanoyl-anthranilic acid) is a potent loop 
diuretic frequently used in the treatment of edematous states associated with cardiac, 
renal, and hepatic failure and for the treatment of hypertension (Boles Ponto and 
Schoenwald, 1990).The pharmacological action of furosemide has been attributed to 
the inhibition of the active reabsorption of CF ions in the thick ascending limb of the 
loop of Henle by binding the Cl" binding site of the Na+/2C17K+ co-transport system 
(Burg et ai, 1973, Vree and Van Der Yen, 1999). At therapeutic doses, furosemide is 
not toxic to humans, although it has been associated with jaundice and 
hypersensitivity (Noce et al, 2000), and there may be a potential risk of 
hepatotoxicity when administered in large doses to patients with acute and chronic 
renal failure (Mitchell et al, 1974). The drug has been marketed in the US since 
1966 (Greenblatt et ai, 1977). Furosemide has been shown to produce massive 
hepatic centrilobular necrosis in mice by a mechanism independent of its diuretic 
action (Mitchell et al, 1974) and therefore represents an important tool as a chemical 
with a toxicological endpoint to study the relationship between chemical structure 
and toxicity.
1.6.1 Biotransformation of furosemide
The metabolic fate of furosemide has been investigated a number of times over the 
years and the identification of metabolites has been the subject of much controversy. 
It has been demonstrated that furosemide foims an acyl-glucuronide in the plasma 
and urine of humans (Beermann et al, 1975, Beermann et al, 1977, Benet, 1979, 
Perez et al, 1979, Smith et al, 1980, Kerremans et al, 1982, Smith and Benet, 
1983). More recently the furosemide glucuronide has been identified in the bile of 
furosemide treated rats and mice (Williams et al, 2007), although the glucuronide 
has not been identified in the urine of rats (Hammarlund-Udenaes and Benet, 1989, 
Prandota and Pruitt, 1991). A number of studies have shown that in humans 
approximately 13 — 17% of an Iv. dose of furosemide is excreted as FS-glucuronide 
in the urine (Smith et al, 1980, Andreasen et al, 1981, Waller et al, 1982, Verbeeck 
et al, 1982). However variations on this amount have been published; Perez et al 
(1979) estimated 3-41% of the furosemide dose was excreted in the urine as FS-
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glucuronide in patients with acute pulmonary edema. Andreasen et aL (1977) found 
that in healthy volunteers this figure was only 2% and in subjects taking furosemide 
6 months prior to the study this figure increased to around 16%. Urinary excretion of 
furosemide has been demonstrated as the main route of elimination in humans and it 
appears that furosemide glucuronidation occurs primarily in the kidney (Kerdpin et 
aL, 2008). In the rat, of the total dose excreted in the bile (21.2 ± 2.6%) 12.8 ± 1.8% 
was excreted as the FS-glucuronide (Williams et al, 2007).
A more controversial metabolite is the N-dealkylated furosemide metabolite (4- 
chloro-5-sulphamoyl-anthranilic acid; CSA in literature) first identified in 1964 by 
Haussler et al. It has been subsequently been identified in the mine of dogs, monkeys 
(Yakatan et al., 1976) and in humans (Prandota and Pruitt, 1975, Andreasen et al, 
1978). However a number of groups failed to find evidence of this metabolite in 
humans (Beermann et al., 1975, Smith et al., 1980, Kerremans et al., 1982, Branch et 
ah, 1977). After employing an acidic extraction process Smith et al. (1980) and 
Perez et al. (1979) were able to produce the N-dealkylated furosemide metabolites 
leading them to believe that the metabolite is an analytical artefact. Supporting this 
argument is the identification of a photodegredation product of furosemide which has 
a similar retention time to N-dealkylated furosemide under certain analytical 
conditions (Hammarlund-Udenaes and Benet, 1989). A recent study identified the N- 
dealkylated furosemide metabolite in the bile of rats and mice without the use of an 
acid extraction method providing clear evidence that it is a genuine metabolite in 
these species (Williams et ah, 2007). Figure 1.11 shows the metabolism of 
furosemide in vivo.
1.6.2 Bioactivation and toxicity of furosemide
At therapeutic doses, furosemide is not toxic to humans, although it has been 
associated with jaundice and hypersensitivity (Noce et al., 2000), and there may be a 
potential risk of hepatotoxicity when administered in large doses to patients with 
acute and chronic renal failure (Mitchell et al., 1974). Due to the risk of hypotension, 
the administration of furosemide is careftilly controlled and generally only small 
doses are required due to its high potency. Furosemide is known to cause a decrease 
in hepatic blood flow by a mechanism dependant on blood volume contraction
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(Gaffney et ctl, 1979), but the hepatotoxic effect is not considered to be an inverse 
result of diuretic action.
Furosemide has been shown to produce massive hepatic centrilobular necrosis in 
mice by a mechanism independent of its diuretic action (Mitchell et al, 1974). The 
hepatocellular damage caused by furosemide is postulated to be the result of CYP450 
enzyme-mediated formation of a toxic metabolite that binds covalently with hepatic 
macromolecules both in vitro and in vivo (Mitchell et aL, 1974, Mitchell et a/., 
1976). It was found that furosemide binds covalently to microsomal protein, and that 
the level of binding parallels the severity of necrosis. This binding is decreased by 
cysteine and GSH, and also by the presence of P450 enzyme inhibitors, suggesting 
bioactivation of the furosemide molecule (Mitchell et al, 1974, Williams et al., 
2007). Early work suggested that an epoxide of furosemide is responsible for the 
hepatotoxicity observed in the mouse. The level of covalent binding was found to be 
increased in the presence of an epoxide hydrolase inhibitor (Wiith et al, 1976). More 
recently, bioactivation of the furan ring was demonstrated by the characterization of 
three key novel metabolites of furosemide from in vivo and in vitro studies: FS y- 
ketocarboxylic acid, FS-SG conjugate, and a mixed Wacetyl lysine and Y-acetyl 
cysteine conjugate (Williams et al, 2007). The formation of a FS y-ketocarboxylic 
acid in vivo is suggestive of formation of an epoxide intennediate (Figure 1.11). 
These studies provide evidence to conclude that the reactive metabolite of 
furosemide is an epoxide. Williams et al, (2007) also show the reactive metabolite 
binds covalently to murine hepatic protein; this does not occur in rats, but is excreted 
in the form of a GSH conjugate, suggesting a possible safety mechanism exists in the 
rat to protect from furosemide induced hepatotoxicity (Williams et al, 2007). As 
well as species differences in the balance of bioactivation and bioinactivation, it is 
possible that furosemide accumulation in the liver due to impaired clearance might 
also be a factor in development of hepatotoxicity in the mouse. Work conducted by 
Spitznagle, et al (1977) indicated that saturation of the biliary excretion of 
furosemide, following a large dose of furosemide or pretreatment with 
sulfobromophthalein (BSP), is closely associated with the appearance of liver 
necrosis in the mouse and of furosemide metabolites covalently bound to liver 
proteins.
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(K. -OH
FS glutathione conjugate
Figure 1.11: Major pathways of metabolism of FS in vivo. Broken arrows show 
postulated pathway for the formation of g-ketocarboxylic acid via a reactive 
furosemide epoxide intermediate (adapted from Williams et al. (2007)).
1.7 NEVIRAPINE
Nevirapine (NVP), used in the treatment of HIV-1 infection, was the first non­
nucleoside reverse transcriptase inhibitor (NNRTI) to be approved by the FDA. Both 
nucleoside and non-nucleoside RTIs inhibit the same target, the reverse transcriptase 
enzyme. Nucleoside RTIs bind at the enzymes active site whereas NNRTIs bind 
within a pocket termed the NNRTI pocket and inhibit both the RNA- and the DNA- 
dependent DNA polymerase activities (De Clercq, 2004). Nevirapine is not effective 
against HIV-2 as the pocket of the HIV-2 reverse transcriptase enzyme has a 
different structure. Nevirapine is used widely in developing countries as it is 
inexpensive and does not require refrigeration. Nevirapine is associated with 
clinically restrictive adverse effects, namely, skin reactions and hepatotoxicity, 
which can occur either simultaneously or separately. Although nevirapine is highly
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effective, the incidence of severe or life-threatening hepatoxicity has lead to the FDA 
giving a black-box warning.
1.7.1 Metabolism and bioactivation of nevirapine
Nevirapine is metabolised to a number of stable metabolites in humans by CYP3A4 
and CYP2B6 (Erickson et al., 1999). Nevirapine also induces activity of these 
enzymes and therefore, its own metabolism. Stable metabolites of nevirapine include 
a number of hydroxylated metabolites; 2-OH NVP, 3-OH NVP, 8-OH NVP and 12- 
OH NVP (Riska et a/., 1999). These hydroxylated metabolites undergo
glucuronidation in phase II metabolism and are excreted in the urine. 12-OH NVP is 
further metabolised to form 4-carboxy NVP (Riska et al., 1999).
aminium cation 
radical
(Takakusa et al 2008)
PH ^ O quinonemethide
s^'n2 (Chen et al 2008)
Figure 1.12: Potential reactive metabolites of nevirapine. Potential toxicophores 
are highlighted by a box.
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Nevirapine has the potential to undergo metabolism to various reactive metabolites 
(Figure 1.12). 12-OH NVP is a substrate for sulphotransferase in rats (Chen et al, 
2008), and it has been proposed that the sulphate ester dissociates to form reactive 
quinone intermediate (Uetrecht, 2006, Chen et al, 2008). Hydroxyheteroaryl 
metabolites are potential precursors of reactive quinone imines (Wen et al., 2009). 
The cyclopropylamine group has the potential to be bioactivated to an aminium 
cation radical via N-dealkylation (Takakusa et al, 2008). Nevirapine could also fonn 
one or more heteroarene epoxide metabolites in either of the pyridine rings. A single 
GSH adduct was identified in HLM and incubations with recombinant CYP 3A4 
(Wen et al., 2009) and nevirapine was shown to bind covalently to RLM (Takakusa 
et al, 2008). Antunes et al (2009) demonstmted the reactivity of 12-sulphoxy 
nevirapine by formation of multiple DNA adducts in reactions with 12-mesyloxy 
NVP.
1.7.2 Nevirapine-induced ADRs
Nevirapine treatment is associated with two clinically restrictive adverse effects; skin 
reactions and hepatotoxicity (Figure 1.13; (Pollard et al, 1998)). These reactions can 
occur simultaneously or one without the other (Claes et al, 2004, Drummond et al, 
2006, Vitezica et al, 2008). The most common adverse event caused by nevirapine is 
skin rash, which occurs in around 16% of patients usually (65%) within the first 6 
weeks of treatment (Pollard et al, 1998, Phanuphak et al, 2007). Severe and life- 
threatening skin rash, in the fonn of Steven-Johns on syndrome (SJS) and toxic 
epidermal necrolysis (TEN), occurs in 0.3-1% of patients taking nevirapine (Pollard 
et al, 1998, Claes et al, 2004, Fagot et al, 2001). Serum liver enzymes are 
frequently elevated in patients taking nevirapine; between 5-15% experience 
asymptomatic increases, however 1-5% of patients experience symptomatic increases 
as a result of severe hepatotoxicity, including clinical hepatitis and hepatic failure 
(Pollard et al, 1998, Phanuphak et al, 2007, Chu et al, 2010, Ciccacci et al, 2010, 
Maniar et al, 2006, Martinez et al, 2001, De Maat et al, 2002). Nevirapine-induced 
hepatotoxicity has been observed in HIV-infected (Maniar et al, 2006, Buyse et al, 
2006) and non-HIV-infected patients (Patel et al, 2004).
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The nature of nevirapine-induced liver injury is not clear; cases of hepatotoxicity 
vary in terms of severity, time to onset and can occur with or without a 
hypersensitivity reaction (Buyse et a/., 2006, De Maat et al, 2003). It is possible that 
the late-occurring reactions may be non-immune in nature, while those occurring in 
the first three months may have an immune pathogenesis (Pirmohamed et aL, 2007). 
The time of onset and the nature of the nevirapine-induced skin rash suggest that the 
reaction is immune-mediated and because of the low incidence it is likely that the 
reaction may be idiosyncratic (Pirmohamed et al., 2007, Chen et al., 2008). It has 
been strongly advocated that nevirapine-induced skin rash and hepatotoxicity are 
immune-mediated reactions (Pirmohamed et al, 2007, Chen et al., 2008); however, 
it is not clear whether this immune reaction is due to reactive metabolites or 
nevirapine itself. Nevirapine-reactive T cells have been observed in a patient with 
early-onset hepatitis in the absence of any cutaneous manifestations. The patients’ T 
cells proliferated in vitro on exposure to nevirapine but not its stable metabolites 
(Drummond et a/., 2006). Claes et al. (2004) reported the rapid and full clinical 
recovery of a patient suffering from nevirapine-induced TEN and toxic hepatitis 
treatment following intravenous treatment with human immunoglobulins and N- 
acetylcysteine (NAC; 300 mg/kg/day continuous infusion). As NAC is a precursor of 
GSH, it is possible that replenishment of GSH stores helped to detoxify nevirapine 
reactive metabolite leading to reduction in toxicity.
Figure 1.13: Adverse effects of nevirapine treatment. Nevirapine treatment is 
restricted by severe skin reactions including SJS and TEN (A) and hepatotoxicity 
(B).
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Due to the idiosyncratic nature of nevirapine-induced ADRs, it is not possible to 
predict which patients will suffer from hepatotoxicity or skin rash. Many studies 
have been conducted to identify patient groups who have increased risk of 
developing treatment-restricting ADRs. It is advised that, unless the clinical benefits 
outweigh the risks, nevirapine therapy is not recommended for woman with CD4 cell 
counts greater than 250 cells/mm3 or men with CD4 cell counts of 400 cells/mm3 
(Kesselring et a!., 2009). The recommended dose of nevirapine, for adults and 
adolescents older than 16 years, is 200 mg once daily for the first 14 days (lead in 
dose), followed by 200 mg twice a day (Barreiro et al, 2000). Nevirapine is 
contraindicated in patients with hypersensitivity to the active substance or to any of 
the excipients and should not be used in patients with severe hepatic impairment or 
raised liver enzymes pre-treatment (AST or ALT >5 x ULN). In a large study 
conducted over seven observation clinics, it was found that undetectable viral load in 
patients starting nevirapine treatment were less likely to develop hypersensitivity 
reactions (Kesselring et al, 2009). Patients with Asian ethnicity were also found to 
have increased risk of developing nevirapine-induced hypersensitivity reactions 
(Kesselring et al, 2009). Patients with a body-mass index (BMI) of less than 18.5 
were found to have an increased risk of developing nevirapine-induced 
hepatotoxicity (Sanne et al, 2005). Characteristics, of those patients who developed 
severe hepatotoxicity, vaiy greatly, and no specific risk factor was common to all 
(De Maat et al, 2003).
1.7.3 Genetic polymorphisms associated with nevirapine-induced toxicity
A major area of research into nevirapine-induced ADRs has focused on genetic 
polymorphisms that predispose patients to skin rash and/or hepatotoxicity (Owen et 
al, 2006). Often genetic polymorphisms in drug metabolising enzymes, drug 
transporters and the major histocompatibility complex are responsible for variation in 
toxic response to a drug (Owen et al, 2006).
There are many polymorphisms of the CYP2B6 isoform that can affect the 
expression and activity of the enzyme (Zanger et al, 2007); the G516T 
polymorphism is associated with reduced catalytic activity. The G516T 
polymorphism in CYP2B6 has been shown to significantly increase plasma
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nevirapine levels in HIV-infected patients in Uganda (Penzak et al., 2007). A 1.5 
fold increase in plasma concentmtions is observed in patients with the homozygous, 
variant allele (546G —» T/T) compared to the common allele (516G —> G/G; Penzak 
et al., 2007). A similar study, of a Swiss patient cohort, found a 1.7 fold increase 
(Rotger et al., 2005). The toxicological result of increased plasma nevirapine 
concentrations is not clear. Preliminary studies conducted in Spain found that a 
positive correlation exists between plasma nevirapine levels and the risk of liver 
toxicity; patients with plasma nevirapine concentrations above 6 jig/ml are thought to 
have a 92% risk of developing liver toxicity (Gonzalez De Requena et al., 2002, 
Gonzalez De Requena et al., 2005). Other groups have not observed any solid 
evidence of a relationship, but recognise the need to monitor plasma nevirapine 
levels when hepatotoxicity is suspected (Almond et al., 2004, Kappelhoff et al., 
2005, Vogel et al, 2009).
The 3435C-^T polymorphism in MDR1 is significantly associated with reduced risk 
of nevirapine-induced hepatotoxicity (Haas et al., 2006). P-glycoprotein is a 
multidrug efflux pump, encoded by MDR1; this membrane-associated protein is 
responsible for actively removing xenobiotics from the cell (Haas et al, 2006). 
Changes in p-glycoprotein activity can effect distribution, metabolism and excretion 
of drugs. Patients who experienced nevirapine-induced hepatotoxicity were less like 
to have at least one MDR1 T allele at position 3435C—»T. The reasons for this 
association are not well understood however, it is possible that altered P-glycoprotein 
activity in the intestine associated with the MDR1 variants alters disposition of 
nevirapine and/or its metabolites that affect intracellular concentrations of nevirapine 
and toxicity in liver (Saitoh and Spector, 2008).
HLA genes encode for histocompatibility proteins which are responsible for antigen 
presentation. Polymorphisms in these genes can influence an individuals’ or 
populations’ immune response to particular xenobiotics. Genetic screening of 
patients for HLA-B*5701 is used routinely before a treatment regimen including 
abacavir is initiated to reduce the risk of hypersensitivity reactions during treatment 
(Mallal et al, 2008). Currently no standard genetic screen is in place in the clinic to 
predict increased risk of nevirapine-induced toxicity; however a number of HLA 
alleles have been identified that show a correlation to increased risk of nevirapine-
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induced hypersensitivity. Studies in Australian (Martin et al., 2005) and French 
(Vitezica et al, 2008) populations demonstrated that HLA-DRB1 *0101 acts as a 
predisposing factor for nevirapine hypersensitivity. In a Japanese patient cohort 42% 
of nevirapine-hypersensitive patients had the HLA-Cw*08 allele, which is 
significantly higher than the nevirapine-tolerant group and the general Japanese 
population (Gatanaga et al, 2007). A study conducted in Thailand reported 
significantly higher number of patients with the HLA-Cw*04 allele in those that 
suffered with nevirapine-induced skin rash (Likanonsakul et al., 2009). In a 
Sardinian patient cohort 46% of the nevirapine-hypersensitive subjects had the HLA- 
Cw*08 and HLA-B*14 alleles compared with 5% of the nevirapine-tolerant group 
(Littera et al, 2006).
1.7.4 Animal model of nevirapine-induced skin rash
Animal models of idiosyncratic drug reactions are rare but can be useful tools for 
investigating the mechanisms of the reactions. Uetrecht and colleagues have 
extensively characterised a dose-dependent, nevirapine-induced skin rash in female 
Brown Norway rats that resembles the idiosyncratic cutaneous reaction seen in 
humans (Shenton et al., 2003, Shenton et al, 2004) and appears to be immune- 
mediated (Shenton et al, 2005), The nevirapine-induced skin rash in female Brown 
Noiway rats is similar to that in human in terms of; the time of onset, females being 
more susceptible than males, incidence increases with dose, escalating dose of 
nevirapine can reduce incidence, rechallenge results in more severe rashes than on 
initial exposure (Shenton et al., 2003). Chen et al. (2008) have proposed that the skin 
rash produced in female Brown Noiway rats by nevirapine and 12-OH NVP may be 
due to nevirapine quinone methide formed through dissociation of 12-OH NVP 
sulphonate in the skin. 12-OH NVP caused a rash at a lower dose then required for 
nevirapine. Histology of nevirapine induced skin rash highlighted various degrees of 
hyperplasia more prominent adjacent to ulcerated areas. Away from the ulceration 
there was primarily mononuclear dermal inflammatory infiltrate. There were CD4+, 
CD8+ and ED1+ (macrophages) cells in both the epidermis and the dermis. 
Keratinocyte cell death was observed similar to that seen in SJS (Shenton et al, 
2003).
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1.8 THESIS AIMS
The aims of this thesis are to investigate covalent binding and the formation of 
thioether metabolites in relation to bioactivation and toxicity of dings will be 
examined. The first three experimental chapters describe investigations into the 
efficacy, toxicity and phannacokinetics of a thiophene analogue of furosemide (TPA) 
and comparisions to that of furosemide, in order to directly compare the two 
heterocycles in the same biological environment. The aims of this section of work 
are:
• To assess the efficacy and toxicity of TPA and compare to that of furosemide.
• To determine and compare the PK parameters of TPA and furosemide.
• To assess and compare species differences in terms of toxicity, 
phannacokinetics and metabolism of furosemide and TPA.
• To analyse the affect of different routes of administration of furosemide and 
TPA in terms of toxicity and pharmacokinetics.
• To identify any thioether adducts of TPA in vivo or in vitro, and investigate 
whether they are an indication of toxicity or successful detoxification.
The final two experimental chapters describe work conducted to investigate whether 
mercapturates of nevirapine could be used as markers of exposure to nevirapine 
reactive metabolites or whether they indicate successful biowactivation of reactive 
metabolites in an animal model. The aims of this section of work are:
• To test in vitro and in vivo systems for a toxicological end-point of 
nevirapine.
• Assessing the potential for nevirapine mercapturates to be used as in vivo 
markers of bioactivation.
• Understanding pathways of nevirapine metabolism leading to formation of 
reactive metabolite(s).
These investigations using furosemide, TPA and nevirapine aim to test the scalability 
of in vitro, pre-clinical and human systems, and to highlight the difficulties in the 
extrapolation of data to the clinic. The work described here aims to assess the current 
systems for detecting potential human hazard and draws attention to areas in which
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more research and development is required. Some current biomarkers are also used 
as a tool to measure or detect drug induced toxicity and their use in both preclinical 
and clinical settings is evaluated.
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CHAPTER 2
HETEROCYCLIC RING SUBSTITUTION IN FUROSEMIDE: 
INVESTIGATING POTENCY AND IN VITRO AND IN VIVO
TOXICITY.
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2.1 INTRODUCTION
Drug induced liver injury (DILI) is the most frequent reason for the withdrawal of 
newly approved dings and accounts for 50% of cases of acute liver failure and 75% 
of idiosyncratic ADRs result in liver transplantation or death (Lee, 2003). Both furan 
and thiophene groups have been associated with reactive metabolite formation and 
ADRs, including DILI, in humans and pre-clinical species. There are examples of 
dings containing a thiophene group that have been withdrawn from the market due to 
concerns over ADRs in the clinic (Dalvie et al., 2002). Conversely, there are 
examples where these heterocyclic moieties have been used successfully in 
therapeutic compounds and are used safely in the clinic (Michele et al, 2010, 
Perzbom et al, 2011, Chung et al, 2000, O'Callaghan et al, 1976). In vitro and in 
vivo toxicity testing methods are employed during ding development in an effort to 
identify any potential human hepatotoxins and allow rational structural changes to be 
made in order to identify a safer lead candidate compound (Uetrecht, 2003, Evans et 
al, 2004, Peters, 2005).
Furosemide (FS), a potent loop diuretic used safely in humans, has been used as a 
model compound for the investigation of DILI through a bioactivation-mediated 
mechanism in mice (Randle et al, 2008, Masubuchi et al, 2007). Furosemide has 
been shown to produce massive hepatic centrilobular necrosis in mice at 400 mg/kg 
{Ip.) by a mechanism independent of its diuretic action (Mitchell et al, 1974). The 
hepatocellular damage caused by furosemide is postulated to be the result of CYP450 
enzyme-mediated formation of a toxic metabolite that binds covalently with hepatic 
macro molecules both in vitro and in vivo (Mitchell et al, 1974, Mitchell et al, 1976, 
Williams et al, 2007). Bioactivation of the furan ring was demonstrated by the 
characterization of a FS y-ketocarboxylic acid in the rat and mouse in vivo, indicative 
of a reactive epoxide intermediate (Williams et al, 2007). Covalent binding of the 
reactive metabolite to hepatic protein and subsequent hepatotoxicity occurs in the 
mouse but not in rats. In rats, the FS y-ketocarboxylic acid is excreted in the form of 
a GSH conjugate, suggesting a possible safety mechanism exists in the rat to protect 
from furosemide-induced hepatotoxicity (Williams et al, 2007).
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Five-membered aromatic heterocyclic rings are widely distributed in nature and are 
often incorporated into new chemical entities during drug design to increase 
pharmacological selectivity and potency (Dalvie et a!., 2002). These chemical 
moieties are used safely and effectively in some therapeutic agents (Kalgutkar and 
Soglia, 2005). In studies where numerous different chemical substitutions are made 
to a lead compound in order to improve its pharmacological properties and/or replace 
a structural liability, authors have noted improved efficacy with a reduction in 
toxicity where a thiophene ring had replaced the original moiety in the lead 
compound (Brendle et al., 2002, Hagen et al., 2001). During optimization of a novel 
4-hydroxy-5, 6-dihydropyrone, for use against HIV, researchers developed a panel of 
second generation compounds, where the aniline moiety was replaced by a number 
of different moieties (Hagen et al., 2001, Turner et al., 1998). Simple heterocycles 
such as furan and thiophene were prepared with encouraging results; these analogues 
displayed excellent activity against the HIV-1 protease enzyme, with a /fi of 1 nM or 
lower. The thiophene analogue also showed improved antiviral activity (EC50 = 0.12 
//M) albeit with a slight increase in toxicity (TC50 = 91 //M) when compared to the 
lead compound (Table 2.1). The conclusion was that the thiophene compound proved 
superior to the lead compound, displaying excellent antiviral efficacy, low toxicity 
and promising bioavailability across all species tested (Hagen et al., 2001).
Compound Structure
•c* (nM)
HIV Protease
ECj* (pM) 
Infected 
CEM cell 
protection
TC,* (pM) 
Uninfected 
CEM cell 
cytotoxicity
4-hydroxy-5.6-dihydropyrone 0.11 0.2 210
Thiophene Analogue
sS!^L,oh
0.13 0.12 91
Furan Analogue X,- 0.78 0.75 190
Table 2.1: Summary of efficacy and toxicity data of 4-hydroxy-5, 6- 
dihydropyrone analogues. Adapted from Hagen et al, 2001.
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In another study, fiiran and thiophene analogues of the anti-leishmanial drug 
pentamidine were synthesised (Brendle et al., 2002). Although widely used, there are 
many drawbacks with pentamidine; it requires a parenteral route of administration, 
making the treatment both more expensive and less practical in developing nations 
(Sundar et al., 2000). Also, the clinical side effects of the drug include renal and 
hepatic toxicity among others (Berman, 1997). A thiophene analogue of pentamidine 
exhibited the greatest potency, possessing 6.2-fold greater antiparasitic activity than 
pentamidine itself (Table 2.2). This compound was 155-fold more potent against 
Leishmania than against a macrophage cell line (Brendle et al., 2002). The 
pharmacological action of furosemide has been attributed to the inhibition of the 
active reabsorption of Cf ions in the thick ascending limb of the loop of Henle by 
binding the Cl binding site of the Na+/2C17K+ co-transport system (Burg et al., 1973, 
Vree and Van Der Yen, 1999). The inhibitory effect of compounds towards the 
Na+/2C17Kf co-transport system can be assessed in vitro.
Compound Structure
IC5o(pM)
L.donovani Macrophage cell line
Pentamidine
"V^rv0-—____'0V=W‘H
2.59 >100
Furan
Analogue 2.76 26.84
Thiophene
Analogue 0.42 65.3
Table 2.2: Summary of efficacy and toxicity data of pentamidine analogues.
Adapted from Brendle et al, 2002.
The standard regimen for preclinical toxicity assessment investigations are conducted 
in at least two species (one rodent and one non-rodent) at doses many multiples of 
the intended dose in humans (Peters, 2005). A retrospective analysis of concordance 
of preclinical toxicity data with human toxicity data revealed that 70% of human
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toxicities were predicted by preclinical animal studies in one or more species (Olson 
et al, 2000), Although furosemide is safe in man its tendency to cause severe liver 
necrosis in mice would result in a pre-clinical hazard signal and may fail during the 
development process today. In light of the discovery that the furan ring in furosemide 
is the bioactivated moiety responsible for development of hepatotoxicty in the mouse 
(Williams et al, 2007), substitution of the ring for another functional group may 
eliminate or reduce this toxicity.
Measurement of serum alanine aminotransferse (ALT) activity levels in preclinical 
models and in the clinic is the gold standard for assessment of liver damage 
(Amacher, 2002, Ozer et al., 2008). In preclinical models histopathology can be used 
to visualize tissue damage and hepatic GSH levels can be measured to assess whether 
depletion has occurred (Owens and Belcher, 1965). In mice, 24 hours following a 
400 mg/kg dose of furosemide, hisopathological analysis of liver sections show 
severe necrosis of hepatocytes in the midzonal and centralobular areas in 92% of 
animals (Mitchell et al, 1974). Serum ALT levels are also raised significantly 
compared to control at this dose, however, furosemide does not significantly deplete 
hepatic GSH levels (Williams et al, 2007). This is unlike the situation with 
paracetamol (APAP) where, in cases of overdose, the electrophilic intermediate 
NAPQI accumulates and cellular stores of GSH become depleted allowing NAPQI to 
bind covalently to critical proteins (follow et al, 1973, Mitchell et al, 1973a, 
Mitchell et al, 1973b, Potter et al, 1973) resulting in cell death of hepatocytes 
(Antoine et al, 2009, El-Hassan et al, 2003, Jaeschke et al, 2006).
Tienilic acid and suprofen are mechanism based inhibitors of CYP 2C9 and have 
been withdrawn from the market because of hepatotoxicity (Lecoeur et al, 1996, 
O'Donnell et al, 2003). Microsomal assays to assess a compounds ability to inhibit 
P450s are routinely used during the drug development process (Hutzler et al, 2009). 
Although primary cultured hepatocytes have been used extensively as an in vitro 
system for toxicological studies, their use is limited due to the loss in expression of 
specific liver functions including cytochrome P450 (Donato et al, 1994). An 
alternative ex vivo model, which enables the investigation of cytotoxicity in parallel 
with metabolism, is freshly isolated hepatocyte suspensions (Graham et al, 2008, 
Tettey et al, 2001). The data generated from furosemide incubated with freshly
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isolated rat and mouse strongly correlated with the in vivo situation, however, it was 
not predictive of human hazard (Williams et a/., 2007). Furosemide has also been 
shown to undergo NADPH dependant covalent binding to rodent and human 
microsomal protein, providing evidence of bioactivation (Williams et al., 2007).
The aim of this chapter was to assess the pharmacological and toxicological outcome 
of substituting the fiiran ring in furosemide to a thiophene ring (Figure 2.1). It also 
provided a means of testing the two potential liabilities in the same biological 
environment. Specifically, the in vivo toxicity of the two analogues was to be 
compared in terms of serum ALT levels and histopathology. The ability of the two 
compounds to deplete hepatic GSH was also to be assessed. It was also of interest to 
investigate the in vitro efficacy of the two compounds towards the target protein, 
Na+/K+/Cf co-transporter, responsible for the diuretic action of the drug. Finally, the 
chapter aimed to assess the in vitro hazard indications for TPA and compare to those 
of furosemide; bioactivation potential was to be assessed in supplemented 
microsomes (covalent binding) and hepatocytes (covalent binding and cytotoxicity).
A B
Figure 2.1: Chemical structure of furosemide (A) and its thiophene analogue 
(TPA; B). The analogue has been synthesized with a sulphur group replacing the 
oxygen group in the fiiran ring.
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2.2 MATERIALS AND METHODS 
2.2.1 Materials
[!4C]-Thiophene analogue of furosemide (TPA; Specific activity 592 Mbq/mmol), 
and unlabelled TPA was provided by Pfizer (Kent, U.K.) and was determined to be 
>98 % pure by HPLC. The 14C label was incorporated into the carboxyl carbon atom 
of TPA, and thus expected to be incorporated in all major metabolites. lOx Hanks 
Balanced salt solution Ca2+ was obtained from Gibco (Invitrogen Ltd, Paisley, U.K.). 
CellTiter 96® AQueous One Solution Cell Proliferation Assay kit was obtained from 
Promega (Southampton, U.K.). Collagenase A was obtained from Roche Diagnostics 
(Lewes, U.K.). Unless otherwise stated, reagents were obtained from Sigma-Aldrich 
Chemical Co. (Poole, U.K.). Ultima Gold scintillation fluid was purchased from 
PerkinElmer LAS (Seer Green, Beaconsfield, Buckinghamshire, U.K.). All solvents 
were of HPLC grade and were products of either Fischer Scientific pic 
(Loughborough, U.K.) or VWR (Lutterworth, U.K.)
2.2.2 Experimental Animals
Protocols described were undertaken in accordance with criteria outlined in a license 
granted under the Animals (Scientific Procedures) Act 1986 and approved by the 
University of Liverpool Animal Ethics Committee. Male Wistar rats and male CD-I 
mice were obtained from Charles River Laboratories (Margate, U.K) housed in a 
light-controlled room at a constant temperature, and supplied with a standard chow 
diet and water ad libitum.
2.2.3 Inhibitory effect of furosemide and TPA towards the Na+/K+/Cf co­
transporter
The effects of furosemide and TPA were investigated in an in vitro Na+/K+/CF 
cotransporter assay (Chassande et a!., 1988). The assay was earned out by Cerep (Le 
Bois 1’Eveque, B.P. 30001, 86 600, Celle PEvescault, France). The results are 
expressed as a percent of control specific activity ((measured specific activity/control
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specific activity) xlOO) obtained in the presence of furosemide and TP A. The IC50 
values (concentration causing a half-maximal inhibition of control specific activity) 
and Hill coefficients (nH) were determined by non-linear regression analysis of the 
inhibition curves generated with mean replicate values using Hill equation curve 
fitting (Y = D + [(A - D)/(l + (C/C50)nH)], where Y = specific activity, D = 
minimum specific activity, A = maximum specific activity, C = compound 
concentration, C50 = IC50 and nH = slope factor). This analysis was performed using 
software developed at Cerep (Hill software) and validated by comparison with data 
generated by the commercial software SigmaPlot© 4.0 for Windows® (© 1997 by 
SPSS Inc.).
2.2.4 Inhibitory effect of furosemide and TPA towards CYP 2C9 in human 
liver microsomes
CYP 2C9 in human liver microsomes (HLM) was assayed for residual activity with 
probe substrate (diclofenac), after a primary incubation with various concentrations 
of furosemide, TPA and tienilic acid as a positive control (0.5% total organic v/v) in 
duplicate in a 96-well plate format at 37°C. Incubations consisted of HLM (0.3mg/ml 
in primary incubation) in 100 mM potassium phosphate buffer (pH 7.4) with a 
NADPH-regenerating system (3 mM MgCb, 1 mM, NADP+, 5 mM isocitric acid, 
and 1 unit/ml iso citrate dehydrogenase). At 0 and 15 minutes aliquots were taken out 
of the primary incubation mixture and transferred into 200 pi of a secondary 
incubation mixture containing diclofenac at 25 pM, a concentration 3 times the 
apparent Tfm for each reaction, to measure residual activity. The 20-fold dilution and 
saturating concentration of probe substrate in the secondary incubation served to 
minimize competitive inhibition and any further inactivation. Secondary incubations 
(6 minutes) were quenched with 400 pi of cold acetonitrile containing an internal 
standard (200 ng/ml 13C6 4-OH diclofenac). Plates were then centrifuged at 3000g 
for 10 minutes and metabolite formation was analyzed by LC-MS/MS using an AB 
Sciex API-4000 (AB Sciex, Foster City, CA, U.S.A). Mass spectral analyses were 
performed using multiple reaction monitoring, with transitions for diclofenac (m/z
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293.9/249.7), 4-hydroxydiclofenac (m/z 309.9 3 265.8), and 13C6 4-OH diclofenac 
(w/z 315.0/272.0).
2.2.5 Preparation of rat and mouse liver microsomes
Rat liver microsomes (RLM) and mouse liver microsomes (MLM) were prepared as 
described previously (Gill et al., 1995). Adult male Wistar rats or male CD-I mice 
were killed by asphyxiation with CO2. Livers were excised into ice-cold 0.067 M 
phosphate buffer, pH 7.4, containing 1.15% (w/v) KCL. After rinsing, any 
extraneous tissue was removed. The livers were roughly chopped with a pair of 
scissors and homogenised initially with three passes of a motor-driven homogeniser 
(Kinematica Polytron PT 3000, Phillip Harris, Manchester, UK), and subsequently 
homogenised with a manual tissue homogeniser. This was followed by centrifugation 
(Optima L-60 preparative ultra centrifuge and Ti55 rotor; Backman, High Wycombe, 
Buckinghamshire) at 10,000g for 25 minutes at 4°C to remove cellular debris (nuclei, 
cell membranes and mitochondria). The resulting supernatant was centrifuged at 
105,000g for 65 minutes at 4°C to sediment the microsomes. The microsomal pellet 
was then resuspended in phosphate buffer containing KCL and centrifuged at 
105,000g for 65 minutes at 4°C. The supernatant was discarded and the microsomal 
pellet resuspended in phosphate buffer minus KCL.
2.2.6 Determination of cytochrome P450 activity of liver microsomes
The protein content of the microsomes was measured by the Lowry assay (Lowry et 
al, 1951) where bovine serum albumin (BSA) was used as a standard. Cytochrome 
P450 content was determined by the difference spectroscopy method of Omura and 
Sato, (1964). Microsomal suspensions were diluted in phosphate buffer (minus KCL) 
to 1 mg/ml. A few grains of solid sodium dithionate were added to both sample and 
reference mixtures with gentle mixing. The sample only was bubbled with carbon 
monoxide (1 bubble/sec) for one minute. Quantitative determination of the 
haemoprotein was then made using an extinction coefficient for the wavelength 
couple 450 - 490 of 91 mM/cm.
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2.2.7 TPA incubations with RLM and MLM
[14C]-TPA (0.1 jaM) was incubated with MLM (1 mg/ml) and RLM (1-2 mg/ml), in 
the presence or absence of NADPH (1 inM) and in the presence or absence of GSH 
(0.1 pM), at 37°C for 1 hour. The reaction was terminated by addition of 1 ml ice- 
cold ACN.
2.2.8 Hepatocyte isolation from male Wistar rats and CD-I mice
Rat and mouse hepatocytes were isolated using a modified two-step in situ 
collagenase perfusion technique based on the method of Seglen, (1976). Male Wistar 
rats (150-170 g) and male CD-I mice (20-30 g) were anesthetized with sodium 
pentobarbital (60 mg/ml, 1 pl/g i.p.). The hepatic portal vein was cannulated, and the 
liver was perfused for 7 minutes at a constant flow rate of 12 ml/min for mice and 40 
ml/min for rats, with a wash buffer containing Hanks’ balanced salt solution (from 
10X stock: magnesium chloride, magnesium sulfate, sodium bicarbonate; Invitrogen, 
Paisley, UK). Wash buffer was also supplemented with 5.8 mM HEPES and 4.5 mM 
NaHCOa. The wash step was followed by a collagenase perfusion using wash buffer 
supplemented with 5 mM CaCL, 0.5 mg/ml collagenase A (Roche Applied Science, 
Indianapolis, IN), and 0.072 mg/ml trypsin inhibitor until the liver constitute had 
been digested. All wash and digestion solutions were kept at 37°C throughout the 
perfusion. After in situ digestion, the liver was excised, and the liver capsule was 
removed to release parenchymal and nonparenchymal cells. The cells were 
suspended in 50 ml of wash buffer supplemented with DNase I (0.1 mg/ml) and 
filtered through a 125 pm mesh (Lockertex, Cheshire, UK). Cell suspensions were 
immediately centrifuged at 30g- for 2 minutes, the resulting supernatant containing 
nonparenchymal cells was removed, and the cells were resuspended in wash buffer 
containing DNase I. This centrifuge step was repeated twice at 50g- with wash buffer 
alone. The cells were resuspended in an incubation buffer (wash buffer supplemented 
with 1 mM MgS04.7H20). Hepatocyte viability was assessed by trypan blue 
exclusion and only used when viability was above 80%. Experimental hepatocyte 
incubations contained a total volume of 6 ml at a cell concentration of 2x106 viable 
cells/ml.
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2.2.9 Assessment of TPA-induced cytotoxicity in freshly isolated rodent 
hepatocytes
Hepatocyte incubations were carried out in an orbital shaker set at 190 rpm for 6 
hours with TP A [0-1.5 mM in MeOH (0.8% v/v) and 0.1 pCi of [14C]-TPA in 
ethanol]. Following incubation, cytotoxicity was determined by trypan blue 
exclusion (100 pi of cell suspension and 20 pi of 0.4% trypan blue solution). 
Cytotoxicity was also determined by reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyl tetrazolium bromide (MTS) solution using the CellTiter 96® AQueous One 
Solution Cell Proliferation Assay kit (Promega, Southampton, UK), according to the 
manufacturer’s instructions. Cell suspension (100 pi) was combined with MTS 
solution (20 pi), incubated at 37°C for 1 hour, and centrifuged at 50g for 2 minutes, 
this was performed in triplicate. The absorbance of the resulting supernatant was 
measured at 490 nm using a microtiterplate reader (Dynex Technologies, Chantilly, 
VA).
2.2.10 Determination of levels of covalent binding in primary rodent 
hepatocytes and microsomes by exhaustive solvent extraction
The microsome incubation mixture (1 ml) or remaining portion of the hepatocyte 
incubation (after cytotoxicity and GSH assessment; 4.6 ml) was placed in an equal 
volume of ice-cold ACN and centrifuged at 880# for 10 minutes. A 100 pi aliquot of 
supernatant was added to 4 ml scintillation fluid (Ultima Gold) and counted in a 
Beckman LSI801 Liquid scintillation counter with external standardisation for 1 
min. The remaining supernatant was evaporated under a steady stream of N2 in a 
50°C water bath. The residue was reconstituted in 300 pi 50% MeOH for HPLC- 
radiochromatographic and LC-MS analysis. The protein pellet from the 880g spin 
was used to determine the levels of [14C]-TPA covalently bound to the 
hepatocyte/microsomal protein. Covalent binding was determined by an exhaustive 
solvent extraction procedure using 70% methanol as described previously 
(Pirmohamed et al, 1995). 5 ml or 3 ml of 100% MeOH was added to either the 
pellet from hepatocytes or microsomes respectively, vortexed and then centrifuged 
for 10 minutes at 2200 rpm. The above wash step was repeated twice more with 70% 
(v/v) MeOH. After each extraction step a 100 pi aliquot of the supernatant was added
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to 4 ml scintillation fluid (Ultima Gold) and counted in a Beckman LSI801 Liquid 
scintillation counter with external standardisation for 1 minute, to ensure that all non- 
covalently bound material had been removed. The remaining supernatant was 
discarded. Following the final extraction, the protein was dissolved in 1 ml of 1 M 
NaOH at 60°C. Aliquots of the solubilized protein were taken for quantification of 
radioactivity by liquid scintillation counting and normalized to protein concentration.
2.2.11 Sample preparation for the determination of GSH levels in primary 
rodent hepatocytes
From the same incubations used for cytotoxicity assessment, the effect of TPA on 
total cellular levels of GSH was determined. Cells (2x106) from the hepatocyte 
incubation were centrifuged at 50# for 2 minutes. The resulting pellet was 
resuspended in 10 mM HC1. One-fifth of lysed hepatocytes were removed for protein 
content determination. The remaining hepatocyte lysate was combined with 6.5% 
(w/v) 5-sulfosalicylic acid (four parts hepatocyte lysate and one part 5-sulfosalicylic 
acid) and stored on ice for 10 minutes before centrifugation at 18,400g for 5 minutes.
2.2.12 Dosing regimen for in vivo furosemide and TPA toxicity investigation
Male CD-I mice (22-24 g) and male Wistar rats (125-149 g) were administered 
either furosemide or TPA [1.21 mmol/kg in PEG; n=4 per group] either orally or via 
an i.p. dose. After 1, 3, 6 and 24 hours the animals were culled by CO2 asphyxiation. 
Blood was taken via cardiac puncture and the livers were removed, snap frozen in 
liquid N2 and stored at -80°C until analysis.
2.2.13 Measurement of alanine transaminase (ALT) activity in serum
Serum alanine transaminase (ALT) levels were determined kinetically at 37°C using 
ThermoTrace Infinity ALT Liquid stable reagent (Alpha Labs, Eastleigh, U.K) 
according to manufacturer’s instructions. ALT levels exceeding 200 U/L that were
64
Chapter 2: Heterocyclic ring substitution in furosemide: potency and toxicity
significantly different from controls were considered to represent hepatotoxicity 
(Kitteringham et ai, 2000).
2.2.14 Histopathological analysis of liver sections from furosemide and TPA 
treated male CD-I mice
At each time point (1, 3, 6 and 24 hours) after administration of either furosemide or 
TPA [1.21 mmol/kg in PEG; n=4 per group] either orally or via an i.p. dose, liver 
sections were taken from the left lateral lobe left and fixed in formalin (Sigma, UK).
Preparation of histology sections
Histology was performed in collaboration with Prof. Anja Kipar from the 
Department of Veterinary Pathology, University of Liverpool. Slices (3-4 mm) of the 
major lobe of the liver were immersed in neutral buffered formalin (10%) for 24 
hours until analysis. A transverse section was taken from the formalin fixed samples, 
which was placed cut side down into a pre-labelled biopsy cassette. Samples were 
processed using a tissue processor. The tissue processor removes water from the 
tissues and replaces it with paraffin wax which solidifies tissue and enables it to be 
cut. Briefly, the samples were dehydrated with a series of increasing concentrations 
of ethanol to remove free and bound water. The samples were then submersed and 
washed in xylene which removes the ethanol. The tissues were then removed from 
their cassette and embedded into a mould of molten paraffin wax with the trimmed 
side down. The cassette was then placed on top of the mould and topped up with wax 
and allowed to solidify. After solidification, excess wax was trimmed ready for 
sectioning.
Hepatic tissue sectioning
Embedded tissues were trimmed to expose all the tissue then cooled on ice. Several 
thin sections were cut to remove any areas of rough tissue. A fresh blade was used to 
cut 4 pm sections and floated onto a clean water bath (45°C) to remove creases. The
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sections were retrieved with a charged microscope slide and allowed to dry in an 
oven.
Hematoxylin and eosm staining of hepatic sections
Sections were double stained with the application of the basic dye hematoxylin, 
which colours basophilic structures with a blue-purple hue and an alcohol-based 
acidic eosin, which stains eosinophilic structures pink. In brief, sections were 
initially submerged in xylene (5 minutes) to remove the wax and then transferred to 
another xylene. The sections were then taken down through descending grades of 
EtOH (100%, 96%, 85%, 70%) to distilled H2O. They were then stained with 
hematoxylin (5 minutes) before being rinsed in running tap water (6 minutes). The 
sections were then stained with eosin (2 minutes) before being washed three times in 
96% EtOH (1 minute). Finally the sections underwent three further washes in 100% 
EtOH, followed by two washes in xylene. The slides were then cover slipped using 
DPX.
2.2.15 Determination of hepatic GSH levels in male Wistar rats and CD-I mice
The glutathione (GSH) assay is based upon the 5, 5-dithiobis (2-nitrobenzoic acid)- 
GSH disulfate recycling procedure first reported by Owens and Belcher (Owens and 
Belcher, 1965). The recycling assay for total GSH equivalents is based upon the 
reactions shown below (Anderson ME., 1985):
2GSH + DTNB ^ GSSG + TNB (1)
GSSG + NADPH + H+ 2GSH + NADP+ (2)
Reduced GSH is oxidized by DTNB to give glutathione disulphide (GSSG) with 
stoichiometric formation of 5-thio-2-nitrobenzoic acid (TNB) (1). GSSG is reduced 
to GSH by the action of the highly specific glutathione reductase enzyme (GSSG 
reductase) and NADPH (2). The rate of TNB formation is followed at 405 nm (or 
412 nm) and is proportional to the sum of GSH and GSSG present.
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Total hepatic GSH (GSH + GSSG) levels were determined spectrophotometrically 
using a microtiter plate assay (Vandeputte et af., 1994). Total hepatic GSH was 
determined for animals administered furosemide and TP A (1.21 mmol/kg) over 1,3, 
6 and 24 hours. In brief, 30-50 mg of liver tissue from the left lobe was homogenized 
in 200 pi 5-sulphosalicylic acid (6.5% (w/v)) and 800 pi stock buffer (143 mM 
NaH2P04, 6.3 mM BDTA, pH 7.4) using ten passes of a glass Teflon homogenizer. 
The protein was allowed to precipitate on ice for 10 minutes before centrifugation at 
14000 rpm for 5 minutes. Supernatants were stored at -80 °C prior to analysis. The 
pellets were resuspended in 1 ml NaOH (1 M) by warming at 60 °C for 1 hour. 
Protein levels were determined as described in section 2.2.16. The supernatants were 
used to determine the total GSH content. 20 pi of sample or GSH standard (0 - 80 
nmol/ml) was added to a 96-well plate followed by 20 pi stock buffer to neutralize 
the pH. 200 pi of assay reagent (1 mM DTNB, 0.34 mM NADPH in 143 mM 
NaH2P04, 6.3 mM EDTA, pH 7.4) was added to each well. The plate was incubated 
at room temperature for 5 minutes. The enzymatic reaction was initiated by the 
addition of 50 pi of GSH reductase (6.96 U/ml). Total GSH was followed kinetically 
at 412 nm for 2.5 minutes (MRX microplate reader with Max Revelation 3.04 
software, Dynotech laboratories, Billinghirst, West Sussex, U.K.). The same assay 
was used for samples from hepatocyte incubations (section 2.2.11)
2.2.16 Determination of protein concentration
Soluble protein concentration was measured using an assay adapted from Lowry et 
al. (1951). The method combines the reactions of cupric ions with the peptide bonds 
under alkaline conditions with the oxidation of aromatic protein residues. The Lowry 
method is based on the reaction of Cu+, produced by the oxidation of peptide bonds, 
with Folin-Ciocalteu Phenol reagent (a mixture of phosphotungstic acid and 
phosphomolybdic acid) in the Folin-Ciocalteu reaction (Lowry et a!., 1951). The 
reaction involves reduction of the Folin reagent by the copper treated protein, 
resulting in differential colour intensity depending on the amount of protein present.
Concentrations were calculated by reference to a BSA standard curve (0 - 200 pg/ml 
in 0.5 M NaOH). Samples (from hepatocytes, microsomes and tissue from in vivo
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experiments) were diluted to fit onto the concentration curve. In a 96-well plate (flat- 
bottom, clear), 50 pi of Lowry reagent (0.5 ml 1% CuS04.5H20, 0.5 ml 2% NaK 
Tartarte, 10 ml Na2C03 in 0.5 M NaOH) was added to 50 pi standard or sample and 
incubated for 15 minutes at room temperature. Subsequently 150 pi of Folin- 
Ciocalteu Phenol reagent (diluted 1 in 10 with dH20) is added to each well and 
incubated for 30 minutes at room temperature before reading the absorbance at 750 
nm (MRX microplate reader with Max Revelation 3.04 software, Dynotech 
laboratories, Billinghirst, West Sussex, U.K.).
2.2.17 Statistical analysis
All results were expressed as mean + standard deviation. Data sets were analysed for 
normality using the Shapiro-Wilk test. Where multiple comparisons were made and 
the data was normally distributed, one-way ANOVA was used with bonferroni 
correction. Where multiple comparisons were made and the data was not normally 
distributed, a Kruskal-Wallis test, for all pah-wise comparisons, was used with either 
Conover-Inman or Dwass-Steel-Chritchlow-Fligner corrections for multiple 
comparisons. All statistical analysis was performed using the StatsDirect statistical 
software.
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2.3 RESULTS
2.3.1 Inhibitory effect of furosemide and TPA towards the Na+/K+/Cf co­
transporter
Furosemide is a potent loop diuretic which reduces water reabsorption by inhibiting 
the Na+/K+/CT cotransporter in the thick ascending limb of the loop of Henle in the 
kidney. The inhibitory effect of furosemide and TPA towards the Na+/K+/Cf 
cotransporter was assessed with bumetanide included as a positive control. TPA was 
shown to be three times more potent than furosemide with IC5o values at 17 pM and 
50 pM respectively (Figure 2.2).
q NaVKVcr cotransport Inhibitor ICso (pM) nH
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Figure 2.2: The inhibitory effect of furosemide (UK-015115; A) and TPA (PF- 
00233088-00; B) towards the Na+/K+/CT cotransporter. The results are expressed 
as a percent of control specific activity ((measured specific activity/control specific 
activity) x 100) obtained in the presence of furosemide and TPA. Table C shows IC50 
and Hill coefficients (nH) of furosemide, TPA and positive control, Bumetanide. 
Adapted from Cerep report
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2.3.2 Inhibitory effect of furosemide and TPA towards CYP 2C9 in human 
liver microsomes
Assays to assess a compounds ability to inhibit P450 enzymess are routinely used 
during the drug development process. Neither furosemide nor TPA inhibited CYP 
2C9 however tienilic acid (TA) displays inactivation of CYP 2C9 through dose- 
dependent decrease in diclofenac turnover to 4-hydroxydiclofenac (Figure 2.3).
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Figure 2.3: Inactivation of CYP 2C9 by furosemide, TPA and TA in HLM. TA
displays dose-dependent inactivation of CYP 2C9 (A), fnrosemide (B) and TPA (C) 
have no effect on CYP 2C9 enzyme activity. Data expressed at mean + standard 
deviation.
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2.3.3 In vitro bioactivation of TPA in CD-I mouse liver microsomes and 
Wistar rat liver microsomes
Covalent binding was measured as an indication of bioactivation of TPA. 
Furosemide has previously been shown to undergo bioactivation in mouse, rat and 
human microsomes (Williams et al., 2007). Significant covalent binding of 
radiolabelled TPA to microsomal protein was observed in CD-I mouse and Wistar 
rat liver microsomes in the presence of NADPH. Inclusion of GSH in these 
incubations significantly reduced levels of covalent binding (Figure 2.4).
140
o> 100 -
Figure 2.4: Determination of the extent of TPA bioactivation. Covalent binding 
of [l4C]-TPA (O.l pCi) incubated with (A) RLM (1-2 mg/ml) and (B) MLM (1 
mg/ml), in the presence or absence of NADPH (1 mM) and in the presence or 
absence of GSH (0.1 mM), at 37°C for 1 hour. Data are expressed as mean + 
standard deviation. RLM n=5; ** p < 0.005, * p < 0.025 using one-way ANOVA 
with Bonferroni correction for multiple comparisons (critical p = 0.025). MLM n=3: 
*** p < 0.001, * p < 0.05 using Kruskal-Wallis all pairwise comparisons (Conover- 
Inman).
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2.3.4 Cytotoxicity of TPA towards primary Wistar rat and CD-I mouse 
hepatocytes
A dose-dependent increase in cytotoxicity and GSH depletion was observed in rat 
hepatocytes incubated with TPA (Figure 2.5 A and B). Dose-dependent GSH 
depletion occurred at lower doses than cytotoxicity. TPA displayed a dose-dependent 
increase in cytotoxicity and covalent binding when incubated with mouse 
hepatocytes which was not associated with a decrease in GSH levels (Figure 2.5 C 
and D).
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Figure 2.5: Effect of TPA (0 - 1.5 mM + [,4C]-TPA (10 pCi); 6 hours) on 
cytotoxicity, GSH content and covalent binding in Wistar rat (A and B) and CD-I 
mouse (C and D) hepatocytes. Data are given as mean + STDEV of 4 to 7 
independent isolations. Rat hepatocytes; ***; p<0.00014, **; p<0.0014, *; p<0.0071, 
comparing to 0 mM TPA incubations (one-way ANOVA with bonferroni correction 
for multiple comparisons, critical p<0.0071). Mouse hepatocytes; ***; pO.001, **; 
p<0.01, *; p<0.05, comparing to 0 mM TPA incubations (Kruskal-Wallis test all 
pair-wise comparisons (Dwass-Steel-Chritchlow-Fligner)).
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2.3.5 Investigation of the hepatotoxicity of furosemide and TPA in the mouse 
and rat, dosed either orally or via an Lp injection.
Serum ALT activity levels were measured as an indicator of hepatic damage. 
Administration of furosemide (1.21 mmol/kg in PEG, Lp.) to male CD-I mice caused 
a significant increase in ALTs of 2742.8 ± 1889.6 U/L, whereas mice administered 
TPA experienced ALT levels of 202.4 ± 141.9 U/L at the same dose, after 24 hours 
(Figure 2.6 A).
Neither furosemide nor TPA (1.21 mmol/kg in PEG) caused an increase of serum 
ALT levels over 100 U/L when administered to male CD-I mice orally (Figure 2.6 
B). In the male Wistar rat neither furosemide nor TPA (1.21 mmol/kg in PEG) caused 
an increase in serum ALT levels over 100 U/L when administered by either oral or 
i.p routes (Figure 2.7 A and B).
Flistological analysis was performed on liver sections from control, furosemide and 
TPA treated male CD-I mice (1.21 mmol/kg in PEG; Lp.), after 24 hours, in order to 
confirm the increase in serum ALT levels was in fact due to hepatic injury. The 
histological findings correlated with the serological evidence; liver sections from the 
male CD-I mouse, at 24 hours post i.p. administration of furosemide (1.21 mmol/kg 
in PEG), exhibited centre lobular coagulative necrosis of hepatocytes (Figure 2.8 B; 
arrows). No drug related pathological changes were observed in liver sections from 
animals from the control and TPA treated groups.
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Figure 2.6: The effect of furosemide and TPA on serum ALT levels when 
administered either orally or by Lp injection to mice. Serum ALT levels after 1, 3, 
6 and 24 hour administration of furosemide and TPA (1.21 mmol/kg in PEG) to male 
CD-I mice either by i.p injection (A) or orally (B). N=3-7; *** p<0.001, ** p < 0.01 
Kruskal-Wallis test using all pairwise comparisons (Conover-Inman).
0 3 6 24 0 3 6 24
Time (Hours)
Figure 2.7: The effect of furosemide and TPA on serum ALT levels when 
administered to male Wistar rat. Serum ALT levels after 1, 3, 6 and 24 hour 
administration of furosemide and TPA (1.21 mmol/kg in PEG) to male Wistar rats i.p. 
(A) and p.o. (B).
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Figure 2.8: Histological analysis of liver sections 24 hours post furosemide and 
TPA treatment to male CD-I mice. Haematoxylin-eosin (HE) staining of liver 
sections from male CD-I mice treated with (A) Vehicle shows the liver does not 
exhibit any pathological change, (B) furosemide (1.21 mmol/kg in PEG; /'./?.) shows 
the liver exhibits centrilobular coagulative necrosis of hepatocytes (arrows) and (C) 
TPA (1.21 mmol/kg in PEG) where the liver does not exhibit any significant drug 
related pathological changes. CV - central vein.
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2.3.6 Effect of furosemide and TPA on hepatic GSH content in vivo.
At each time point, after administration of either furosemide or TPA by either ROA, 
liver sections were taken from the left lateral lobe and reserved to determine hepatic 
GSH content. GSH was significantly depleted in the mouse after 24 hours following 
administration of TPA, but not turosemide, (1.21mmol/kg in PEG, /'./?; Figure 2.9).
A
1 3
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Figure 2.9: The effect of furosemide and TPA on hepatic GSH levels when 
administered Lp. in mice. (A) Hepatic GSH levels after 0, 1, 3, 6 and 24 hour 
administration of furosemide or TPA (1.21 mmol/kg in PEG; /'./?.) to male CD-I mice. 
(B) Spread of data points at 24 hours. Data is expressed as mean + standard 
deviation. n=3; * p < 0.05 using Kruskal-Wallis all pairwise comparisons (Conover- 
Inman).
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2.4 DISCUSSION
The investigations described in this chapter aimed to assess the pharmacological and 
toxicological outcome of substituting the fiiran ring in fiirosemide with a thiophene 
ring. It also aimed at assessing the two potentially toxic moieties in the same 
biological environment. In an in vitro assay the inhibitory effect of TPA was 
discovered to be three times more potent towards the Na+/K+/Cl‘ cotransporter than 
fiirosemide. Inclusion of a thiophene ring in a lead compound for improved 
pharmacological and toxicological properties has been tested previously for the HIV 
protease inhibitor 4-hydroxy-5, 6-dihydropyone (Hagen et al., 2001, Turner et al., 
1998) and the anti-leishmanial drug pentamidine (Brendle et al., 2002). In both cases 
the thiophene ring substituted compound displayed improved potency while retaining 
a good safety profile. Despite evidence that the thiophene ring can improve 
pharmacological and toxicological profile of compounds, there are many examples 
where the thiophene ring has itself been the structural liability in a compound. The 
thiophene containing drug, tienilic acid (TA) undergoes bioactivation to an £-oxide 
which forms an adduct with CYP2C9 (the enzyme responsible for its formation) via 
an alkylation reaction (Lecoeur et aL, 1994). 1 in 10,000 patients taking TA suffered 
from auto-immune hepatitis (Dansette et al., 1991), an immune-mediated 
idiosyncratic ADR. Another outcome of this bio activation is that TA is a mechanism 
based inhibitor of CYP 2C9 and so has the potential to increase the levels of co­
administered compounds that are also CYP 2C9 substrates. This can be particularly 
important if the co-administered drug has a narrow therapeutic window (e.g. S- 
warfarin). Thus, it would be important when adding a thiophene moiety into a new 
compound to check that the compound is not a mechanism based inhibitor of CYP 
2C9. In the present study TA (positive control) was shown to be an inhibitor of CYP 
2C9 that became more potent following a 15 minute pre-incubation period as judged 
by an increased ability to prevent formation of 4-OH diclofenac. No such mechanism 
based inhibition of CYP 2C9 was seen with either furosemide or TPA.
Furosemide has previously been shown to undergo covalent binding to microsomal 
protein in NADPH supplemented mouse, rat and human micrcosomes indicating that 
furosemide is bioactivated (Williams et al., 2007). Rodent liver microsomes were 
used to assess the potential of TPA to be bio activated and covalently bind to
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microsomal protein. Significant covalent binding of radiolabelled TPA to 
microsomal protein was observed in CD-I mouse and Wistar rat liver microsomes in 
the presence of NADPH. Inclusion of GSH in these incubations significantly reduced 
levels of covalent binding. Samples from microsomes were analysed by HPLC and 
mass spectrometry, but no metabolites could be identified. Thiophenes can be 
bioactivated to either reactive epoxide intermediates or thiophene S-oxides 
(Kalgutkar et ai, 2005). Thiophenes can undergo P450 mediated hydroxylation to 2- 
and 5- hydroxythiophene and oxidation to a reactive thiophene S-oxide ( Mansuy et 
ai, 1991a, Mansuy, 1991b, Dansette et ah, 1992), proved by the identification of 
thiophenes S-oxide dimers in in vitro and in vivo studies of thiophene (Treiber et at., 
1997). Studies with the 2-aroylthiophene-containing NS AID, suprofen, provides 
evidence that the thiophene ring could potentially undergo bioactivation to an 
epoxide. Incubations of suprofen with NADPH and semicarbazide, trapped a 
pyridazine derivative, suggesting initial epoxidation of the thiophene ring (O'Donnell 
et a!., 2003).
Freshly isolated rodent hepatocytes were used to assess the cytotoxicity and 
metabolism (Chapter 4) of TPA in the same test system. In mouse hepatocytes, 
furosemide caused a significant, dose- and time-dependent decrease in cell viability 
and, similar to the in vivo situation, there was no decrease in GSH levels (Williams et 
ai, 2007). TPA caused a dose-dependent decrease in cell viability in freshly isolated 
mouse hepatocytes, with no decrease in the levels of GSH. In vivo, it was shown that 
TPA only caused a significant decrease in hepatic GSH after 24 hours; in the freshly 
isolated hepatocyte model, it may be that an incubation time of 6 hours was not 
enough to deplete GSH to the same degree. Alternatively, the bioactivation product 
of TPA might preferentially bind to protein in this system, indeed the levels of 
covalent binding significantly increased in a dose-dependent manner. Although 
furosemide did not elicit hepatotoxicity or deplete hepatic GSH levels in the rat in 
vivo, in freshly isolated rat hepatocytes furosemide displayed dose- and time- 
dependent cytotoxicity and GSH depletion (Williams et al, 2007). The same was 
observed for TPA; although it did not elicit acute toxicity in rats in vivo, in freshly 
isolated rat hepatocytes, a dose-dependent decrease in cell viability and GSH content 
was observed. In vivo TPA may undergo detoxification through conjugation with
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GSH and be cleared fi'om the system and not covalently bind to hepatic protein or 
elicit toxicity. In isolated hepatocytes in suspension, TPA may deplete the finite pool 
of GSH in hepatocytes which could lead to cell death. Furthermore, unlike a whole 
animal system, TPA and metabolites cannot be eliminated from the suspension.
In concordance with previous studies, we have demonstrated that furosemide causes 
hepatic necrosis in mice (Mitchell et al, 1974, Williams et al., 2007, Wong el al, 
2000). Liver injury was assessed by the measurement of serum ALT activity levels at 
time points after furosemide administration and histological examination at 24 hours 
confirmed the serological evidence. It has been shown previously that the level of 
furosemide covalent binding to liver proteins coincides with increased ALT levels in 
the mouse at an Ip. dose of 1.21 mmol/kg (Williams et al, 2007). However, when 
furosemide is administered at the same dose via the oral route, no significant increase 
in serum ALT activity levels are observed. This suggests that, in addition to 
bioactivation and covalent binding, liver accumulation of furosemide may be 
required for induction of hepatotoxicity. This observation is supported by a study 
linking covalent binding and development of liver necrosis in the mouse, with 
inhibition of biliary excretion of furosemide following a large dose of furosemide or 
pretreatment with sulfobromophathlein (Spitznagle et al, 1977).
TPA, despite only a one atom difference from furosemide, induced no hepatotoxicity 
in either rats or mice {i.p. or p.o.) and the histological analysis of livers from mice 
treated with TPA (1.21 mmol/kg i.p.) after 24 hours confirms this. In previous work 
there was no evidence of TPA covalently binding to liver proteins to a significant 
degree in vivo (Butler, 2006). In agreement with more recent reports (Williams et al, 
2007), furosemide failed to elicit a hepatotoxic response in rats in these 
investigations. Lagarriga et al (1977) demonstrated toxicity of furosemide (1.21 
mmol/kg) in rats following a pre-dose of phenobarbital, a CYP P450 inducer. 
Phenobarbital has been shown to increase acetaminophen (APAP)-mediated 
hepatotoxicity in cultured human hepatocytes by inhibition of uridine 5’- 
diphosphate-gluccuronosyltransferases (UGTs) and therefore blocking the 
detoxifying glucuronidation pathway of APAP (Kostrubsky et al, 2005). The 
furosemide-induced toxicity observed in rats in the work by Lagarriga et al (1977) 
may be due to induction of CYP 2B and 2C enzymes by leading to relatively higher
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degree of oxidative metabolism, bioactivation and covalent binding. An alternative 
explanation may be that inhibition of UGTs by phenobarbital may inhibit 
glucuronidation, leading to a higher level of bio activation to a reactive metabolite.
In concordance with previously published data, it was found that lurosemide (1.21 
mmol/kg i.p) did not significantly deplete hepatic GSH levels in either rats or mice hi 
vivo (Mitchell et ah, 1974, Williams et aL, 2007, Wong et al., 2000). This suggests 
that in the mouse, the reactive metabolite furosemide covalently binds preferentially 
to hepatic proteins rather than binding to hepatic GSH and subsequently induces 
toxicity. This is in contrast to other hepatotoxins such as APAP where GSH 
depletion greater that 90% is required before APAP can covalently bind to hepatic 
proteins and induce hepatotoxicity (Davis et al, 1974). Conversely TP A (1.21 
mmol/kg ip) caused a small but statistically significantly depletetion of hepatic GSH 
levels compared to control at 24 hours. Despite this GSH depletion, there was 
minimal evidence of ALT elevation and the livers were histologically normal. 
Possible explanations of the differences in GSH depletion include TPA being a better 
substrate for glutathione transferases (GSTs) compared to furosemide and so more 
GSH conjugation is taking place leading to significant GSH depletion. Equally, more 
than one GSH conjugate could be formed compared to the one FS-GSH conjugate 
identified in previous studies (Williams et al, 2007).
In light of the fact that furosemide causes liver necrosis in mice in vivo, as well as a 
number of in vitro hazard signals, the aims of this chapter were to investigate the 
effect of substituting the fiiran ring in furosemide with a thiophene ring, on the 
pharmacological and toxicological profile of the compound. TPA was shown to be 
three times more potent towards the Na+/K+/Cf cotransporter than furosemide, with 
IC50 values of 17 pM and 50 pM respectively. TPA displayed an improved safety 
profile in vivo in terms of serum ALT activity levels compared to furosemide (237.3 
and 4441.4 U/L respectively, 1.21 mmol/kg i.p for 24 hours). However, in in vitro 
systems, rodent liver microsomes and freshly isolated hepatocytes, the two analogues 
were comparable in tenns of cytotoxicity, GSH depletion and covalent binding 
hazard signals. The work in this chapter provided evidence that the novel thiophene 
analogue of furosemide underwent bioactivation, and that the reactive metabolite(s) 
produced can covalently bind to hepatic protem in vitro. It was shown that the degree
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of covalent binding could be reduced with the inclusion of GSH in microsomal 
incubations. Investigating the pharmacokinetics and metabolism of TPA in vitro and 
in vivo may provide a rationale for the differences in the toxicological profile of 
these two structurally similar compounds.
A particularly interesting finding from the work in this chapter was the observation 
that i.p, administration of furosemide-induced hepatotoxicity in male mice, yet, at the 
same dose, orally administered furosemide failed to do so. This suggests that the 
toxicity of furosemide could be partly attributed to high concentrations in the liver, in 
addition to bioactivation to a reactive metabolite. Conducting pharmacokinetic and 
toxicokinetic studies using the two compounds, in both rats and mice, via i.p. and 
oral routes of administration may put this finding into context, as exposure time and 
hepatic furosemide levels can be measured over time.
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CHAPTER 3
HETEROCYCLIC RING SUBSTITUTION IN FUROSEMIDE: 
INVESTIGATING THE EFFECT OF STRUCTURAL CHANGES
ON PHARMACOKINETICS.
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3.1 INTRODUCTION
In the previous chapter (Chapter 2) it was shown that the thiophene analogue of 
furosemide, TP A, was more potent than furosemide against the pharmacological 
target. In addition, it was shown that the novel thiophene analogue of furosemide 
undergoes bioactivation and can covalently bind to hepatic protein in vitro. TP A was 
more toxic than furosemide towards freshly isolated hepatocytes, where it caused 
dose-dependent GSH depletion and covalent binding. However, in vivo, no toxicity 
of the compound was observed. In contrast furosemide causes hepatotoxicity 
following i.p. dosing in mice. There are a number of possible explanations that may 
help to explain the differing in vivo toxicity profiles; (1) the two compounds have 
very different levels of exposure in vivo so that concentrations of TPA and therefore 
the toxic metabolite are not reached or (2) the two compounds have different 
metabolic/excretory pathways. In this chapter the pharmacokinetics (PK), 
toxicokinetics (TK) and liver concentrations of furosemide and TPA are investigated 
in order to provide further understanding of the species and route dependent 
differences in toxicity observed in Chapter 2.
Drugs that are administered orally have a number of barriers to contend with in order 
to enter the systemic circulation. The solubility and intestinal permeability of a 
compound are the two main determinants of the fraction of a dose of compound 
absorbed after oral dosing. In addition, some drug molecules undergo metabolism in 
the gut wall, and those molecules that successfully cross the intestine will then enter 
the liver, through the portal vein, and may be subject to first-pass metabolism before 
entering the circulation. Therefore, after oral administration, the plasma levels of 
drug usually only represent a fraction of the initial dose; this is described 
quantitatively as bioavailability. In contrast when a compound is dosed 
intraperitoneally {i.p ) the compound will bathe the external surface of the liver as 
well as being absorbed in to the systemic circulation and it is possible that following 
i.p. dosing the local concentration in the liver and the plasma exposure is 
significantly higher than after oral dosing (Giuliano et al, 2005, Ytrestoyl and 
Bjerkeng, 2007).
If liver concentrations are higher after i.p, dosing, this may explain why toxicity of 
furosemide is seen only after this ROA. The possibility that this is a plausible
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rationale for the toxicity findings with furosemide come from previous studies with 
amodiaquine. Amodiaquine is an anti-malarial drug that has been associated with 
immune-mediated hepatotoxicity in rats. An amodiaquine-induced positive immune 
response was observed in rats regardless of the ROA, but the magnitude of the 
response was in the order intraperitoneal administration ( i-P ) > intramuscular 
administration (i.m.) > oral administration {p.o.) (Clarke et al., 1990).
Drugs and their metabolites can be cleared from the body through a number of 
mechanisms, but the primary routes are through renal and hepatic clearance, which 
includes biliary excretion and metabolism. The degree and rate of parent drug 
clearance from the body will directly influence drug plasma concentration; rapid 
elimination of parent drug will reduce the risk of toxicity but may also reduce the 
effectiveness of therapy. The AUC (area under plasma concentration-time curve) and 
Cmax (maximum plasma concentration) can be used as a measure of drug exposure in 
toxicology. Biliary excretion is one of the primary routes of drug elimination; polar 
drugs and metabolites, such as glucuronides and glutathione conjugates, can be 
excreted via the bile in an active process by efflux transport proteins (Lai, 2009). 
Inhibition of biliary excretion can lead to drug accumulation in the liver. Work 
conducted by Spitznagle, et al (1977) indicated that saturation of the biliary excretion 
of furosemide, following a large dose of furosemide or pretreatment with 
sulfobromophathlein (a compound used to compete with the biliary excretion of 
various compounds (Cantarow and Wirts, 1948)), is closely associated with the 
appearance of liver necrosis in the mouse and of furosemide metabolites covalently 
bound to liver proteins.
Reference Assay Subjects Dose Cmax T™ (h) T1/2 (h) (rrt'mn) F (%)
Beermann et a/. (1975) Radiolabelled 7 5 -12 % dose 1 1.5 ±0.28 65
Tilstone etal. (1978) Radiolabelled 11 68.9 ±7.1
Branch etal. (1977) Fluorometric 6 80 mg/kg 50
Hammailund etal. (1984) HPLC 8 40 mg 0.23-0.77 mg/L 1.9-3.3 97.1 ±6.2 43.3
Smithefa/. (1980) HPLC 9 80 mg 111 ± 17 42.8
Vree etal. (1995) HPLC 7 2.2 ± 0.84 ug/ml 1.98 ±0.98 53 ±7
Table 3.1: Pharmacokinetic parameters of furosemide in human subjects 
administered furosemide orally.
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Furosemide is a weak acid and although it is stable in gastric and duodenal fluid for 
two hours (Beennann et al., 1975) it is incompletely absorbed from the GI tract 
(Hammarlund et al., 1984, Lee and Chiou, 1983). Estimates of furosemide 
absorption are 30% in the rat (Lee and Chiou, 1983), 50-60% from an oral solution 
dosing in the dog (Yakatan et al., 1976) and 43-69% in humans (see Table 3.1 for 
references). In the rat 40% of the administered furosemide dose remained in the GI 
tract for 8-9 hours after dosing (Lee and Chiou, 1983), and as furosemide absorption 
was calculated as 30% in this study, the remaining 30% had undergone metabolism 
either through hepatic fust pass metabolism (-10%) or metabolism in the gut wall 
(-20%; (Lee and Chiou, 1983, Kim et al, 2000)). Beennann et al (1975), after 
administering radio labelled furosemide orally to healthy volunteers, found that total 
urinary excretion was 55.1 ± 32 % and the total fecal excretion was 34.7 ± 5.2% after 
5 days. Following an z.v. dose the total urinary excretion, for the two subjects 
exposed, was 82% and 84%, and total fecal excretion was 6% and 9% (Beennann et 
al, 1975). Using this data the bioavailability was calculated to be 66% ((% in urine 
after oral dose / % in urine after i.v. dose)* 100%). Low biliary excretion of parent 
compound has also been reported in rats (Lee and Chiou, 1983, Inui et al, 1982). 
This is in contrast to the excretion in the mouse where furosemide undergoes 
significant biliary excretion; more than 30% of furosemide is excreted in bile after 
doses of 50 and 100 mg/kg (Spitznagle et al, 1977).
The aim of this chapter was to determine the PK and TK parameters of furosemide 
and TPA in rats and mice in order to further understand the exposure and clearance 
of the two compounds and correlate the information with toxicity data. PK analyses 
were to be conducted in rats and mice to compare the ADME parameters of 
furosemide and TPA. With the aim of providing a rationale for the differences 
observed in toxicity between furosemide and TPA, and also between different ROA, 
TK analyses were planned, at 400 mg/kg, to allow the plasma and liver exposure of 
the two compounds to be measured in both rats and mice, hi vitro plasma and liver 
protein binding experiments were to be conducted at a range of furosemide and TPA 
concentrations (based on exposures calculated in the PK and TK studies) in order to 
contextualize the PK and TK data.
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3.2 MATERIALS AND METHODS
3.2.1 Materials
[14C]-Thiophene analogue of furosemide (TPA; Specific activity 592 Mbq/mmol), 
and unlabelled TPA was provided by Pfizer (Kent, U.K.) and was determined to be 
>98 % pure. The i4C label was incorporated into the carboxyl carbon atom of TPA, 
and thus expected to be incorporated in all major metabolites. Unless otherwise 
stated, reagents were obtained from Sigma-Aldrich Chemical Co. (Poole, U.K.). 
Ultima Gold scintillation fluid was purchased from PerkinElmer LAS (U.K.), Seer 
Green, Beaconsfield, Buckinghamshire, U.K. All solvents were of HPLC grade and 
were products of either Fischer Scientific pic (Loughborough, U.K.) or VWR 
(Lutterworth, U.K.)
3.2.2 Experimental animals
Protocols described were undertaken in accordance with criteria outlined in a license 
granted under the Animals (Scientific Procedures) Act 1986 and approved by the 
University of Liverpool Animal Ethics Committee. Male Wistar rats and male CD-I 
mice were obtained from Charles River Laboratories (Margate, U.K), housed in a 
light-controlled room at a constant temperature, and supplied with a standard chow 
diet and water ad libitum.
3.2.3 Dosing Regimen
The PK studies were conducted at Pfizer, UK.
Male CD-I mice (35-40 g) were administered furosemide or TPA [5 mg/kg in 10% 
DMSO 90% water; /.v.]. Blood samples (100 pi) were taken and animals were culled 
at different time points (Table 3.2). The pharmacokinetic study conducted in male 
Wistar rats (350-400 g) was performed as an z.v./oral (p.o.) crossover study over 3 
days. On day one animals were administered either furosemide or TPA [1 mg/kg in 
10% DMSO and 90% water; i.v.] followed by a wash-out period on day two, and on 
day three they were administered either furosemide or TPA [3 mg/kg in 10% DMSO
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90% water; p.o.\. Sample collection times for days 1 and 3 are given in Table 3.3 
below.
The TK studies were conducted at the University of Liverpool and are described in 
section 2.2.2.
Collection Times (hours)
Mouse 0 0.25 0.5 1 2 4 6 10 24
1 100 pi 100 pi T
2 100 pi 100 pi T
3 100 pi 100 pi T
4 100 pi 100 pi T
Table 3.2: Blood sampling and culling times for the CD-I mouse PK study with 
furosemide or TPA. T = terminal sample.
Sample Type Collection Times (hours)
Blood (175pl) PD 0.1* 0.3 0.5 0.75** 1 2 4 7 10 16 22
Urine 0-22
Table 3.3: Blood and urine collection times for the Wistar rat PK study with 
furosemide or TPA. PD = pre-dose, */.v. only and **p.o. only
3.2.4 Plasma protein binding of furosemide and TPA to rat and mouse plasma
The extent of plasma protein binding in vitro was detenuined by equilibrium dialysis 
using a Rapid Equilibrium Dialysis (RED) Device (Thermo Scientific Pierce Protein 
Research Products, Rockford, IL, U.S.A.). Samples of rat and mouse plasma (200 pi, 
n = 6) containing compound at various concentrations (based on Cmax values at 
different doses and ROA) were dialyzed against Dulbecco’s phosphate buffered 
saline (dPBS; 350 pi) for 4 hours at 37°C and 450 rpm. After dialysis, the plasma and
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buffer were transferred into a clean 96-well block for analysis. Compounds were 
extracted and the concentrations of drug in plasma and buffer were determined by 
LC-MS analysis, as described below. For the plasma TK data, log(drug 
concentration) was plotting against the fraction unbound values (MasterPlexQT 
(version 5; MiraiBio Group, Hitachi Solutions America LTD.)); the curve was then 
used to predict the fraction unbound at each time point. Plasma protein binding 
values were determined using the following equation:
Plasma protein binding (%) = 100 — (buffer concentration plasma concentration) x 100
3.2.5 Blood-plasma partitioning of furosemide and TPA in human and rat 
whole blood
The extent of drug partitioning into the cellular fraction of blood was determined by 
incubation of the compounds (1 pg/ml) in whole blood (human, rat) for 0, 60 and 90 
minutes at 37°C and 450 rpm. After the time point was reached a whole blood 
sample was taken and the plasma was collected by centrifugation for 1 minute at 
10,000 rpm. The whole blood and plasma samples were transferred to a clean 96- 
well block for analysis. Compounds were extracted and the concentrations of drug in 
plasma and buffer were determined by LC-MS/MS analysis, as described below.
3.2.6 Liver sample preparation for LC-MS/MS analysis
Liver concentrations of furosemide and TPA were determined in liver from animals 
administered furosemide or TPA (1.21 mmol/kg) over 1, 3, 6 and 24 hours. In brief, 
500 mg of liver tissue was homogenized in 2.5 ml dPBS (pH 7.5)) using a glass 
Teflon homogenizer. 100 pi of liver homogenate was added to 200 pi ice-cold ACN. 
The protein was allowed to precipitate on ice for 10 minutes before centrifugation at 
14000 rpm for 5 minutes. The supernatant was used for quantification of compounds 
by LC-MS/MS.
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3.2.7 Liver protein binding of furosemide and TPA to rat and mouse liver
The extent of liver protein binding was determined by equilibrium dialysis using 
Rapid Equilibrium Dialysis (RED) Device. Samples of rat or mouse liver 
homogenate (200 pi, ;? = 6) containing compound at various concentrations (based 
on Qnax values at different doses and ROA) were dialyzed against Dulbecco’s 
phosphate buffered saline (dPBS; 350 pi) for 4 hours at 37°C and 450 rpm. After 
dialysis, the liver homogenate and buffer were transferred into a clean 96-well block 
for analysis. Compounds were extracted and the concentrations of drug in liver 
homogenate and buffer were determined by LC-MS analysis, as described below. 
Liver protein binding values were determined using the following equation:
T. . . . .. {bufferconcentratwn\
Liver protein binding (%) = 100 - {—r^------------------------- x 100
V liver concentration J
3.2.8 Furosemide and TPA quantification in plasma and liver by LC-MS/MS
Plasma or liver homogenate (50 pi) were extracted by liquid-liquid extraction using 
ethyl acetate in a 96-well format and the organic layer was dried down by a stream of 
N2 and then reconstituted in methanol (75 pi). All samples were quantified using an 
AB Sciex API-4000 (Turbo V lonspray source) triple quadruple mass spectrometer 
(AB Sciex, Foster City, CA, U.S.A.) and an Agilent 1100 binary pump LC system 
(Agilent Tech. Inc., Palo Alto, CA, U.S.A.). Chromatographic separation was 
achieved using a Zorbax XDB Cl8 analytical column (4.6 x 50 mm, 5 pm particle 
size); column temperature was 45°C. The aqueous mobile phase (H20/MeOH, 90/10 
v/v; pH 7) contained 10 mM Ammonium Acetate and the organic mobile phase was 
MeOH. The flow rate was 0.6 ml/min. Detection was by negative-ion electrospray 
ionisation. MRM transitions for furosemide and TPA and MS working parameters 
are given in Table 3.4. PK and TK parameters were calculated using WinNonLin 
software (Pharsight, St. Louis, MO, U.S.A.).
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Parameters FS MRM TPA MRM
Source temperature (°C) 500.0 500.0
Nebulizing gas (gas-1) (arbitrary
units)
10.00 10.00
Ion spray voltage (V) 4500 4500
Collision energy (eV) -30.00 -24.00
Declustering potential (V) -26.00 -26.00
Focusing potential (V) -220.0 -170.0
Entrance potential (V) -10.00 -10.00
Mode of analysis Negative Negative
Ion transition products (m/z) 328.9/204.9 344.9/300.8
Table 3.4: Main working parameters for LC-MS/MS MRM quantification of 
furosemide and TPA
3.2.9 Pharmacokinetic and toxicokinetic parameter definitions and 
calculations
Area under the plasma concentration-time curve (AUQ describes the amount of drug 
in the circulation over time, after the dose has been administered. In WinNonLin 
(Pharsight, St. Louis, MO, U.S.A.), AUC is calculated using linear, linear/log 
trapezoidal or linear up/log down rules.
CmaxJs the maximum concentration of drug in the circulation after administration, 
and Tmax is the time at which this concentration is achieved.
Volume of distribution (Vrd is a theoretical concept that allows the fraction of drug in 
the circulation and fraction of drug in the tissues to be calculated. Blood volume is 
roughly 60 - 80 ml/Kg; a drug that does not distribute into tissues and remains in the 
circulation will have a Vd of about 0.08 L/Kg. Drugs that distribute into extracellular 
water will have a Vd of about 0.2 L/kg, the volume of total body water is 0.6 1/kg and 
if a drug has a Vd greater than this it distributes significantly into the tissues. Vd is
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calculated either from the initial concentration (Co), which is extrapolated from the 
plasma concentration vs. time profile, or by using the AUC.
Vd= Dose / Co
Vd = Dose x F / AUC x
Clearance (Cl) values describe the volume of blood totally cleared of drug per unit 
time. Clearance values that approach the hepatic blood flow indicate that metabolic 
clearance is high; hepatic blood flow for man, rat and mouse are approximately 20, 
70 and 90 ml/min/Kg respectively.
C/ = Dose/AUC
Blood arriving at the kidneys and liver will only have a fraction of total drug present 
in the body at that time as distribution into tissues will have occurred. The duration 
the drug is in the body will therefore be a function of clearance and fraction of drug 
in the blood. The amount of drug in the blood is related to the Vd and so the 
elimination rate constant (TCd is calculated by the following equation.
^el = C//Vd
The half-life (tm\ is the time taken for the plasma concentration of a drug to decline 
by 50%. It can be calculated as follows:
t\n = In 2 / Xei = (In 2 x Vd) / Cl
Drugs can bind, with differing affinities, to plasma and tissue proteins; only drug 
molecules in the unbound state are free to interact with pharmacological target, off- 
target proteins and be subject to elimination. It is therefore routine to calculate the 
fraction of free drug in the circulation and quote the above parameters in terms of 
unbound fraction of drug. The method for determining plasma protein binding is 
described in section 3.2.3.
Bioavailability (F) compares the concentration of the drug in systemic circulation 
following non-intravenous with the concentration of the same drug following 
intravenous administration.
F = (AUCorai / AUCiv) x (Doseiv / Dose0rai)
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In addition to calculating the plasma AUC, Cmax and F values, the liver AUC was 
also determined for the toxicokinetic study. Liver protein binding was determined to 
contextualize the data (section 3.2.6).
3.2.10 Statistical analysis
All results were expressed as mean + standard deviation. Data sets were analysed for 
normality using the Shapiro-Wilk test. An unpaired T-test was used for single 
comparisons of normal data. Where multiple comparisons were made and the data 
was normally distributed, one-way ANOVA was used with bonferroni correction. All 
statistical analysis was performed using the StatsDirect statistical software.
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3.3 RESULTS
3.3.1 The extent of protein binding of furosemide and TPA to rat and mouse 
plasma and liver tissue
Plasma protein binding (PPB) values of furosemide and TPA for each species were 
detennined in vitro at concentrations similar to those achieved in the plasma in vivo 
at low doses (1 mg/kg; Table 3.5). For the toxicokinetic study, a range of 
concentrations of furosemide and TPA were used in the in vitro binding assay in 
order to construct a plasma dose-response curve for each species (PPB values for 20 
pM are shown in Table 3.6). The curves were then used to calculate the fraction 
unbound based on the total plasma concentration at a given time point (Figure 3.1). 
Liver protein binding (LPB) was carried out at the Cmax concentrations (Table 3.7).
Species Compound Concentration
(nM)
Fraction
Unbound PPB %
Mouse
FS 3024 0.028 97.2
TPA 2899 0.018 98.2
Rat
FS 3024 0.013 98.7
TPA 2899 0.007 99.3
Table 3.5: Plasma protein binding data determined for PK parameter 
contextualization. Concentrations chosen based on Cmax values in PK studies.
Species Compound Fraction Unbound PPB %
Mouse
FS 0.0144 98.6
TPA 0.0103 99.9
Rat
FS 0.0129 98.7
TPA 0.0264 97.4
Table 3.6: Plasma protein binding data determined for TK parameters 
contextualization. Values of fraction unbound were determined with 20 pM of 
either FS or TPA. The complete range of concentrations were used to construct the 
curves in Figure 3.1
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A
R2 = 0.997 
a = 0.01378 
b = 1.38584 
c = 6805.5 
d = 1.55547
Log (FS Concentration)
B
R2 = 0.998 
a = 0.00979 
b = 1.70315 
c = 2925.6 
d = 0.37049
Log (TPA Concentration)
R2 = 0.999 
a = 0.01239 
b = 1.56735 
c = 47857.0 
d = 24.38408
Log (FS Concentration) nM
R2 = 0.983 
a = 0.00 
b = 0.70954 
c = 26.6271 
d = 0.05405
Figure 3.1: Dose-
response curves showing 
drug concentration vs 
fraction unbound. The
degree of binding of FS 
(A and C) and TPA (B 
and D) was determined, in 
vitro, in mouse (A and B) 
and rat (C and D) plasma 
over a range of 
concentrations. The
equation of the dose- 
response curves is as 
follows:
y =
A-D + D
Log (TPA Concentration) nM
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Species Compound
Concentration
(HM)
Fraction
Unbound LPB %
48.4 0.109 89.1
FS
Mouse 302 0.079 92.1
TPA 162 0.056 94.4
FS 6.05 0.097 90.3
Rat
TPA
23.2 0.042 95.8
406 0.05 95.0
Table 3.7: Liver protein binding data determined for TK parameters 
contextualization. Concentrations chosen based on liver Cmax values in TK studies.
3.3.2 Determination of the pharmacokinetic parameters of furosemide and 
TPA in male Wistar rats and CD-I mice
The pharmacokinetic parameters for furosemide and TPA in both male Wistar rats 
and male CD-I mice (dosing regimens, Tables 3.2 and 3.3) are described in Tables 
3.8 and 3.9 respectively. AUC graphs are shown in Figures 3.2 and 3.3, where data 
points are missing samples were not collected.
Furosemide and TPA comparison
In the mouse the unbound clearance was calculated to be 107 and 300 ml/min/kg for 
furosemide and TPA respectively and free systemic exposure reached 3485 and 1370 
nM for ftirosemide and TPA respectively, suggesting that, after i.v. dosing, 
furosemide is retained in the system longer and at higher concentrations compared to 
TPA, which would reflect the toxicity data gathered in Chapter 2. In the Wistar rat 
the PK parameters of furosemide and TPA are comparable; clearance, systemic 
exposure and bioavailability values are all similar.
Species comparison
The species difference between the rat and mouse in terms of furosemide toxicity has 
previously been explained by a species specific FS-GSH conjugate formed in the rat 
(Williams et al., 2007). However, the PK data presented here shows that species 
differences in PK may also contribute to the susceptibility of the mouse to
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fiirosemide-induced liver damage. The free Cmax and half-life are all greater in the 
mouse model (3485 nM, 0.7 hours) compared to that of the rat (80.9 nM, 0.18 hours) 
and the unbound clearance in the rat, at 1147 ml/min/kg, is much faster than in the 
mouse (at 107 ml/min/kg) suggesting that the mouse has greater exposure to 
furosemide.
ROA comparison
In the mouse the free AUC and free Cmax are greater when fiirosemide is given via an 
Ip. dose (742 ng.h/ml and 3485 nM) compared to an oral dose (p.o.) (250 ng.h/ml 
and 466 nM).
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Figure 3.2: Plasma concentration vs. time plots of FS (A) and TPA (B) in the 
Wistar rat. Graphs plotted using WinNonLin show total compound concentrations 
in plasma over time following a bolus 1 mg/kg /'.v. (o) dose or 3 mg/kg p.o. (•) dose.
FS
(/>.;
1 mg/kg)
FS
(p.o.;
3mg/kg)
TPA
(/.v.; 1 
mg/kg)
TPA
(p.o.; 3 
mg/kg)
AUCo-o (ng.h/ml) 664 ±438 330 ±109 1336 ±424 558 ±154
Free AUCo-« 
(ng.h/ml) 8.60 ± 5.7 4.3 ± 1.4 9.4 ±3.0 3.9 ± 1.1
Total Cmax (nM) 6219 ±2815 477 ± 99.1 9544 ±3517 541 ± 280
Free Cmax (nM) 80.9 ± 36.6 5.63 ±2.2 73.8 ±27.2 4.2 ±2.17
Tmax (h) - 0.47 ± 0.2 - 0.5 ±0.38
T1/2 (h) 0.18 ±0.03 - 0.3 ±0.31 -
Cl (ml/min/kg) 25.0 ± 13.2 - 12.4 ±5.36 -
Clu (ml/min/kg) 1147 ±588 - 1174 ±370 -
Vdss (L/Kg) 0.38 ± 0.24 - 0.3 ±0.11 -
Vduss (L/Kg) 17.3 ±11.1 - 23.9 ± 17.1 -
F (%) - 14.0 ± 14.2 - 14.9 ±4.93
Table 3.8: Plasma PK parameters of furosemide and TPA administered either 
orally or via an i.v. dose to male Wistar rats. N=3 for each group. Parameters were 
calculated using WinNonLin software and are expressed as mean ± standard 
deviation.
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Figure 3.3: Plasma concentration vs. time plots of FS (A) and TPA (B) in the 
CD-I mouse. Graphs plotted using WinNonLin show total compound concentrations 
in plasma over time following a bolus 1 mg/kg i.v. (o) dose or 5 mg/kg p.o. (•) dose.
FS
(i.v;
1 mg/kg)
FS
(P-o.;
5mg/kg)
TPA
(i.v.;
1 mg/kg)
TPA
(p.o.; 5 
mg/kg)
AUCo-. (ng.h/ml) 26,485 8912 15,254 5194
Free AUC0-» (ng.h/ml) 742 250 275 93.5
Total Cmax (nM) 124,471 16,640 79,758 7347
Free Cmax (nM) 3485 466 1370 126
Tmax (h) - 0.5 - 0.25
Ti/2 (h) 0.7 - 0.6 -
Cl (ml/min/kg) 3 - 5.4 ;
Clu (ml/min/kg) 107.1 - 300 -
Vdss (L/Kg) 0.2 - 0.3 -
VdUss (L/Kg) 6.1 - 14.4 -
F (%) - 34 - 34
Table 3.9: Plasma PK parameters of FS and TPA administered either orally or
via an i.v. dose to male CD-I mice. Parameters were calculated from a composite 
profile of 4 mice over 24 hours using WinNonLin.
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3.3.3 Determination of the toxicokinetic parameters of furosemide and TPA in 
male Wistar rats and CD-I mice
TK studies were undertaken to determine the kinetics of furosemide and TPA at a 
higher dose where toxicity is observed for furosemide in the mouse. The 
concentrations of the compounds were also measured in the liver to identify possible 
accumulation that might contribute to hepatotoxicity.
Liver and plasma exposure levels of furosemide and TPA were determined over 24 
hours in male CD-I mice and male Wistar rats administered either furosemide or 
TPA (1.21 mmol/kg in PEG) either orally or via an Lp- dose (Tables 3.10, 3.11, 3.12 
and 3.13). The furosemide and TPA plasma AUC increased supraproportionally 
(from 240-fold to 4300-fold) as the dose was increased from 3 or 5 mg/kg to 400 
mg/kg orally in the mouse and rat suggesting that, in both species, clearance for both 
compounds becomes saturated at high oral doses (Figure 3.8 B).
The plasma and liver exposure of both TPA and furosemide were comparable in the 
mouse {Lp. ROA; Figure 3.8 A) suggesting that the two compounds undergo similar 
disposition and clearance at high doses (~400 mg/kg). When comparing the rat and 
mouse in terms of furosemide exposure {Lp. ROA), plasma levels, in terms of free 
AUC, were comparable; however total liver exposure in the mouse was more than 
twice that in the rat with AUC values at 3032 and 1280 pg.h/ml respectively (Figure 
3.8 C). Oral administration of furosemide in the mouse resulted in significantly 
reduced plasma and liver exposure compared to Lp. administration (Figure 3.8 D). 
The free plasma AUC when furosemide is delivered via an Lp. injection to a mouse 
is 3 times that of an oral delivery (495 pg.h/ml Lp. and 153 pg.li/ml p.o.). Likewise, 
the free liver AUC when furosemide is delivered via an i.p. injection is more than 4 
times that of an oral delivery (3032 pg.h/ml Lp. and 646 pg.h/ml p.o.).
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Figure 3.4: Plasma concentration vs. time plots of FS (A) and TPA (B) in the 
Wistar rat. Graphs plotted using WinNonLin show total compound concentrations 
in plasma over time following a bolus l.21 mmol/kg i.p. (□) orp.o. (•) dose.
.. *»
FS {IP) FS (PO) TPA (IP) TPA (PO)
Total AUCo-oo 
(pg.h/ml) 4932 ± 2298 1123 ±372 8213 ±3324 2586 ± 950
Free AUCo-. 
(pg.h/ml) 1057 ±1008 21.4 ± 12.0 405±162 118 ±53.1
Tmax (h) 1.00 ±0.00 5.25 ±1.50 1.50 ±1.00 4.50 ±1.73
Total Cmax (pg/ml) 1103 ±484 86.4 ± 32.8 479 ± 292 193 ±98.7
Free Cmax (pg/ml) 542 ± 543 1.81 ±1.15 38.8 ± 15.6 9.35 ±5.15
Total C24 (pg/ml) 2.30 ±0.56 7.51 ±8.91 80.2 ± 70.2 16.9 ± 13.2
Free C24 (pg/ml) 0.03 ±0.01 0.10 ±0.12 3.63 ± 3.52 0.58 ±0.57
Cl (ml/kg/hr) 94.4 ± 40.0 389 ±136 54.9 ± 23.4 167 ±45.4
Clu (ml/kg/hr) 707 ± 539 23112 ±10982 1114 ± 482 3801 ±1211
Table 3.10: Plasma toxicokinetic parameters of FS and TPA (1.21mmol/kg in 
PEG; p.o. or i.p.) in male Wistar rats. Parameters were calculated using 
WinNonlin software. Mean ± standard deviation; n=4.
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Figure 3.5: Liver concentration vs. time plots of FS (A) and TPA (B) in the 
Wistar rat. Graphs plotted using WinNonLin show compound concentrations in 
liver over time following a bolus 1.21 mmol/kg i.p. (□) orp.o. (•) dose.
FS (/P) FS (PO) TPA (/P) TPA (PO)
Total AUCo-» 
(pg.h/ml) 1280 ±228 141 ±51.2 4459 ±1157 578 ± 222
Free AUCo-« 
(pg.h/ml) 128 ±22.8 14.1 ±5.1 223 ± 57.9 28.9 ±11.1
Total Cmax (pg/g) 308 ± 39.0 10.2 ±5.77 696 ±164 42.7 ±23.7
Free Cmax (pg/g) 30.8 ± 3.89 1.02 ±0.58 34.8 ±8.2 2.13 ±1.18
Total C24 (pg/g) 0.08 ±0.08 1.03 ±1.11 26.3 ±20.0 3.75 ±2.88
Free C24 (pg/g) 0.01 ±0.01 0.10±0.11 1.31 ±1.0 0.19 ±0.14
Table 3.11: Liver toxicokinetic parameters of FS and TPA (1.21mmol/kg in 
PEG; p.o. or i.p.) in male Wistar rats Parameters were calculated using WinNonlin 
software. Mean ± standard deviation; n=4.
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Figure 3.6: Plasma concentration vs. time plots of FS (A) and TPA (B) in CD-I 
mice. Graphs plotted using WinNonLin show compound concentrations in plasma 
over time following a bolus 1.21 mmol/kg i.p. (□) oxp.o. (•) dose.
FS (IP) FS (PO) TPA (IP) TPA (PO)
Total AUCo.« 
(pg.h/ml) 5505 ±1520 2125 ±1467 6587 ±1399 4329 ±1486
Free AUCo-» 
(pg.h/ml) 495 ± 485 153±156 1350 ±850 441 ±101
Tmax (h) 3.25 ±2.06 3.50 ± 3.00 1.50 ± 1.00 2.75 ±2.36
Total Cmax (pg/ml) 433 ± 340 209±171 778 ± 345 499 ± 265
Free Cmax (pQ/tnl) 103±156 23.4 ±31.0 373 ± 270 164±160
Total C24 (pg/ml) 74.2 ± 30.3 5.36 ±4.18 58.0 ± 16.6 88.4 ± 97.4
Free C24 (pg/ml) 2.22 ± 1.40 0.08 ± 0.06 2.15 ±0.78 7.00 ± 10.4
Cl (ml/kg/hr) 78.9 ± 30.0 314 ± 262 63.1 ± 15.0 99.8 ±33.0
Clu (ml/kg/hr) 1526 ±1210 12211 ±14752 443 ± 350 940 ± 222
Table 3.12: Plasma toxicokinetic parameters of FS and TPA (1.21 mmol/kg in 
PEG; p.o. or i.p.) in male CD-I mice. Parameters were calculated using WinNonlin 
software. Mean ± standard deviation; n=4
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Figure 3.7: Liver concentration vs. time plots of FS (A) and TPA (B) in CD-I 
mice. Graphs plotted using WinNonLin show compound concentrations in liver over 
time following a bolus 1.21 mmol/kg i.p. (□) or p.o. (•) dose.
FS (IP) FS (PO) TPA (IP) TPA (PO)
Total AUCo-« 
(pg.h/ml) 3032 ±1162 646 ± 448 5092 ±1850 1362 ±742
Free AUCo-- 
(pg.h/ml) 243 ± 93.0 51.7 ±35.8 306 ±111 81.7 ±44.5
Total Cmax (pg/g) 634±159 81.1 ±97.6 1191 ±613 281 ±187
Free Cmax (pg/g) 50.7 ± 12.8 6.49 ± 7.8 71.4 ±36.8 16.9 ±11.2
Total C24 (pg/g) 17.1 ±8.5 1.75 ±0.77 23.1 ± 13.3 38.0 ±58.9
Free C24 (pg/g) 1.37 ±0.68 0.14 ±0.06 1.39 ±0.08 2.28 ±3.53
Table 3.13: Liver toxicokinetic parameters of FS and TPA (1.21 mmol/kg in 
PEG; p.o. or i.p.) in male CD-I mice. Parameters were calculated using WinNonlin 
software. Mean ± standard deviation; n=4
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Figure 3.8: Summary graphs of TK comparisons between (A) furosemide and 
TPA, in male CD-I mice (1.21 mmol/kg /./?.), (B) dose of furosemide, in male CD-I 
mice {p.o.), (C) species, in male CD-I mice and Wistar rats (furosemide 1.21 
mmol/kg i.p.) (D) ROA, in male CD-I mice (furosemide 1.21 mmol/kg). Data are 
expressed as mean + standard deviation (except B for 5 mg/kg where the data was 
composite). * p=0.05, ** p=0.01 unpaired T test.
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3.4 DISCUSSION
The aims of this chapter were to investigate whether the differences in hepatotoxicity 
observed between fnrosemide and TPA could be explained by differences in 
pharmacokinetics. TPA did not induce severe hepatotoxicity in mice when 
administered via an i.p. or oral route. It has been observed that in mice, following a 
large dose of fnrosemide or pretreatment with sulfobromophathlein (BSP; BSP has 
been used previously to compete with the biliary excretion of a number of 
compounds including bilirubin (Cantarow and Wirts, 1948, Spitznagle et al, 1977)), 
saturation of biliary excretion of fiirosemide occurred and that it was is closely 
associated with the appearance of liver necrosis (Spitznagle et al, 1977). Here, it was 
hypothesised that the differences in the toxicity of fiirosemide and TPA in the mouse 
may be due to the saturable, dose-dependent nature of fiirosemide excretion and not 
that of TPA. In Chapter 2 it was found that i.p. administration of fiirosemide-induced 
hepatotoxicity in male mice. However, at the same dose, orally administered 
fiirosemide failed to do so, suggesting that the toxicity of fiirosemide could be partly 
attributed to accumulation in the liver, as well as bioactivation.
The bio availability of fiirosemide and TPA were similar in both rats (-14%) and 
mice (-35%) suggesting that the two compounds are absorbed and undergo pre­
systemic metabolism to a similar extent. The bio availability of fiirosemide in rats in 
the literature ranges from around 30 to 60% (Lee and Chiou, 1983, Kim et al, 2000, 
Kim et al, 1993, Park et al, 1998).
Plasma protein binding (PPB) of TPA was 99.3% and 98.2 % in rat and mouse, 
respectively at 1 jig/ml. PPB of fiirosemide in the mouse was 97.2 % at 1 pg/ml. In 
the rat PPB of fiirosemide was 98.7% (at 1 pg/ml); in the literature PPB ranged from 
87.2 ± 5.3% to 96.81% (Table 3.14). The extent of fiirosemide binding to plasma 
protem is in the range of 96-98% in humans (Table 3.16). The substantial amount of 
binding is reflected in the low volume of distribution, which is in the range of 0.07- 
0.21 L/kg in humans (Table 3.16) and 0.12-0.25 L/kg in rats (Table 3.14). The 
calculated half-life of fiirosemide from the literature data ranges from 0.43 to 1.53 
horns in humans (Table 3.16) and 0.68 - 1.25 horns in rats (Table 3.14) after an i.v. 
dose. The volume of distribution and half-life of fiirosemide in rats determined in 
this study were 0.38 ± 0.24 L/Kg and 0.18 ± 0.03 hours respectively. Hammarlund et
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al. (1982) observed that increasing the dose of furosemide given to rats increased the 
half-life. This change could be detected as a change in the apparent volume of 
distribution caused by decreased protein binding at increasing plasma concentrations 
of furosemide. The data collected from the literature support this conclusion: 
increasing the dose from 10 mg/kg to 20 mg/kg decreased plasma protein binding 
from 96.81 ± 0.3% to 87.2 ± 5.3% (Table 3.14).
In the mouse the unbound clearance was calculated to be 107 and 300 ml/min/kg for 
furosemide and TPA respectively and free systemic exposure reached 3485 and 1370 
nM of furosemide and TPA respectively, suggesting that furosemide is retained in 
the system longer and at higher concentrations which would reflect the toxicity data 
gathered in Chapter 2. In the Wistar rat the PK parameters of furosemide and TPA 
are comparable; clearance, systemic exposure and bioavailability values are all 
similar. The species difference between the rat and mouse in terms of furosemide 
toxicity has previously been explained by a species specific FS-GSH conjugate 
formed in the rat (Williams et al., 2007). However, the PK data presented here shows 
that species differences in PK may also contribute to the susceptibility of the mouse 
to furosemide-induced liver damage. The free Cmax, half-life and bioavailability are 
all greater in the mouse model (3485 nM, 0.7 hours, 34%) compared to that of the rat 
(80.9 nM, 0.18 hours, 14%) and the clearance in the rat, at 1147 ml/min/kg, is faster 
than in the mouse (at 107 ml/min/kg). If the clearance values represent elimination of 
parent drug from the system (and not metabolic clearance to a reactive metabolite) 
than the data would suggest that the mouse has greater exposure to furosemide.
Toxicity is observed in the mouse at a dose many times greater than that used in the 
PK study. In order to understand the disposition of the compounds at a ‘toxic’ dose a 
toxicokinetic study was carried out. In addition, the drug levels in the liver were also 
measured over time. The plasma and liver exposure of both TPA and furosemide 
were comparable in the mouse {i.p. ROA) suggesting that the two compounds 
undergo similar disposition and clearance at 400 mg/kg. The furosemide and TPA 
plasma AUC increased supraproportionally (~240-fold to 4300-fold) as the dose was 
increased from 3/5 to 400 mg/kg orally in the mouse and rat suggesting that, in both 
species, clearance for both compounds becomes saturated at high oral doses. This has
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been observed previously; the metabolic clearance of furosemide decreased with 
increasing dose in the rat (Hammarlund and Paalzow, 1982).
As well as comparing the two analogues, the investigation also allowed comparisons 
to be made between species and ROA, in terms of plasma and liver drug 
concentrations relative to toxicity observed. Species differences in furosemide- 
induced hepatotoxicity between rats and mice have been investigated. Identification 
of a FS y-ketocarboxylic acid in mice and rats in vivo suggested the existence of a 
reactive epoxide intermediate (Williams et al., 2007). It was proposed that this 
reactive metabolite covalently bound to hepatic protein, and toxicity was observed in 
mice; however in rats this does not occur. A species specific GSH conjugate was 
identified in the bile of furosemide dosed rats, suggesting a possible safety 
mechanism exists in the rat to protect from furosemide-induced hepatotoxicity 
(Williams et al., 2007). The investigations presented in this chapter highlight that 
increased furosemide liver exposure (or reduced clearance of reactive metabolite) in 
mice may also contribute to the species differences in furosemide-induced 
hepatotoxicity. The free plasma AUCs of furosemide in the rat and mouse were 
comparable (i.p. ROA), however liver exposure in the mouse was twice that in the 
rat, with free liver AUC values at 243 and 128 pg.h/ml respectively.
Oral administration of furosemide in the mouse resulted in significantly reduced 
plasma and liver exposure compared to i.p. administration. The free plasma AUC 
when furosemide is delivered via an i.p. injection is 3 times that of an oral delivery 
(495 pg.h/ml ip. and 153 pg.li/ml p.o.). Likewise, the free liver AUC when 
furosemide is delivered via an i.p. injection is 5 times that of an oral delivery (243 
pg.Mnl i.p. and 51.7 pg.h/mlp.o.). The massive difference observed may be a result 
of poor bioavailability after an oral dose and essentially a direct liver load after 
administration into the peritoneal cavity.
The aims of this chapter were to use pharmacokinetic and toxicokinetic studies to 
help explain the differences observed in furosemide-induced hepatotoxicity between 
furosemide and its thiophene analogue (TPA). Despite differences observed in the 
PK parameters, a high-dose toxicokinetic study revealed that the two compounds 
undergo very similar disposition, suggesting that toxicity of furosemide in mice may 
be attributed to different metabolic fate of furosemide. Comparisons were also made
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between species and ROA, in terms of plasma and liver drug concentrations relative 
to toxicity observed. These comparisons provided evidence that liver accumulation 
may also be a contributing factor to furosemide-induced hepatotoxicity in the mouse.
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CHAPTER 4
HETEROCYCLIC RING SUBSTITUTION IN FUROSEMIDE: 
INVESTIGATING THE EFFECT OF STRUCTURAL CHANGES 
ON IN VITRO AND IN VIVO BIOTRANSFORMATION.
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4.1 INTRODUCTION
The findings reported in Chapter 3 revealed that furosemide (FS) and its thiophene 
analogue (TPA) have a similar disposition in mice in vivo, and therefore failed to 
explain the differences between the hepatotoxicity of the two compounds described 
in Chapter 2. Species differences in furosemide-induced hepatotoxicity have been 
observed previously and explained by alternative detoxication mechanisms 
(Williams et al., 2007). It was shown that the TPA undergoes bioactivation and can 
covalently bind to hepatic protein in vitro. In light of this observation it was 
hypothesized that TPA may undergo a different, and more effective, mechanism of 
detoxification compared to furosemide.
It has been demonstrated that furosemide forms an acyl glucuronide, which is found 
in the plasma and urine of humans (Beermann et al, 1975, Beermann et al, 1977, 
Benet, 1979, Perez et al, 1979, Smith et al, 1980, Smith and Benet, 1983, 
Kerremans et ah, 1982). More recently the furosemide glucuronide has been 
identified in the bile of furosemide-treated rats and mice (Williams et al, 2007). In 
humans, approximately 13 - 17% of an z.v, dose of furosemide is excreted as 
furosemide glucuronide in the urine (Smith et al, 1980, Andreasen et al, 1981, 
Waller et al, 1982, Verbeeck et al, 1982). In the rat, of the total dose excreted in the 
bile (21.2 ± 2.6%), 12.8 ± 1.8% was excreted as the furosemide glucuronide 
(Williams et al, 2007). The furosemide glucuronide has been shown to be unreactive 
in terms of covalent binding to human serum albumin in vitro (Bolze et al, 2002). A 
more controversial metabolite is the N-dealkylated furosemide metabolite (4-chloro- 
5-sulphamoyl-anthranilic acid; CSA in literature) first identified in 1964 by Haussler 
et al. It has subsequently been identified in the urine of dogs and monkeys (Yakatan 
et al, 1976) and in humans (Prandota and Pruitt, 1991, Andreasen et al, 1978). 
However a number of groups failed to find evidence of this metabolite in humans 
(Beermann et al, 1975, Smith et al, 1980, Kerremans et al, 1982, Branch et al, 
1977). A recent study identified the N-dealkylated furosemide metabolite in the bile 
of rats and mice without the use of an acid extraction method (Williams et al, 2007); 
providing clear evidence that it is a genuine metabolite in these species.
The hepatocellular damage caused by furosemide is postulated to be the result of 
P450 enzyme-mediated formation of a toxic metabolite that binds covalently with
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hepatic macromolecules both in vitro and in vivo (Mitchell et al., 1974, Mitchell et 
ah, 1976). It was found that furosemide binds covalently to microsomal protein, and 
that the level of binding parallels the severity of necrosis. Furosemide covalent 
binding is decreased by cysteine and GSH, and also by the presence of P450 enzyme 
inhibitors, suggesting bioactivation of the furosemide molecule (Williams et al., 
2007, Mitchell et al, 1974). Early work suggested that an epoxide of furosemide is 
responsible for the hepatotoxicity observed in the mouse (Wirth et al, 1976).
More recently, bioactivation of the furan ring was demonstrated by the 
characterization of three key novel metabolites of furosemide from in vivo and in 
vitro studies: FS y-ketocarboxylic acid, FS-SG conjugate, and a mixed TV-acetyl 
lysine and TV-acetyl cysteine conjugate (Williams et al, 2007). The formation of a FS 
y-ketocarboxylic acid in vivo is suggestive of formation of an epoxide intermediate. 
The reactive metabolite binds covalently to murine hepatic protein; this does not 
occur in rats; the reactive metabolite is excreted in the form of a GSH conjugate, 
suggesting a possible safety mechanism exists in the rat to protect them from 
furosemide-induced hepatotoxicity (Williams et al, 2007). As well as species 
differences between the balance of bio activation and bio inactivation, it is possible 
that furosemide accumulation in the liver due to impaired clearance might also be a 
factor in development of hepatotoxicity in the mouse, as demonstrated in Chapter 3.
Although prior to these studies little was known about the metabolism of TPA, some 
metabolic pathways can be speculated upon for this compound based on previous 
studies using other thiophene containing drugs. Tienilic acid (TA) is a diuretic drug, 
which was released in the US in 1979 as an antihypertensive. In 1980, TA was 
withdrawn from the US market due to severe secondary hepatotoxic effects and renal 
toxicity (Zimmerman et al, 1984). The major product of TA metabolism is 5- 
hydroxy TA, formed from the hydroxylation of the C-5 position on the thiophene 
ring; however oxidised intermediates of this pathway have been shown to bind 
covalently to microsomal proteins (Dansette et al, 1991). Studies using electrospray 
ionization mass spectrometric analysis have deduced that the reactive intermediate 
could be an epoxide or the TA 5-oxide (Koenigs et al, 1999), although the formation 
of the TA 5-oxide is more widely supported (Mansuy et al, 1991, Dansette et al, 
1992, Lopez-Garcia et al, 1994). OSI-930 is an investigational, thiophene anticancer
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agent that also undergoes microsomal bioactivation to an S-oxide; however studies 
have shown that it is well tolerated in pre-clinical models and in human volunteers 
(Medower et ai, 2008). Suprofen is a thiophene NSAID, which, within a short time 
after its release, displayed severe adverse effects associated with renal toxicity. 
Within 40 minutes to 8 hours of administration, patients suffered from flank pain and 
renal failure normally associated with chronic dosing ofNSAIDs (Hart et ai, 1987).
Tienilic Acid (TA) Suprofen
OSI-930
Figure 4.1: Examples of thiophene-containing compounds believed to undergo 
metabolism to either an S-oxide or an epoxide intermediate.
Although previous studies suggested hypothetically a reactive acyl glucuronic acid 
conjugate might mediate the nephrotoxicity observed with suprofen (Mori et ai, 
1985, Smith and Liu, 1993), the fact that TA and suprofen produce the same renal 
toxicity symptoms and the confirmation that the CYP2C subfamily is present in the 
kidney, suggests they might share the same bioactivation pathway (Kalgutkar et ai, 
2005). Like TA, suprofen has been shown to be a mechanism-based CYP2C9
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inhibitor in vitro (O'Donnell et a/., 2003, Hutzler et al., 2009) and one of its major 
metabolites is 5-hydroxy suprofen (Mori et al., 1984, Mori et al, 1985). Mechanism- 
based P450 inhibition signifies localised generation of a reactive drug metabolite, 
and a trend towards clinical hepatotoxicity has been associated with marked 
Mechanism-based P450 inhibition (Reese et al, 2010). Similar to reports by Koenigs 
et al (1999), O'Donnell et al (2003) obtained evidence for the formation of a 
reactive epoxide intermediate, by the addition to recombinant CYP2C9 incubations 
of semicarbazide affording a pyridizine adduct of y-thioketo a,p-unsaturated 
aldehyde open-ring structure. It could be deduced that either the epoxide or the y- 
thioketo a,p-unsaturated aldehyde is responsible for the covalent binding and 
subsequent inactivation of CYP2C9.
TA covalently bound to CYP2C9
Figure 4.2: Postulated bioactivation pathway of tienilic acid. Formation of 5- 
hydroxy TA and covalent binding of the reactive TA S-oxide to CYP2C9. Adapted 
from Dalvie et al (2002).
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.COOH
5-Hydroxysuprof en
Suprofcn-4, 5-epoxide
CYP2C9-NU
CYP2C9 - NuH
Suprofen covalently bound to CYP2C9
Figure 4.3: Postulated bioactivation pathway of suprofen. Formation of 5- 
hydroxysuprofen and covalent binding of the reactive suprofen epoxide to CYP2C9. 
Adapted from O’Donnell et al. (2003).
The investigations presented in this chapter aimed to elucidate the metabolism of 
TPA in vivo and in vitro. In particular it was intended to explore the detoxification 
products of TPA's reactive metabolite(s) in mice and rats and compare them with 
those of furosemide. To assess the degree of glucuronidation of furosemide or TPA 
in multiple species, glucuronidation assays in hepatic microsomes were employed. 
The biliary metabolites of TPA in the rat were investigated using radiometric HPLC 
and LC-MS/MS techniques. TPA metabolism was investigated, in vitro, in rat and 
mouse hepatocytes as a surrogate for an appropriate in vivo system (Gebhardt et al., 
2003).
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4.2 MATERIALS AND METHODS
4.2.1 Materials
[14C]-Thiophene analogue of fiirosemide (TPA; specific activity 592 Mbq/mmol) and 
unlabelled TPA were provided by Pfizer (Kent, U.K.) and was determined to be >98 
% pure by HPLC. The 14C label was incorporated into the carboxyl carbon atom of 
TPA, and thus was expected to be retained in all major metabolites. Unless otherwise 
stated, reagents were obtained from Sigma-Aldrich Chemical Co. (Poole, U.K.). 
Ultima Gold scintillation fluid was purchased from PerkinElmer LAS (U.K.), Seer 
Green, Beaconsfield, Buckinghamshire, U.K. All solvents were of HPLC grade and 
were products of either Fischer Scientific pic (Loughborough, U.K.) or VWR 
(Lutterworth, U.K.)
4.2.2 Experimental animals
Protocols described were undertaken in accordance with criteria outlined in a license 
granted under the Animals (Scientific Procedures) Act 1986 and approved by the 
University of Liverpool Animal Ethics Committee. Male Wistar rats and male CD-I 
mice were obtained from Charles River Laboratories (Margate, U.K), housed in a 
light-controlled room at a constant temperature, and supplied with a standard chow 
diet and water ad libitum.
4.2.3 In vitro assessment of glucuronidation rate of furosemide and TPA in 
UDPGA-supplemented hepatic microsomes
Incubations contained: 0.76 mg/ml microsomal protein of either rat liver microsomes 
(RLM), mouse liver microsomes (MLM) or human liver microsomes (HLM), 50 
pg/ml of alamethicin (a peptide that forms membrane pores, and thereby enhances 
microsomal glucuronidation; without affecting P450 activity (Fisher et ai, 2000)), 5 
mM MgCL, 100 mM Tris-HCl (pH 7.4), 2% BSA (used to increase the microsomal 
glucuronidation of many substrates (Kilford et al., 2009)) and 5 mM UDPGA (not 
added to control incubations) to give a total volume of 600 pi. Alamethicin solution 
was prepared by dissolution in methanol. The substrates, furosemide and TPA, were
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at 5 j.iM and the positive control, naloxone (a highly selective substrate of the 
UGT2B7 isofomi (Di Marco et al., 2005)), was at 1 pM. Before the addition of 
UDPGA, the mixture was preincubated on ice for 15 minutes and then transferred to 
a shaking incubator for 5 minutes at 37°C. To initiate the reaction, UDPGA was 
added to a final concentration of 5 mM, and 50 pi aliquots were removed at 0, 5, 10, 
20, 30, 60, 120, 180, and 240 minutes. A Pfizer global internal standard (100 pi of 
1000 ng/ml) in acetonitrile containing 2% phosphoric acid was used to terminate the 
reaction at each time point. Levels of parent compound were measured for each time- 
point using an LC-MS/MS method described below.
4.2.4 LC-MS/MS method for substrate-depletion assay of incubation with 
UDPGA-supplemented hepatic microsomes
LC-MS/MS analyses were performed using an AB Sciex API 4000 Q-trap mass 
spectrometer with TurboIonSpray source (AB Sciex, Foster City, CA, USA) and an 
Agilent 1100 binary pump LC system (Agilent Tech. Inc., Palo Alto, CA, U.S.A.). 
Analytes were resolved on an Onyx monolithic Cl8 column (100 x 3.0; 
Phenomenex, Macclesfield, Cheshire, U.K.) using a gradient of ACN containing 
0.1% formic acid (0% for 0.30 minutes, 0-100% over 0.95 minutes) in water 
containing 5% ACN and 0.1% formic acid at a flow rate of 1.2 ml/min. Data were 
acquired and processed with the Analyst software (ver. 1.4; AB Sciex). Mass spectral 
analyses were performed using multiple reaction monitoring, with transitions for 
furosemide (m/z 331/81), TPA (m/z 345/190), and Naloxone (m/z 328/212).
4.2.5 Investigation of biliary TPA metabolites in the Wistar rat
Male Wistar rats (200-400 g) were terminally anaesthetised with urethane (1.4 g/ml 
in isotonic saline; 1.0 ml/kg i.p.) and cannulated via the trachea, femoral vein and the 
common bile duct. Drug-free bile was collected over 30 minutes before 
administration of TPA. [14C]-TPA (10 pCi) and 151 pmo 1/kg unlabelled TPA 
dissolved in DMSO was administered i.v. via the femoral vein over 5 minutes. Bile 
was then collected hourly for 3 hours into microcentrifuge tubes. Protein within the 
bile was precipitated by addition of an equal volume of ice-cold acetonitrile. The
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samples were centrifuged at 2200 rpm for 10 minutes. The resultant supernatant was 
collected, and stored at -20°C until analysis by radiometric HPLC and LC-MS/MS.
4.2.6 Investigation of TPA metabolites in Wistar rat and CD-I mouse freshly 
isolated hepatocytes
Details of the hepatocyte isolation procedure and incubation details are given in 
sections 2.2.8 and 2.2.9, respectively.
4.2.7 Detection and identification of biliary [14C]-TPA metabolites in the 
Wistar rat by radiometric HPLC and LC-MS/MS using an API 2000 
instrument
The metabolites of [14C]-TPA were resolved with an UltraCarb C8 column (25 x 
0.46 cm, 5-jluti particle size; Thermo Fisher Scientific, Runcorn, Cheshire, U.K.). 
The mobile phase consisted of a combination of acetonitrile and 10 mM ammonium 
formate buffer (adjusted to pH 3.5 with formic acid). A sample aliquot of 50 pi was 
injected onto the column, and eluted at 0.9 ml/min with a gradient of 10 to 60% ACN 
over 30 minutes, maintaining 60% ACN for 10 minutes, and finally reverting to 10% 
acetonitrile over 5 minutes. The eluent gradient was delivered with a Dionex Summit 
HPLC system (Dionex Corporation, Sunnyvale, CA, U.S.A.). The analytes were 
detected by a UVD 170S UV detector (Dionex) at 240 nm and a radioactivity detector 
(Radiomatic Flo-Onepeta A250, PerkinElmer LAS (U.K.), Seer Green, Beaconsfield, 
Buckinghamshire, U.K.).
LC-MS/MS analyses were performed using an AB Sciex API 2000 mass 
spectrometer with TurboIonSpray source (AB Sciex, Foster City, CA, USA) 
interfaced to a Perkin Elmer Series 200 pump and Perkin Elmer Series 200 
autosampler (Perkin Elmer, Seer Green, Beaconsfield, Buckinghamshire, U.K.). 
Analytes were resolved on an UltraCarb C8 column according to the method 
described above. Eluate split-flow to the LC-MS interface was approximately 200 
pl/min and nitrogen was used as collision gas. TPA and metabolites were detected in 
the multiple-reaction monitoring (MRM) mode with the transitions given in Table
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4.1. Data were acquired and processed with the Analyst software (ver. 1.4; AB 
Sciex). The main working parameters are given in Table 4.1.
Parameters Selected Reaction Monitoring
Source temperature (°C) 400
Nebulizing gas (gas-1) (arbitrary units) 50
Heater gas (gas-2) (psi) 80
Curtain gas (arbitrary units) 20
Ion spray voltage (V) -4200
Collision energy (eV) -18
Declustering potential (V) -91
Focusing potential (V) -270
Entrance potential (V) -9.5
Dwell time (ms) 150
Mode of analysis Negative
Ion transition products (m/z)
M1 668/620, 668/306; M2 670/306,
670/363, 670/249; M3 249/205, 249/79;
M4 521/345, 521/301, 521/176.
Table 4.1: Main working parameters of API 2000 for tandem mass 
spectrometric analyses of TPA and TPA metabolites
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4.2.8 Detection and identification of [14C]-TPA metabolites, generated by 
freshly isolated rodent hepatocytes, by radiometric HPLC and LC- 
MS/MS using API 4000-Qtrap and LTQ Orbitrap instruments
LC-MS/MS analyses were performed using an AB Sciex API 4000-Qtrap mass 
spectrometer with TurboIonSpray source (AB Sciex, Foster City, CA, U.S.A.) 
interfaced to an Agilent 1100 binary pump LC system (Agilent Technologies. Inc., 
Palo Alto, CA, U.S.A.). Analytes were resolved on an UltraCarb C8 column 
according to the method described above. Eluate split-flow to the LC-MS interface 
was approximately 200 jil/min and nitrogen was used as collision gas. TP A and 
metabolites were detected in the negative ion MRM mode with the transitions given 
in Table 4.1. Data were acquired and processed with the Analyst Software (ver, 1.4; 
AB Sciex).
Product ion analyses were performed using an LTQ Orbitrap mass spectrometer 
(Thermo Scientific, Hemel Hempstead, UK) interfaced to an Agilent 1100 binary 
pump LC system (Agilent Technologies. Inc., Palo Alto, CA, U.S.A.). Analytes were 
resolved on a Phenomenex Kinetex CIS column (150 x 2.1 mm; 2.6 pm). Eluate 
flow was 250 pl/min and the mobile phases used were 2 mM ammonium formate and 
10:90 water:ACN.
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4.3 RESULTS
4.3.1 In vitro assessment of glucuronidatlon of furosemide and TPA
Glucuronidation of furosemide and TPA were assessed using UDPGA-supplemented 
RLM, MLM and HLM incubations. Naloxone was used as a positive control (Kilford 
et al, 2009, Di Marco et al., 2005). In incubations including naloxone and UDPGA 
cofactor, the levels of parent compound decreased rapidly compared to incubations 
omitting UDPGA, where parent compound levels remained constant throughout the 
experiment. However, in incubations containing UDPGA and either furosemide or 
TPA, parent compound levels did not decrease; suggesting little furosemide- or TPA- 
glucuronide was formed. It is known that naloxone undergoes much more rapid 
glucuronidation than furosemide by HLM and, especially, RLM (Di Marco et al., 
2005)
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Figure 4.4: Assessment of glucuronidation of furosemide, TPA and naloxone in 
RLM. Graphs show levels of parent compound, (A) furosemide, (B) TPA and (C)
naloxone, over time, with (▼) and without (•) UDPGA. Data presented as mean + 
standard deviation for n = 3.
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Figure 4.5: Assessment of glucuronidation of furosemide, TPA and naloxone in 
MLM. Graphs show levels of parent compound, (A) fiirosemide, (B) TPA and (C)
naloxone, over time, with (T) and without (•) UDPGA. Data presented as mean + 
standard deviation for n = 3.
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Figure 4.6: Assessment of glucuronidation of furosemide, TPA and naloxone in 
HLM. Graphs show levels of parent compound, (A) furosemide, (B) TPA and (C)
naloxone, over time, with (T) and without (•) UDPGA. Data presented as mean + 
standard deviation for n = 3.
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4.3.2 Identification of biliary [14C]-TPA metabolites in the Wistar rat by 
radiometric HPLC and LC-MS/MS
Analysis of the biliary metabolites of TPA in the rat and mouse has been performed 
previously (Butler, 2006). Figure 4.7 shows the radiochromatogram and LC-MS/MS 
profile of metabolites of TPA in rat bile. The parent compound (TPA) eluted at 28.9 
minutes on the radiochromatogram and constituted 31.4 ± 0.81% (mean ± SEM) of 
the excreted dose. A corresponding peak on the LC-MS total-ion chromatogram (m/z 
345, [M-l]') eluted at 29.2 minutes, and in-source fragmentation gave confirmation 
that this was the parent compound by fragments at m/z 301 (loss of CO2 from the 
carboxylic acid function) and m/z 78 (NSO2). At 5.0 minutes a small peak (Ml) was 
seen on the radiochromatogram. A peak of m/z 668 eluting at a similar time was seen 
by LC-MS analysis. Fragments at m/z 345 (TPA anion), m/z 306 (OS') and m/z 249 
(loss of the thiophene-2-ylmethyl moiety from TPA anion) suggest that Ml (1.36 ± 
0.65% excreted dose) could correspond to a GSH conjugate of a monooxygenated 
species, i.e,, schematically, M+GSH+O. Apparent formation of m/z 345 from m/z 
668 implies neutral loss of GSH-2H (305 amu) and dehydration of the [OJTPA 
moiety. Neutral loss of 305 amu from GSH conjugates is somewhat unusual but has 
been observed previously (Wen et ah, 2008), A wide radioactive peak with a 
retention tune of 14.6 minutes could potentially be overlapping peaks of two separate 
metabolites (amounting to 47.58 ± 3.75% of excreted dose). LC-MS analysis 
identified two putative metabolites, m/z 670 (M2) and m/z 249 (M3) eluting at 15.4 
minutes and 15.7 minutes respectively. Fragmentation patterns, from Butler, 2006, 
(PhD thesis, University of Liverpool), of these compounds suggest M2 may be 
another TPA-GSH conjugate, with hypothetically an 18 amu increment on the 
thiophene ring and M3 may be the TPA N-dealkylated metabolite; in which case, M3 
will be identical to the N-dealkylated metabolite of furosemide described by 
Williams et al. (2007). The radioactive peak eluting at 21.2 minutes (M4) 
corresponds to a peak of m/z 521 on the LC-MS chromatogram. Fragments at m/z 
345 (TPA) and m/z 175 (dehydroglucuronic acid anion; (Bosken et al, 2000)) 
suggest that M4 (19.62 ± 3.64% of excreted dose) is a TPA-glucuronide metabolite.
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Figure 4.7: Radiometric HPLC and API 2000 LC-MS/MS analysis of TPA and 
metabolites in rat bile. (A) Radiochromatogram and (B -F) extracted ion-current 
(XIC) chromatograms (negative-ion analysis) of (B) Ml at m/z 668, (C) M2 at m/z 
670, (D) M3 at m/z 249, (E) M4 at m/z 521 and (F) parent compound (TPA) at m/z 
345. 0 to 1 hour biliary metabolites of [l4C]-TPA administered to anaesthetised rats 
(144 fimol/kg TPA + lOpCi [l4C]-TPA in DMSO administered i.v).
4.3.3 Identification of [14C]-TPA metabolites in freshly isolated Wistar rat 
hepatocytes.
The radiochromatogram of TPA metabolites in rat hepatocytes (Figure 4.8) shows 
drug-related compounds with retention times similar to those of metabolites found in 
rat bile, suggesting that they could be N-dealkylated TPA, TPA glucuronide and two 
TPA-GSH conjugates (Figure 4.7). The MRM data, generated using the 4000-Qtrap 
mass spectrometer, indicated the presence of an N-dealkylated TPA metabolite and 
the glucuronide metabolite (Figure 4.9).
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Time (Minutes)
Figure 4.8: Radiochromatogram of metabolites of |14C]-TPA from rat 
hepatocytes. Incubations contained 0.6 pCi [l4C]-TPA (50 pM) in 6 ml incubation 
for 6 hours. Retention times of metabolites are consistent with those seen in rat bile 
(Figure 4.7).
Time (Minutes)
Figure 4.9: LC-MS/MS MRM analysis of TPA and metabolites in rat 
hepatocytes, using the API 4000-Qtrap instrument. (A) Total ion-current (TIC) 
chromatogram of TPA metabolites from hepatocytes and XIC chromatograms for 
MRM transitions (B) m/z 345 —> m/z 301 (TPA), (C) m/z 249 —► m/z 205 (N- 
dealkylated TPA) and (D) m/z 521 —> m/z 345 (TPA glucuronide).
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Data generated using the LTQ-Orbitrap mass spectrometer, operating in negative-ion 
mode, detected the presence of multiple putative metabolites ([M-H]') at m/z 650, 
668 and 670; masses consistent with substitution of GSH (GSH-2H), addition of 
GSH + O and addition of GSH + 2H + O, respectively (Figure 4.10). Detection of a 
Cl isotope peak for each of the species provided confirmation that they were drug- 
related compounds. For both the m/z 668 (TPA + GSH + O) and m/z 670 (TPA + 
GSH + 2H + O) metabolites, MS/MS (product-ion) data were generated (Figure 4.13 
and 4.15). The signals from the two peaks at m/z 650 were weak and therefore no 
MS/MS data were generated.
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TPA + GSH -2H
c 100 -1
TPA + GSH +0
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TPA + GSH +2H +0
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Figure 4.10: LC-MS analysis for putative GSH adducts of TPA (1000 pM) 
formed in rat hepatocytes, using the LTQ Orbitrap mass spectrometer. XIC
chromatograms of (A) m/z 650, corresponding to the substitution of glutathione for 
hydrogen; (B) m/z 668, corresponding to the addition of GSH to monoxygenated 
TPA; and (C) m/z 670, corresponding to the addition of GSH to monoxygenated and 
reduced TPA. (NB, for ‘A’ and ‘B’, the sequence of additions is representative and 
does not imply knowledge of the metabolic pathway).
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Figure 4.11: XIC chromatogram for m/z 650 (A) and full ion scans for peaks 
detected in the XIC chromatogram for m/z 650 (B, C). Analysis carried out using 
a LTQ Orbitrap mass spectrometer.
The full ion scans from the peaks detected in the XIC chromatogram for m/z 650 
(Figure 4.11 A) indicated that the first eluting peak (RT 4.35 minutes) may be a 
dehydration ([M-I-H2O]') fragment of an m/z 668 metabolite; m/z 668 (and its ' Cl 
isotopologue at m/z 670) were the most abundant ions present (Figure 4.11 C) and 
the retention time (4.35 minutes) was essentially the same as that of the second 
eluting peak in the XIC chromatogram for m/z 668 (4.31 minutes; Figure 4.10 B). 
Dehydration is a common mass spectral fragmentation of GSH adducts of 
oxygenated drugs and metabolites (Madden et al., 1996, Chen et a/., 2002, 
Subramanian et al., 2002) but can also occur in the case of non-oxygenated GSH 
adducts (Maggs et al., 1995, Wen et al., 2009); implying that the GSH residue can 
undergo dehydration. An m/z 650 ion and its 7C1 isotopologue were the most 
abundant ions in the full ion scan from the later eluting peak (RT 4.53 minutes; 
Figure 4.11 B), indicating a possible TPA metabolite with a GSH substituent, 
however the signals were too low to generate any MS/MS data. Unfortunately, the 
later eluting peak of m/z 650 may also represent a dehydration fragment of an m/z
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668 species (Figure 4.10 B; RT 4.57 minutes); a somewhat abundant m/z 668 ion was 
present in the full scan of this peak (Figure 4.11 B).
4.31
m/z
Figure 4.12: XIC chromatogram for m/z 668 (A) and full ion scans for peaks 
detected in the XIC chromatogram for m/z 668 (B, C). Analysis carried out using 
a LTQ Orbitrap mass spectrometer.
The m/z 668 ion was the most abundant in the full ion scans (Figure 4.12 B and C) 
for both major peaks detected in the XIC chromatogram for m/z 668 (Figure 4.12 A). 
An MS/MS product ion spectrum (Figure 4.13 A) of the first eluting peak (RT 3.02) 
showed fragments at m/z 620 (loss of SO (48 amu) from a thiophene S-oxide moiety 
(Dansette et a/., 2005, Shimizu et ai, 2009), m/z 344.9 (loss of 305 amu ([GSH-2H]) 
and 18 amu (H2O)) and m/z 300.9 (loss of 44 amu (CO2) from m/z 345). There was 
also a fragment at m/z 272, found generically in the negative-ion spectra of GSH 
adducts (Subramanian et a/., 2002, Dieckhaus et ai, 2005), representing GS’ minus
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H2S (Figure 4.12 A). An MS/MS product ion spectrum (Figure 4.13 B) of the second 
eluting peak of m/z 668 (RT 4.31) showed fragments at m/z 361 ([M-l-GSFI]") and 
m/z 306 (GS‘). There was also a fragment at m/z 249 representing the N-dealkylated 
TP A (Figure 4.13 B). How these two GSH adducts relate structurally to the 
radiolabelled peak of m/z 668 found in rat bile is not entirely clear: the biliary 
metabolite yielded fragments at m/z 345 (seen in mass spectrum of hepatocyte 
metabolite ‘m/z 668 F), 306 (‘m/z 668 IF) and 249 (‘m/z 668 IF). Neutral loss of 
GSH, i.e. retro-Michael elimination of GSH, is often seen in positive-ion spectra of 
GSH adducts (Wen et al, 2008, Leblanc and Sleno, 2011, Yan and Caldwell, 2005), 
including those of certain oxygenated thiophenes (Dansette et al., 2005, Shimizu et 
al, 2009). The same loss might be expected in negative-ion spectra of GSH adducts 
but these spectra are often dominated by GS‘, i.e. the glutathione anion, and its 
fragments (Subramanian et al, 2002, Dieckhaus et al, 2005). The present case, with 
a dominant [M-l-GSH]", is clearly an exception to this observation. The complete 
absence of losses of 48 amu and H20 from the parent ion of the second M+O+GSH 
metabolite implies the structures of these metabolites are fundamentally different. 
Divergent bioactivation pathways of a thiophene, yielding, ultimately, isomeric GSH 
adducts, are known (Dansette et al, 2005, Shimizu et al, 2009) but the diagnostic 
fragmentations of the TPA ‘m/z 668’ adducts differ more markedly than those of 
published isomeric structures. Thus MS/MS data from both peaks suggest two GSH 
adducts of a molecular weight of 669 may be formed from TPA.
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Figure 4.13: MS/MS analysis of TPA metabolites, from rat hepatocytes, detected 
at m/z 668. Analysis carried out using a LTQ Orbitrap mass spectrometer.
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4.38
Figure 4.14: XIC chromatogram for m/z 670 (A) and full ion scans for peaks 
detected in the XIC chromatogram for m/z 670 (B, C). Analysis carried out using 
a LTQ Orbitrap mass spectrometer.
The full ion scans from the peaks detected in the XIC chromatogram (Figure 4.14 B- 
D) for m/z 670 suggest that the peak at RT 4.38 minutes may be interference from the 
coterminal m/z 668 metabolite; m/z 668 and the putative 37C1 isotope peak at m/z 670 
were the most abundant ions present (Figure 4.1.4 C) and the retention time (4.38 
minutes) was essentially the same as that of the second eluting peak in the XIC 
chromatogram for m/z 668 (4.31 minutes; Figure 4.12 A). Full ion scans of both the 
first (4.2 minutes) and last (4.63) eluting peaks show that the most abundant ion is 
m/z 670 (and the 37C1 isotope peak at m/z 672), suggesting that these peaks are TPA- 
related and may be formed by addition of GSH, O and 2FI. MS/MS data were only 
generated for the last eluting peak as the signals of the others were too weak. An 
MS/MS product ion spectrum of the last eluting peak of m/z 670 (RT 4.63; Figure
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4.15) showed GSH fragments at m/z 272 (GS‘ minus H2S) and m/z 254 ([272-H2O)]') 
another known negative-ion fragment of GSH adducts (Subramanian et ai, 2002, 
Dieckhaus et al., 2005) as well as m/z 306 (GS‘). Fragments at m/z 345 (TPA anion) 
and m/z 249 (loss of the thiophene-2-ylmethyl moiety from the TPA anion) were also 
detected. The abundant ion at m/z 608 ([M-62]') cannot be assigned to 
fragmentations characteristic of either GSH adducts or thiophene S-oxides. 
Hypothetically, it can be attributed to independent loss of H2O and CO2 (from a 
carboxylic acid function?). Loss of GSH from m/z 670 would yield the ion at m/z 
363. Dehydration of m/z 363, in turn, would yield m/z 345. These fragmentations do 
not allow a derivation of the metabolites’ structure and metabolic origin but do imply 
the adduct is not an S-oxide. The retro-Michael elimination of GSH and formation of 
GS' suggest a structural similarity with ‘m/z 668 IT (Figure 4.13), while the unusual 
formation of the ion at m/z 608 indicates an additional, major, biotrans format ion. 
Nevertheless, the TPA+0+GSH-2H adduct might as easily be a product of a discrete 
metabolic pathway as a derivative of‘m/z 668 IT.
m/z 670 (RT 4.63 minutes)
248 9720 
254.0748 
272.0850
„„„ „ 362 9853
31^.8815
344.0734 396
Figure 4.15: MS/MS analysis of a TPA metabolite, from rat hepatocytes, 
detected at m/z 670. Analysis carried out using a LTQ Orbitrap mass spectrometer.
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4.3.4 Identification of |,4C]-TPA metabolites in freshly isolated CD-I mouse 
hepatocytes.
The radiochromatogram of TPA metabolites in mouse hepatocytes shows drug- 
related compounds with retention times similar to those of metabolites found in rat 
bile (Figure 4.16). Based on co-elution with metabolites seen in rat bile it is 
suggested that TPA was metabolised to N-dealkylated TPA, TPA glucuronide and 
one/two TPA-GSH conjugates in mouse hepatocytes. The MRM data generated 
using the 4000-Qtrap mass spectrometer indicated the presence of the N-dealkylated 
TPA metabolite and the glucuronide metabolite (Figure 4.17)
Time (Minutes)
Figure 4.16: Radiochromatogram of metabolites of [14C]-TPA from mouse 
hepatocytes. Incubations contained 0.6 pCi [l4C]-TPA (50 pM) in 6 ml incubation 
for 6 hours. Retention times of metabolites are consistent with those seen in rat bile.
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Figure 4.17: LC-MS/MS MRM analysis of TPA and metabolites in mouse 
hepatocytes, using the API 4000-Qtrap instrument. (A) Total ion-current (TIC) 
chromatogram ot TPA metabolites from hepatocytes and XIC chromatograms for 
MRM transitions (B) m/z 345 -» m/z 301 (TPA), (C) m/z 249 —► m/z 205 (N- 
dealkylated TPA) and (D) m/z 521 —► m/z 345 (TPA glucuronide).
Data generated using the LTQ-Orbitrap mass spectrometer operating in negative-ion 
mode, detected the presence of TPA metabolites at m/z 668 and 670, masses 
consistent with addition of GSH + O and GSH + O + 2H, respectively, but not, as in 
the case of rat hepatocytes (Figure 4.10), at m/z 650 (Figure 4.18 A). Detection of a 
' Cl isotope peak for each of the metabolites provided confirmation that they were 
drug-related. MS/MS data were not generated for any of the putative GSH adducts 
detected in mouse hepatocyte samples as the signals were too weak.
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Figure 4.18: LC-MS analysis for putative GSH adducts of TPA (1000 pM) 
formed in mouse hepatocytes, using the LTQ Orbitrap mass spectrometer. XIC
chromatograms of (A) m/z 650, corresponding to the substitution of glutathione for 
hydrogen; (B) m/z 668, corresponding to the addition of GSH to monoxygenated 
TPA; and (C) m/z 670, corresponding to the addition of GSH to monoxygenated and 
reduced TPA. (NB, for ‘A’ and ‘B’, the sequence of additions is representative and 
does not imply knowledge of the metabolic pathway).
The full ion scans from the peaks detected in the XIC chromatogram for m/z 668 
(Figure 4.19 A) indicated that the later eluting peak (RT 4.46 minutes) may overlap 
the m/z 670 metabolite as the retention time (4.46 minutes) was similar to that of a 
peak in the XIC chromatogram for m/z 670 (4.51 minutes; Figure 4.18 C) and the m/z 
670 ion was more abundant. An m/z 668 ion and its '7C1 isotopologue were the most 
abundant ions in the full ion scan from the first eluting peak (RT 3.08 minutes; 
Figure 4.19 C), indicating a possible TPA metabolite with addition of GSH + O. 
However, MS/MS data could not be generated to confirm this deduction.
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Figure 4.19: XIC chromatogram for m/z 668 (A) and full ion scans for peaks 
detected in the XIC chromatogram for m/z 668 (B, C). Analysis carried out using 
a LTQ Orbitrap mass spectrometer.
An m/z 670 ion and its 37C1 isotopologue were amongst the most abundant ions in the 
full ion scan (Figure 4.20 B) from the peak detected in the XIC chromatogram for 
m/z 670 (RT 4.51 minutes; Figure 4.20 A), indicating a possible TPA metabolite with 
addition of GSH + O + 2H. However, MS/MS data could not be generated to confirm 
this deduction.
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Figure 4.20: XIC chromatogram for m/z 670 (A) and full ion scan for the peak 
detected in the XIC chromatogram for m/z 670 (B). Analysis carried out using a 
LTQ Orbitrap mass spectrometer.
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4.4 DISCUSSION
The principal aims of the work described in this chapter were to investigate whether 
the differences between the hepatotoxicity of furosemide and TPA in mice could be 
explained by differences between bioactivation and detoxification of the compounds ’ 
reactive metabolites. TPA did not induce severe hepatotoxicity in mice when 
administered via an i.p or oral route. TPA did however significantly deplete hepatic 
GSH at 24 hours compared to vehicle control and was shown to undergo 
bioactivation and bind covalently to hepatic protein in vitro. The reactive metabolite 
of furosemide binds covalently to murine hepatic protein in vivo and elicits 
hepatotoxicity. This does not occur in rats, in which the metabolite is excreted in the 
form of a GSH conjugate; suggesting a possible safety mechanism exists in rats to 
protect them from furosemide-induced hepatotoxicity (Williams et a!., 2007). It was 
suggested that TPA’s reactive metabolite may be a better substrate for GSTs in the 
mouse liver and therefore undergoes detoxification via GSH conjugation. Elucidating 
the putative detoxification pathways of TPA and comparing them with those of 
furosemide may provide a rational for the differences between the hepatotoxicity of 
the two compounds.
The work described in Chapter 2 provided evidence that TPA undergoes 
bio activation, and that the reactive metabolite(s) produced can bind covalently to 
hepatic protein in vitro. It was also shown that the degree of covalent binding could 
be reduced by the inclusion of GSH in microsomal incubations. The thiophene ring is 
often bioactivated in drugs and other xenobiotics to either a thiophene S-oxide or an 
epoxide (Medower et a!., 2008, Kalgutkar et al, 2005, Dansette et al., 2005, 
Machinist et al, 1995, Dalvie et al, 2002, Chen et al, 2011) and has been associated 
with toxicity in certain cases (O'Donnell et al, 2003, Lecoeur et al, 1996, Graham et 
al, 2008). A common mechanism for the detoxification of reactive drug metabolites 
occurs via GSH conjugation (Williams et al, 2007). GSH conjugation can occur 
either spontaneously or through an enzyme (GST) mediated reaction (DeLeve et al, 
1991); GSH conjugation ofNAPQI, the reactive metabolite of APAP, is spontaneous 
and GSH depletion is required before covalent binding to proteins and toxicity 
ensues (Mitchell et al, 1973b). The reactive metabolite of furosemide does not 
undergo conjugation with GSH in the mouse in vivo, however it was shown in 
Chapter 2 that TPA caused GSH depletion at 24 hours. The identification of drug
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metabolite-GSH adducts in a preclinical setting is sometimes treated as a hazard 
signal as it is indicative of reactive metabolite formation (Reese et al, 2010, Gan et 
a!., 2009), conversely it could be argued that a GSH adduct is an indication of an 
effective detoxification system. In the latter case, it follows that individuals will 
become vulnerable to drug toxicity if then* tissue GSH is depleted substantially 
(Nishiya et ah, 2008, Shimizu et ah, 2011). The FS-GSH conjugate is only seen in 
the rat, where there is no evidence of covalent binding to hepatic protein or 
hepatotoxicity (Williams et ah, 2007).
In an investigation into the biliary metabolites of TPA in the rat, two TPA-GSH 
adducts were detected. The metabolic pathways of TPA are similar to those of 
furosemide. Fragments at m/z 345 (TPA anion), m/z 306 (GS') and m/z 249 
(dealkylated TPA) suggest that Ml (1.36 ± 0.65% excreted dose) could correspond 
to a GSH conjugate with an additional oxygen. LC-MS/MS analysis identified, 
tentatively in the case of M2, the two co-eluting metabolites M2 (m/z 670) and M3 
(m/z 249), which represented 47.58 ± 3.75% of the excreted dose. Fragmentation 
patterns of these compounds (Butler, 2006) suggest M2 may be another TPA-GSH 
conjugate, with a 18 amu (nominally, O + 2H) addition to the thiophene ring, and M3 
may be the TPA N-dealkylated metabolite. Fragments at m/z 345 (TPA) and m/z 175 
(dehydroglucuronic acid anion) suggest that M4 is a TPA-glucuronide metabolite 
(19.62 d= 3.64% of excreted dose); presumably, by analogy with the corresponding 
metabolites of furosemide (Williams et ah, 2007, Mizuma et ah, 1998), the acyl 
glucuronide. As observed previously for furosemide (Di Marco et ah, 2005), the rate 
of furosemide and TPA glucuronidation in hepatic microsomal incubations was 
relatively slow compared to naloxone. Because of their chemical reactivity, unstable 
acyl glucuronides have been associated almost generically, if somewhat 
inconclusively, with a potential for causing clinical drug toxicity (Regan et ah, 
2010). furosemide’s acyl glucuronide is relatively stable under standard in vitro 
conditions (Stachulski et al., 2006), and it seems unlikely that substitution of its 
fiiran ring with a thiophene ring will affect chemical reactivity greatly. However, 
LC-MS/MS analysis of TPA’s metabolites in rat bile and rat hepatocytes, revealed 
multiple closely eluting peaks in the mass chi*omatograms corresponding to the TPA 
glucuronide. This pattern is characteristic of an (unstable) acyl glucuronide that has
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undergone positional isomerisation through acyl migration at pH >7.0 (Stachulski et 
al.t 2006, Kenny et al., 2004).
Biliary metabolites of furosemide are well represented by furosemide metabolism in 
hepatocytes (Williams et al., 2007). Freshly isolated rat and mouse hepatocytes were 
used to investigate TP A cytotoxicity (Chapter 2) and metabolism. Although TP A did 
not induce hepatotoxicity in vivo, it was cytotoxic in freshly isolated rat and mouse 
hepatocytes, caused GSH depletion and underwent covalent binding, all in a dose- 
dependent manner. The radiochromatogram of TPA metabolites in rat hepatocytes 
shows drug-related compounds with retention times similar to those found in rat bile. 
This study identified the presence of an N-dealkylated TPA metabolite and the 
glucuronide metabolite from rat and mouse hepatocytes. Analysis using the LTQ- 
Orbitrap mass spectrometer detected the presence of metabolites at m/z 668 and 670 
in mouse hepatocytes, masses consistent with addition of GSH; however the 
identities of these metabolites could not be confirmed with MS/MS analysis as the 
signals were too weak. Analysis of metabolites from rat hepatocytes using the LTQ- 
Orbitrap mass spectrometer detected the presence of metabolites at m/z 650, 668 and 
670, masses consistent with substitution or additions of GSH; the identities of the 
GSH adducts were confirmed with MS/MS analysis.
GSH adducts formed by metabolic pathways that result in net substitution of 
hydrogen or by addition of GSH to an oxygenated intermediate, such as an S-oxide 
or an epoxide (Dansette et al, 2005, Shimizu et al, 2009), with retention of the 
oxygen, are well documented (Zheng et al, 2007, Wen and Fitch, 2009a). The 
structure of the m/z 650 [M-H]' ion given in Figure 4.21 (A) is certainly the 
conventional representation of a thiophene-ring substituted GSH adduct (O'Donnell 
et al, 2003). However, the data described here suggests, quite strongly, and certainly 
in one case that the m/z 650 analyte ions are dehydration fragments of the m/z 668 
[M-H]" metabolite ions (schematically, equivalent to M+O+GSH; figure 4.21 B) 
based on the fact that they are chr o mato graphic ally coincidental. Thiophene-ring 
substitution adducts (M+GSH-2H), as observed metabolites, are in most cases 
thought to be formed, in vitro or in vivo, by spontaneous dehydration of the primary 
GSH addition product (M+O+GSH); derived from an epoxide or S-oxide 
intermediate (O'Donnell et al, 2003). The interesting exceptions are GSH adducts of
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2,5-diaminothiophene derivatives, apparently derived from 2,5-diimine thiophene 
reactive intermediates (Hu et al, 2010). Although it is probable that adducts of the 
M+O+GSH type (i.e. m/z 668 for [M-H]") will in practice be seen only rarely because 
of dehydration, or possibly thiolysis (Valadon et al., 1996), in situ or during sample 
work up, two such metabolites were isolated in the case of 2-phenylthiophene 
(Dansette et al., 2005); one derived from an epoxide, the other from the iS'-oxide 
intermediate. The two M+O+GSH adducts of TPA formed by rat hepatocytes, based 
upon their mass spectral fragmentations, also had markedly different structures, and 
thereby are likely to be end products of divergent pathways of metabolic activation.
One of the metabolites ('m/z 668 F) gave a fragmentation ([M-SO]‘ ) highly 
diagnostic of an S-oxide (Dansette et al, 2005, Shimizu et al., 2009). The structure, 
and possible metabolic origins, of the other adduct ('m/z 668 IF) could not be 
deduced from the mass spectral data. Retro-Michael elimination of GSH was 
obtained from the GSH adduct of 2-phenylthiophene S-oxide but not from the ex­
epoxide adduct (Dansette et al, 2005). Both of the 2-phenylthiophene adducts but 
neither of the TPA adducts underwent parent-ion dehydration. Exceptionally, neither 
of the TPA metabolites, unlike the 2-phenylthiophene adducts, eliminated 
pyi'oglutamate (129 amu); the essentially generic neutral fragment of GSH thioether 
conjugates (Wen et al, 2008, Subramanian et al, 2002).
The M2 adduct (m/z 670), represented schematically by the addition of GSH, an 
oxygen atom and two hydrogens to TPA, has no counterpart amongst the many GSH 
(and GSH ethyl ester) adducts of various structural types reported by Zheng et al 
(2007), Wen and Fitch (2009a) and Wen et al (2009). Therefore the precise structure 
and mechanism of formation of M2 remain ambiguous. Valadon et al. (1996) 
observed some open-ring intermediate structures from their study of the NADPH- 
dependent microsomal metabolism of a tienilic isomer in the presence of 
mercaptoethanol. They proposed an addition of thiol to an S-oxide, with subsequent 
thiol additions caused thiophene ring opening (note, however, then stable end 
products were closed-ring structures). Conceivably a similar pathway in the 
metabolism of TPA could yield the structure shown in Figure 4.21 (E). The proposed 
metabolic activation pathways of TPA are shown in Figure 4.22.
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rrVz 650.0(1)
Molecular Formula: C??H?6CIN5O10S3
nVz 650.0(11)
Molecular Formula: C^H^CINjO^Sa
rrVz 668.0(1)
Molecular Formula: C22H28CIN501,S3
nVz 668 0(11)
Molecular Formula: C^H^ClN^O^Sa
TPA ♦ GSH + 2H + O 
nVz 670.1
Molecular Formula: C^H^CINjOnSa
'oh
Figure 4.21: Proposed structures of TPA GSH adducts. No MS/MS data was 
generated for the compounds at m/z 650 I (A), 650 II (B), therefore their structures 
have been tentatively assigned; they may be in-source dehydration products of an m/z 
668 analyte ion. A neutral loss of 48 amu signifies that 668 I (C) is an 5-oxide; m/z 
668 II (D) peaks can be assigned to a GSH adduct by virtue of the neutral loss of 
GSH but it does not yield fragments that allow characterization, the structure 
presented here is tentative. Assumed structure of m/z 670 (E), based on the masses 
detennined during analysis using the LTQ-Orbitrap mass spectrometer.
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The aim of this chapter was to describe the metabolism of TPA in vivo and in vitro, 
and compare it to that of furosernide. It was hypothesized that the differences 
between the hepatotoxicity of furosernide and TPA reported in Chapter 2 could be 
explained through identification of differential detoxification mechanisms. A TPA- 
GSH adduct was identified in rat bile and another metabolite was tentatively 
assigned to a TPA-GSH adduct. Additionally, rat and mouse hepatocyte incubations 
with TPA also produced TPA-GSH adducts; suggesting that a successful 
detoxification mechanism exists in both species, potentially contributing to a lack of 
hepatotoxicity of TPA.
(rrVz 668 (II); TPA + GSH + O)
Figure 4.22: Proposed metabolic pathways of TPA. The metaboplic pathways 
represented by double arrows signify uncharacterised metabolic pathways producing 
GSH adducts of uncertain structure; the two adduct structures {m/z 668 II and m/z 
670) in are representative of potential structures.
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CHAPTER 5
NEVIRAPINE MERCAPTURATES AS MARKERS OF IN VITRO 
AND IN VIVO BIOACTIVATION AND TOXICITY
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5.1 INTRODUCTION
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used 
in the treatment of HIV-1 infection. Adverse effects of nevirapine include skin rash 
and hepatotoxictiy. The incidence of nevirapine-induced skin rash in man has been 
reported in 3.4 - 48% of adults (Carr and Cooper, 2000, Pollard et a!., 1998, 
Phanuphak et al, 2007, Barreiro et al.> 2000, Bersoff-Matcha et al, 2001, Bonnet et 
ah, 2002, Pujari et al, 2004, Earner and Myers, 1998, Havin' et al, 1995). Severe or 
life-threatening skin reactions, including Stevens - Johnson syndrome (SJS), toxic 
epidermal necrolysis (TEN) and hypersensitivity, have been observed in 1.5% of 
patients (Carr and Cooper, 2000, Pollard et al, 1998, Phanuphak et al, 2007, Fagot 
et al, 2001, Claes et al, 2004). Nevirapine has been associated with varying degrees 
of hepatotoxicity (De Maat et al, 2002, Chu et al, 2010, Brtick et al., 2008), and can 
cause severe or life-threatening hepatotoxicty in around 1.0 - 3.2% of HIV patients 
(Pollard et al, 1998, Pujari et al, 2004, Martinez et al, 2001, Sanne et al, 2005). 
There is evidence to suggest that nevirapine undergoes bioactivation to a reactive 
metabolite (Takakusa et al, 2008, Wen et al, 2009, Antunes et al., 2010); a common 
mechanism for the detoxification of reactive metabolite occurs via GSH conjugation 
(Williams and Naisbitt, 2002). Human urinary mercapturates (breakdown products of 
GSH-adducts) have been used as biomarkers of human exposure to reactive species 
(Seutter Berlage et al, 1977). The investigations in this chapter aimed to assess 
whether nevirapine mercapturates are indicative of bioactivation and toxicity in the 
rat, in vivo and in vitro.
Freshly isolated hepatocyte suspensions have been shown to be an important tool in 
investigations into the bio activation-dependant mechanisms of idiosyncratic 
hepatotoxins (Higaki et al, 1989, Masubuchi et al, 1998, Graham et al, 2008). They 
provide a physiological relevant system to assess the toxicological outcomes of phase 
I and phase II metabolism of drugs, as they contain all sub-cellular organelles and all 
metabolically relevant enzymes and co-factors, at levels that reflect the in vivo 
situation (Elaut et al, 2006). Rat hepatocytes were found in be a good system to 
study bioactivation-dependant toxicity of amodiaqume and methapyrilene, both 
human idiosyncratic hepatotoxins (Graham et al, 2008, Tafazoli and O'Brien, 2009). 
However, there are limitations with this system; not all human idiosyncratic 
hepatotoxins induce toxicity in rat hepatocytes. Isoniazid, is thought to induce
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idiosyncratic hepatotoxicity through metabolism of the parent compound, however 
fails to induce cytotoxicity in rat hepatocytes.
Animal models of idiosyncratic drug reactions can provide a means of investigating 
mechanisms of toxicity. However, these models are rare as is it difficult to reproduce 
an infrequent clinical ADR, reproducibly, in a laboratory species. Uetrecht and 
colleagues have extensively characterised a dose-dependent, nevimpine-induced skin 
rash in female Brown Norway rats (Shenton et ah, 2003, Shenton et ah, 2005, 
Popovic et ah, 2006, Chen et ah, 2008, Uetrecht et ah, 2010). The rash appears to be 
immune-mediated (Shenton et ah, 2005), resembling the idiosyncratic cutaneous 
reaction seen in humans (Shenton et ah, 2003, Shenton et ah, 2004), and keratinocyte 
cell death was observed similar to that seen in SJS (Shenton et ah, 2003). The 
nevirapine-induced skin rash in Brown Norway rats holds other similarities to that 
seen in humans in terms of; the time of onset, females being more susceptible than 
males, incidence increases with dose, escalating dose of nevirapine can reduce 
incidence, rechallenge results in more severe rashes than on initial exposure (Shenton 
et ah, 2003, Uetrecht et ah, 2010).
Nevirapine has the potential to be bioactivated to various reactive intermediates 
(Figure 5.1) and evidence for the bioactivation of nevirapine has been shown in 
various in vitro studies. Nevirapine has been shown to bind covalently to RLM 
(Takakusa et ah, 2008). A single GSH adduct was identified in HUM and incubations 
with recombinant CYP 3A4 (Wen et ah, 2009). The pathway of metabolism through 
12-hydroxy nevirapine has been implicated in formation of the nevirapine reactive 
metabolite. Antunes et ah (2009) demonstrated the reactivity of 12-sulphoxy 
nevirapine by formation of multiple DNA adducts in reactions with 12-mesyloxy 
nevimpine. 12-OH NVP was found to be a substrate for sulphotransferase in rats 
(Chen et ah, 2008), and it has been proposed that the sulphate ester dissociates to 
form reactive quinone methide intermediate (Chen et ah, 2008, Uetrecht, 2006). The 
quinone methide could also be generated by enzymic oxidation (Wen et ah, 2009). 
Hydroxyheteroaiyl metabolites (Riska et ah, 1999) are potential precursors of 
reactive quinine imines (Wen et ah, 2009). The cyclopropylamine group has the 
potential to be bioactivated to an aminium cation radical via N-dealkylation
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(Takakusa et aL, 2008). Nevirapine could also form one or more heteroarene epoxide 
metabolites in either of the pyridine rings.
GSH conjugation of drug reactive metabolites is a common mechanism 
detoxification (Williams et aL, 2002). The identification of drug metabolite-GSH 
adducts in a preclinical setting is sometimes treated as a hazard signal as it is 
indicative of reactive metabolite formation (Gan et aL, 2009, Reese et aL, 2010), 
conversely it could be argued that a GSH adduct is an indication of an effective 
detoxification system. In light of improved bioanalytical techniques, urinary 
mercapturates (breakdown products of GSH-adducts) have been used as biomarkers 
of human exposure to reactive species and in the quantitative assessment of in vivo 
bioactivation (Seutter Berlage et aL, 1977).
With the aim to assess the plausibility of using nevirapine mercapturates as a 
translational marker of nevirapine bioactivation and toxicity, the work presented in 
this chapter intended to test the current model of nevirapine-induced skin toxicity 
and correlate with formation of nevirapine mercapturates. Freshly isolated rat 
hepatocytes were used initially, as a well defined in vitro system, to investigate the 
bioactivation and toxicity of nevirapine. Uetrecht’s model of nevirapine-induced skin 
rash in Brown Norway rats was employed to test the hypothesis in vivo. A dosing 
schedule over three weeks was designed to measure nevirapine mercapturate levels 
over time and to assess the degree of toxicity induced. Nevirapine and nevirapine 
metabolites were to be quantified by a LC-MS/MS MRM method against chemically 
synthesized and biologically produced standards. Nevirapine-induced toxicity is 
measured primarily by histopathological analysis of the skin and other tissues. 
Observational information regarding the condition of the nevirap ine-treated animals 
was also recorded by a pathologist. Clinical chemistry markers of liver toxicity were 
also to be measured in light of nevirapine-induced hepatotoxicity in man; these 
included hepatic GSH concentration and serum ALT activity measurements.
Cell death is the ultimate cause of tissue injury in DILI and drug-induced skin 
reactions. Proteins released from apoptotic and necrotic cells have been used as 
biomarkers of dmg-induced cell death (Antoine et aL, 2009). Serum quantification 
HMGB1 was to be measured by ELISA throughout the time course of nevirapine 
treatment. High mobility group box protein 1 (HMGB1) is released passively from
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necrotic cells and is and thought to have a role in alerting the innate immune system 
to dying cells (Scaffidi et al, 2002, Kono and Rock, 2008), which will be a key 
determinant in the extent of tissue damage.
ch3h 0
Aminiumcation
Figure 5.1: Potential bioactivation pathways of nevirapine.
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5.2 MATERIALS AND METHODS 
5.2.1 Materials
Nevirapine and standards of two known metabolites of nevirapine (3-OH NVP and 
12-OH NVP), were gifts from Pfizer Global Research and Development (Sandwich, 
Kent, U.K.)- They were 99% pure as determined by HPLC and NMR. Nevimpine 
was also purchased from Bosche Scientific (New Brunswick, NJ, U.S.A.). lOx Hanks 
Balanced salt solution Ca2+ was obtained from Gibco (Invitrogen Ltd, Paisley, U.K.). 
CellTiter 96® AQueous One Solution Cell Proliferation Assay kit was obtained from 
Promega (Southampton, U.K.). Collagenase A was obtained from Roche Diagnostics 
(Lewes, U.K,), Unless otherwise stated, reagents were obtained from Sigma-Aldrich 
Chemical Co. (Poole, U.K.). Ultima Gold scintillation fluid was purchased from 
PerkinEhner LAS (Seer Green, Beaconsfield, Buckinghamshfre, U.K.). All solvents 
were of HPLC grade and were products of either Fischer Scientific pic 
(Loughborough, U.K.) or VWR (Lutterworth, U.K.)
5.2.2 Experimental animals
Protocols described were undertaken in accordance with criteria outlined in a license 
granted under the Animals (Scientific Procedures) Act 1986 and approved by the 
University of Liverpool Animal Ethics Committee. Male wistar rats were obtained 
from Charles River Laboratories (Margate, U.K.) and female Brown Noiway rats 
were obtained from Harlan Laboratories (Bicester, Oxfordshire, U.K.). Animals were 
housed in a light controlled room at a constant temperature and, unless otherwise 
stated, supplied with a standard chow diet and water ad libitum.
5.2.3 Dosing regimen for 21 day nevirapine administration in food to female 
Brown Norway rats
Female Brown Norway rats (150 - 200 g) were singly housed after a 7 day 
acclimatization period and given nevirapine in food (60 - 80 mg/kg/day; 1.12 g 
nevirapine / kg food; Sequoia Research Products, Pangboume, U.K.). Animals were 
weighed daily and food (and therefore dose) was adjusted accordingly. Food was
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weighed on a daily basis and dose received was calculated (Figure 5.2). On days 6, 
13 and 20, 3 nevirapine dosed animals and 3 control animals were placed in 
metabolism cages for 24 hours; urine and feces was collected over this time and 
stored at -80°C until analysis. Animals receiving nevirapine were culled by CO: 
asphyxiation on days 7, 14 and 21 and control animals (receiving normal chow) were 
culled on day 21 (n=3 for each group). Animals were sheared and pictures were 
taken of affected areas (non-affected corresponding areas in control animals). Blood 
was taken via cardiac puncture and selected parts of the liver were removed, snap 
frozen in liquid N2 and stored at -80°C until analysis. Selected organs (liver, kidney, 
heart, lungs, spleen, adrenal glands, small intestine, large intestine, popliteal and 
mesenteric lymph nodes and brain) and skin sections (from footpad, ear, tail, 
interscapular, ventral neck and lumbo-sacral region) were taken and fixed in 4% 
paraformaldehyde (PFA) until histopathological analysis. The remaining skin was 
removed as a whole and fixed in 10% formalin. After routine paraffin wax 
embedding, sections (3-5 pM) of [list organs] were prepared, stained with 
hematoxylin and eosin and examined by light microscopy.
100.0
10 11 12 13 14 15 16 17 18 19 20 21
Time (Days)
Figure 5.2: Daily average dose of nevirapine received over 21 days. Female 
Brown Norway rats were singly housed and given nevirapine in food (1.12 g 
nevirapine / kg food). Animals were weighed daily and given enough food to give a 
dose of 150 mg/kg/day nevirapine; the graph shown the actual dose of nevirapine 
received (60-80 mg/kg/day).
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5.2.4 Determination of hepatic glutathione levels in female Brown Norway rats 
following nevirapine treatment
The glutathione (GSH) assay is based upon the 5, 5-dithiobis (2-nitrobenzoic acid)- 
GSH disulfate recycling procedure fust reported by Owens and Belcher (1965) and is 
described fully in section 2.2.10.
5.2.5 Determination of protein concentration
Soluble protein concentration was measured using the Lowry assay adapted from 
Lowiy et a!, 1951 and is described in section 2.2.12.
5.2.6 Histological analysis of skin and liver sections from nevirapine treated 
female Brown Norway rats
Histological analysis (section 2.2.15) was earned out on PFA fixed skin sections 
described earlier.
5.2.7 Measurement of alanine transaminase (ALT) activity in female Brown 
Norway rat serum following nevirapine treatment
Serum alanine transaminase (ALT) levels were determined kinetically at 37°C using 
ThermoTrace Infinity ALT Liquid stable reagent (Alpha Labs, Eastleigh, U.K) 
according to manufacturer’s instructions. ALT levels exceeding 200U/L that were 
significantly different from controls were considered to represent Hepatotoxicity 
(Kitteringham et aL, 2000).
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5.2.8 Measurement of HMGB1 levels in female Brown Norway rat serum 
following nevirapine treatment
Serum HMGB1 levels were determined by ELISA (Shino-test Corporation, Tokyo, 
Japan) according to manufacturer’s instructions using a chicken anti-HMGBl 
antibody as a catcher antibody (1 pg/well) compared to known standards using 
S.S’jSjS’-tetramethyl-benzidine turnover by a peroxidise-linked anti-HMGBl 
antibody. The detection limit was 0.1 ng/ml.
5.2.9 Hepatocyte isolation from male Wistar rats and female Brown Norway 
rats
Rat hepatocytes were isolated using a modified two-step in situ collagenase 
profusion based on Seglen (1976) as described in section 2.2.7.
5.2.10 Assessment of nevirapine-induced cytotoxicity in freshly isolated rat 
hepatocytes
Hepatocyte incubations were carried out in an orbital shaker set at 190 rpm for 6 
hours with nevirapine [0 - 500 pM in MeOH (1% v/v). Following incubation, 
cytotoxicity was determined by trypan blue exclusion (100 pi of cell suspension and 
20 pi of 0.4% trypan blue solution). Cytotoxicity was also determined by reduction 
of 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl tetrazolium bromide (MTS) solution 
using the CellTiter 96® AQueous One Solution Cell Proliferation Assay kit 
(Promega, Southampton, UK), according to the manufacturer’s instructions. Cell 
suspension (100 pi) was combined with MTS solution (20 pi), incubated at 37°C for 
1 hour, and centrifuged at 50g for 2 minutes, this was performed in triplicate. The 
absorbance of the resulting supernatant was measured at 490 nm using a 
microtiterplate reader (Dynex Technologies, Chantilly, VA).
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5.2.11 Sample preparation for the determination of GSH levels in primary rat 
hepatocytes
From the same incubations used for cytotoxicity assessment, the effect of nevirapine 
on total cellular levels of GSH was determined. Cells (IxlO6) from the hepatocyte 
incubation were centrifuged at 50g for 2 minutes. The resulting pellet was 
resuspended in 10 mM HC1. One-fifth of lysed hepatocytes were removed for protein 
content determination. The remaining hepatocyte lysate was combined with 6.5% 
(w/v) 5-sulfosalicylic acid (four parts hepatocyte lysate and one part 5-sulfosalicylic 
acid) and stored on ice for 10 minutes before centrifugation at 18,400g for 5 minutes. 
The GSH levels were determined as described section 2.2.10.
5.2.12 Quantification of nevirapine and nevirapine metabolites in rat urine 
using LC-MS/MS
Mass spectrometric analysis was carried out at the University of Liverpool (U.K.) 
and Pfizer, U.K using synthetic and biologically produced standards (Srivastava et 
al.,2010).
Liverpool - LC-MS/MS analyses were performed using an AB Sciex API 2000 mass 
spectrometer with TurboIonSpray source (AB Sciex, Foster City, CA, U.S.A.) 
interfaced to a Perkin Elmer Series 200 pump and Perkin Elmer Series 200 
autosampler (Perkin Elmer, Seer Green, Beaconsfield, Buckinghamshire, U.K.). 
Analytes were resolved on a Hypersil BDS Cl 8 column (25 x .046 cm, 5 pm particle 
size; Thermo Fisher Scientific, Runcorn, Cheshire, U.K.). The mobile phase 
consisted of 15 mM ammonium formate (adjusted to pH 4 with formic acid; 
aqueous) and ACN containing 0.05% formic acid (organic). A sample aliquot of 5 pi 
was injected onto the column, and eluted at 1 ml/min with a gradient profile as 
described in Table 5.2 (LC-MS/MS 1). Eluate split-flow to the LC-MS interface was 
approximately 200 pl/min. Nitrogen was used as the curtain and collision gas. The 
interface temperature was 200 °C. Nevirapine and metabolites were detected in the
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multiple-reaction monitoring (MRM) mode with the transitions described in Table 
5.3. Data were processed with Analyst 1.4. software (AB Sciex).
Method Column Mobile Phase Gradient
LC-MS/MS 1 Hypersil BDS A: Ammonium formate (pH 4) 0 min 5% B
C18 B: ACN (0.05% FA) 5 min 17% B
(25 cm) 15 min 25% B
19 min 50% B
19 min 50% B
26 min 5% B
LC-MS/MS 2 Onyx A: Water (5% ACN, 0.07% 0 min 0% B
C18 FA) 1 min 0% B
(10 cm) B: ACN (0.1% FA) 6 min 30% B
8 min 95% B
9 min 95% B
9 min 0% B
13 min 0% B
Table 5.2: LC methods used for the quantification of nevirapine and nevirapine 
metabolites by LC-MS/MS
Pfizer - LC-MS/MS analyses were performed using an AB Sciex API 4000 mass 
spectrometer with TurboIonSpray source (AB Sciex, Foster City, CA, U.S.A.). The 
LC system used was an Agilent 1100 binary pump LC system (Agilent Tech. Inc., 
Palo Alto, CA, U.S.A.). Analytes were resolved on an Onyx CIS column (100 x 10 
mm; Phenomenex, Macclesfield, Cheshire, U.K.). The mobile phase consisted of 
dLLO containing 5% ACN and 0.1% formic acid (aqueous) and ACN containing 
0.1% formic acid (organic). A sample aliquot of 20 pi was injected onto the column, 
and eluted at 1 ml/min with a gradient described on Table 5.2 (LC-MS/MS 2). 
Nitrogen was used as the curtain and collision gas. The interface temperature was 
750 °C. Nevirapine and metabolites were detected in the multiple-reaction 
monitoring (MRM) mode with the transitions described in Table 5.4. Data were 
processed with Analyst 1.4.1 software (AB Sciex).
160
Chapter 5: Nevirapine mercapturates as markers of in vitro and in vivo bioactivation and toxicity’
Parameters Selected Reaction Monitoring
Source temperature (°C) 200.0
Nebulizing gas (gas-1) (arbitrary units) 30.00
Heater gas (gas-2) (arbitrary units) 30.00
Curtain gas (arbitrary units) 35.00
Ion spray voltage (V) 5000
Collision energy (eV) 30.00
Declustering potential (V) 20.00
Focusing potential (V) 200.0
Entrance potential (V) 10.00
Dwell time (ms) 150.0
Mode of analysis Positive
Ion transition products (m/z)
NVP: 266.8/226.1
12-OH NVP: 282.9/265.0
3-OH NVP: 282.9/213.9
Ml: 428.0/265.0
M2: 428.0/299.0
Table 5.3: Main working parameters for tandem mass spectrometric analyses of 
nevirapine and nevirapine metabolites (University of Liverpool).
161
Chapter 5: Nevirapine mercapturates as markers of in vitro and in vivo bioactivation and toxicity ’
Parameters Selected Reaction Monitoring
Source temperature (°C) 750.0
Nebulizing gas (gas-1) (arbitrary units) 40.00
Heater gas (gas-2) (arbitrary units) 40.00
Curtain gas (arbitrary units) 35.00
Ion spray voltage (V) 4500
Collision energy (eV) 27.00 - 54.00
Declustering potential (V) 59.00-104.0
Entrance potential (V) 10.00
Dwell time (ms) 50.0
Mode of analysis Positive
Ion transition products (m/z)
NVP: 266.8/226.1
12-OH NVP: 282.9/265.0
3-OH NVP: 282.9/213.9
Ml: 428.0/265.0
M2: 428.0/299.0
Table 5.4: Main working parameters for tandem mass spectrometric analyses of 
nevirapine and nevirapine metabolites (Pfizer, U.K.).
5.2.13 Statistical analysis
All results were expressed as mean + standard deviation. Data sets were analysed for 
normality using the Shapiro-Wilk test. For single comparisons of normal data an 
unpaired T-test was used. Where multiple comparisons were made and the data was 
normally distributed, one-way ANOVA was used with bonferroni correction. Where 
multiple comparisons were made and the data was not normally distributed, a 
Kruskal-Wallis test, for all pair-wise comparisons, was used with either Conover- 
Inman or Dwass-Steel-Chritchlow-Fligner corrections for multiple comparisons. All 
statistical analysis were performed using the StatsDirect statistical software.
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5.3 RESULTS
5.3.1 Investigating the effect of nevirapine on the viability and GSH levels of 
freshly isolated hepatocytes in suspension
The effect of nevirapine on the viability and GSH levels on hepatocytes freshly 
isolated from male Wistar and female Brown Norway rats was investigated in order 
to identify bioactivation-dependent toxicity. Male Wistar rats are used as this is the 
strain in which most experience has been had in terms of hepatocytes isolations; 
female Brown Norway rats were chosen as this strain has been found to be sensitive 
to a nevirapine-induced toxicity. Nevirapine failed to induce statistically significant 
cytotoxicity in freshly isolated hepatocytes in either strain (Figure 5.3 A and B). 
GSH levels were significantly depleted at 500 pM nevirapine in male Wistar rat 
hepatocytes (Figure 5.3 A). In female Brown Norway rat hepatocytes GSH levels 
were significantly depleted at 200 and 500 pM nevirapine (Figure 5.3 B).
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Figure 5.3: Assessment of the dose-dependent effect of nevirapine on the 
viability and GSH levels on hepatocytes freshly isolated from male Wistar rats 
and female Brown Norway rats. Effect of nevirapine (0 - 500 pM; 6 hours) on 
cytotoxicity and GSH content in male Wistar (A) and female Brown Norway (B) rat 
hepatocytes. Data are given as mean + standard deviation of 3-4 independent 
isolations. **; p<0.0017, *; p<0.0083, comparing to 0 pM nevirapine incubations 
(one-way ANOVA with bonferroni correction for multiple comparisons, critical 
p<0.0083).
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5.3.2 21 day time-course of nevirapine-induced skin rash development in
female Brown Norway rats
On day 7, 14 and 21 after each animal was sheared, lesions on the body were 
analysed by eye and counted (Table 5.4). Photographs of the lesions were taken 
(Figure 5.4) and histopathology was performed on affected areas (Figure 5.5).
Nevirapine-induced skin rash increased in severity in a time-dependent fashion. On 
day 7 no abnormalities of the skin or ears were observed in any animal. On day 14, in 
all animals, both ears displayed multifocal linear dark red areas (approximately 0.2 
cm), predominately towards the rim of the ear. The skin on the lumbo-sacral region 
exhibited several (5-10), approximately 1 mm, raised dark red crusts. Similar 
findings were observed 2-3 cm caudal of the shoulder area along the mid-line and 
on the left hand or right and left hand side. On day 21 the skin between the shoulders 
of all animals exhibited several (7 - 10), partly confluent (2-5 cm), raised (1-7 
mm) dark red crusts. The lesions were more severe on the left shoulder and were 
distributed over the entire body surface from the ears to the pelvic area.
Day Animal Skin Lesions
7
1 None
2 None
3 None
14
4 Mild
5 Moderate
6 Mild
21
7 Moderate
8 Moderate
9 Severe
21 (control)
10 None
11 Mild
12 Mild
Table 5.4: Severity of skin lesions of nevirapine treated female Brown Norway 
rats over 21 days. Female Brown Norways rats were administered nevirapine
(70 - 90 mg/kg/day) in the diet for either, 7, 14 or 21 days. Skin was examined and 
grading in terms of number of lesions was performed; mild =1-5, moderate = 6-20 
and severe = >21 (Shenton et a/., 2003).
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Figure 5.4: Appearance of the skin on the shoulders and cranial back of 
nevirapine treated female Brown Norway rats. Photographs show a control rat on 
day 21 of a normal chow diet and nevirapine treated rat on day 21 of a diet 
containing nevirapine. Dose received was approximately 70 - 90 mg/kg/day.
Mild sporadic microscopic findings occurred in the skin of control animals and 
consisted of a mixed (lymphocytes, plasma cells, macrophages and neutrophils) 
inflammatory infiltrate in the dermis of two rats (interscapular region), accompanied 
by focal serocellular crust and epidermal hyperplasia in one. These findings were 
focally extensive, mild in severity and are consistent with minor everyday trauma 
occurring naturally in laboratory animals. Similar findings occurred with comparable 
incidence and severity in the 3 nevirapine-treated rats culled on day 7 and were not 
deemed test article-related. On day 14 skin from the lumbo-sacral region of all 3 
nevirapine treated animals displayed ulceration extending to the deeper dermis 
associated with the presence of degenerate neutrophils, serocellular crust formation, 
moderate epidermal hyperplasia, multifocal epidermal spongiosisand/or moderate 
mixed cellular perivascular infiltrate in the dermis. Similar lesions were detected in 2 
animals, in the skin from the throat and from the ear, respectively. On day 21 lumbo­
sacral skin of all 3 nevirapine treated animals, and skin from the shoulder in two 
animals, displayed severe ulceration accompanied by epidermal and dermal mixed 
cell infiltration, multifocal serocellular crust formation, intracorneal pustules and/or 
moderate epidermal hyperplasia and spongiosis.
165
Chapter 5: Nevirapine mercapturates as markers of in vitro and in vivo bioactivation and toxicity'
Figure 5.5: Histological analysis of skin sections from female Brown Norway 
rats following nevirapine treatment. Skin from the interscapular area of a rat from 
the control group (A) shows a focal serocellular crust associated with mild epidermal 
hyperplasia and mild mononuclear cell inflammatory infiltrate in the superficial 
dermis and the epidermis. Skin from the lumbo-sacral region of a rat administered 
nevirapine for 21 days (B) displayed locally extensive serocellular crusts with an 
underlying superficial ulceration, accompanied by marked neutrophilic infiltration 
and epidermal hyperplasia. Multiple, differently sized ulcers with serocellular crust 
occurring on the skin from the lumbo-sacral region (C and D) in a rat administered 
nevirapine for 21 days. H&E, 10 x magnification.
5.3.3 Hepatic and serum biochemical analysis from 21 day time-course of 
nevirapine treatment in female Brown Norway rats
No significant difference was observed in hepatic GSH levels or serum ALT levels 
between control and nevirapine treated animals (Figure 5.6 A and B). Although no 
significant increase in serum HMGB-1 concentration was observed, there does 
appear to be a trend of increasing levels over time of nevirapine treatment (Figure 5.6 
C).
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B
Control NVP
Treatment Group
Day 7 NVP Day 14 NVP Day 21 NVP Day 21 Control
Treatment Group
Treatment Group
Figure 5.6: The effect of nevirapine treatment on hepatic GSH, serum ALT 
activity and HMGB-1 concentration in female Brown Norway rats. Female 
Brown Norway rats were given nevirapine in food (60 - 80 mg/kg/day). Hepatic 
GSH concentration (A), serum ALT activity (B) and serum HMGB1 levels (C) were 
measured 7, 14 and 21 for dosed animals and on day 21 only for control animals. 
Data presented as mean + standard deviation of n=3.
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5.3.4 Quantification of nevirapine and nevirapine metabolites in the urine from 
female Brown Norway rats treated with nevirapine
Nevirapine and nevirapine metabolites were quantified used mass spectrometry 
(Figure 5.7); no significant trends were identified with any of the metabolites over 
time.
12-OH NVP
-3 500 - 3-OH NVP
400 -
300 -
200 -
100 -
Day 14 Day 21
Day 14 Day 21
Figure 5.7: Quantification of nevirapine and metabolites in rat urine. Female 
Brown Norway rats were given nevirapine in food (60 - 80 mg/kg/day) for 21 days; 
on days 6, 13 and 20, urine was collected. Nevirapine and hydroxylated metabolites 
(A) and nevirapine mercapturates (B) were quantified. Data is presented as mean + 
standard deviation of n=3.
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5.4 DISCUSSION
The investigations in this chapter aimed to assess the potential of nevirapine 
mercapturates to be used as quantitative markers of nevirapine bioactivation and 
toxicity. Freshly isolated rat hepatocyte suspensions have been used successfully for 
the investigation of bioactivation and toxicity of human idiosyncratic hepatotoxins 
(Higaki et al., 1989, Masubuchi et al.t 1998, Graham et al., 2008), however 
limitations in this system have also been identified. Nevirapine has been shown to 
cause severe or life-threatening liver toxicity in 1.0 - 3.2% of HIV patients (Pollard 
et ah, 1998, Pujari et ah, 2004, Martinez et ah, 2001, Sanne et ah, 2005). Nevirapine 
failed to induce cytotoxicity in hepatocytes isolated from both male Wistar rats and 
female Brown Norway rats in the current study. Significant GSH depletion was 
observed in isolated hepatocytes from both male Wistar and female Brown Norways 
rats.
The animal model of nevfrapine-induced skin rash, established by Uetrechf s group, 
was successfully replicated in these investigations. The time course of skin rash 
development was consistent with previous reports (Shenton et ah, 2003). Various 
degrees of hyperplasia more prominent adjacent to ulcerated areas and mononuclear 
dermal inflammatory infiltrate have been described previously and histopathological 
findings in skin samples taken from rump and between shoulder blades are consistent 
with the studies presented here, however only one animal on day 14 group displayed 
moderate mixed cellular infiltration (Shenton et ah, 2003). In rats administered 
nevfrapine for 21 days, multiple skin lesions are present at different sites on the body 
and show increased severity when compared to control animals, However, 
histopathological analysis of skin samples from control and treated rats indentified 
that lesions are consistent with self induced trauma.
No evidence of liver injury was seen in the female Brown Norway rats following 
chronic nevfrapine administration, as previously described (Shenton et ah, 2003); 
histological analysis of liver tissue found no evidence of drag-induced insult, ALT 
levels were not significantly raised and hepatic GSH levels remained normal 
throughout. Skin rash was observed in animals from day 14 onwards, both visibly 
and by histopathological analysis. HMGB-1 is a non-organ-specific biomarker of 
necrosis and inflammation and data must be considered with other biomarkers and
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histopathological data. Serum HMGB-1 levels were not significantly elevated at any 
time point in the 21 day experiment; however, there does appear to be a non­
significant increase which would have to be further explored with repeat studies with 
more animals per group. The most common drug-induced skin reaction is an 
exanthemous drug emption, which accounts for about 95% of all drug rashes. In this 
relatively mild rash, apoptosis is seen in a small number of basal keratinocytes 
(Uetrecht, 2009). TEN and SJS appear to be mediated by CD8+ T cells that induced 
massive necrosis of epidermal cells ultimately resulting in blister formation and skin 
detachment (Lerch and Pichler, 2004).
Investigations using integrated mass spectrometry and NMR (nuclear magnetic 
resonance) techniques have identified nevirapine mercapturates in human and rat 
urine following administration of nevirapine (Srivastava et al, 2010). Amongst the 
human pharmaceuticals the mercapturate conjugates of APAP (Siegers et al., 1984), 
phenacetin (Veronese et al., 1985), felbamate (Dieckhaus et aL, 2002) and valproic 
acid (Gopaul et al., 2003) have been used for the quantitative assessment of in vivo 
bioactivation. Nevirapine and its urinary metabolites were quantified by mass 
spectrometry on day 7, 14 and 21 of the study; no time-dependant trend in any 
nevirapine metabolite was observed. It would be premature to conclude that 
quantification of nevirapine mercapturates would not be able to provide the same 
type of marker in animals or in the clinic; the data discussed here is based on a small 
study of just three animals per group. To further assess the hypothesis further 
quatification of other GSH breakdown products could be utilized; for example 
measuring cysteine conjugates.
Although no correlation between skin rash and mercapturate levels were identified, 
the work presented here may provide a platform for future studies. All animals in this 
study developed a rash and there was no negative control; we might expect to see a 
difference in mercapturate levels between a nevirapine-sensitive strain compared to a 
non-sensitive strain, or in a strain where less than 100% incidence of skin rash is 
observed. In light of evidence to suggest that metabolism of nevirapine through the 
12-OH NVP pathway is responsible for bioactivation, using enzyme inhibitors to 
block this pathway and chemically inhibit bioactivation and toxicity, would provide a 
means to establish a quantitative relationship between the two processes.
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CHAPTER 6
CHEMICAL INHIBITION OF THE NEVIRAPINE 
BIO ACTIVATION PATHWAY
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6.1 INTRODUCTION
In Chapter 5, the model of nevh’apine-induced skin rash in female Brown Norway 
rat, was successfully replicated. However, no correlation between nevirapine 
mercapturate level and the onset of skin rash was observed. The results from the 
previous chapter also highlighted a need for a negative control or chemical inhibition 
of bioactivation in the chronic nevirapine experiments, and so various enzyme 
inhibitors were investigated. These experiments would also provide further 
mechanistic data on the bioactivation pathway of nevirapine. There is evidence to 
suggest that bio activation of nevirapine through the 12-hydroxynevirapine (12-OH 
NVP) pathway is responsible for nevkapine-induced skin rash (Chen et ah, 2008). 
This chapter aimed to characterize the thioether end-products of the 12-OH NVP 
pathway.
Metabolism of nevirapine through the 12-OH NVP metabolic pathway has been 
implicated in development of nevirapine-induced skin rash in rats (Chen et ah, 2008, 
Chen et al, 2009). It was discovered that 12-OH NVP causes skin rash in female 
Brown Norway rats at a lower dose than nevirapine itself (Chen et al, 2008). In 
experiments where the 12-methyl hydrogens were replaced by deuterium (which 
decreases 12 hydroxylation and rash but does not affect other properties of the drug), 
urinary levels of 12-OH NVP were decreased and skin rash in female Brown Norway 
rats was reduced by 80% (Chen et al, 2008). It has previously been shown that 12- 
OH NVP is a substrate for sulphotransferase in rats (Chen et al, 2008), and it has 
been proposed that the sulphate ester dissociates to form a reactive quinone methide 
intermediate (Chen et al, 2008, Uetrecht, 2006). Antunes et al (2009) demonstrated 
the reactivity of 12-sulphoxy nevirapine by formation of multiple DNA adducts in 
reactions with 12-mesyloxy nevirapine.
In an effort to relate these findings with the immunological aspects of the ADR, 
Uetrecht and colleagues removed lymph nodes from Brown Norway rats treated with 
nevirapine or 12-OH NVP, and measured the response of lymphocytes to nevirapine 
and 12-OH NVP by cytokine production and proliferation (Chen et al, 2009). 
Lymphocytes from animals re-challenged with nevkapine or 12-OH NVP 
proliferated on freatment with nevkapine, but not with 12-OH NVP (Chen et al, 
2009). Sknilarly, nevkapine-reactive T cells have been observed in a patient with
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carly-onset hepatitis in the absence of any cutaneous manifestations. The patient’s T 
cells proliferated in vitro on exposure to nevirapine but not its stable metabolites 
(Drummond et al., 2006).
Evidence to suggest that metabolism to 12-OH NVP is not a required step for the 
formation of nevirapine-induced toxicity has been described. No relationship 
between serum 12-OH NVP concentrations and skin rash has been identified in 
patients (Hall and MacGregor, 2007) and high serum nevirapine concentrations 
correlated with incidence of skin rash in rats (Chen et al, 2008). Furthermore, 
alternative bioactivation pathways of nevirapine have been hypothesized that do not 
require 12-OH NVP formation. The quinone methide could also be generated by 
enzymic oxidation (Wen et al, 2009). Nevirapine could also form one or more 
heteroarene epoxide metabolites in either of the pyridine rings (Figure 6.1).
Epoxide intermediates
\
Quinonemethide
NVP-12-0 sulfonate
CH3H O
NVP-3-mercapturate
(Major)
NVP-12-GSH
mercapturate
(Minor)N-Ac-cys
Figure 6.1: Possible routes of bioactivation of nevirapine.
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The work presented in this chapter aimed to test the hypothesis that 12-OH NVP is a 
precursor of a nevirapine mercapturate by administering 12-OH NVP directly to rats 
and identifying its thioether metabolites, if any. In light of the data presented in 
Chapter 5, it was also of interest to assess possible chemical inhibitors of nevirapine 
bioactivation (aminobenzotriazole and 2, 6-dichloro-4-nitrophenol), in order to 
further elucidate the mechanism underlying the ADR.
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6.2 MATERIALS AND METHODS 
6.2.1 Materials
Nevirapine and standards of two known metabolites of nevirapine (3-OH NVP and 
12-OH NVP), were gifts from Pfizer Global Research and Development (Sandwich, 
Kent, U.K.). They were 99% pure as determined by HPLC and NMR. Nevirapine 
was also purchased from Bosche Scientific (New Brunswick, NJ, U.S.A.). Unless 
otherwise stated, reagents were obtained from Sigma-Aldrich Chemical Co. (Poole, 
U.K.). Ultima Gold scintillation fluid was purchased from PerkinElmer LAS (Seer 
Green, Beaconsfield, Buckinghamshire, U.K.). All solvents were of HPLC grade and 
were products of either Fischer Scientific pic (Loughborough, U.K.) or VWR 
(Lutterworth, U.K.)
6.2.2 Experimental animals
Protocols described were undertaken in accordance with criteria outlined in a license 
granted under the Animals (Scientific Procedures) Act 1986 and approved by the 
University of Liverpool Animal Ethics Committee. Male wistar rats were obtained 
from Charles River Laboratories (Margate, U.K). Animals were housed in a light 
controlled room at a constant temperature and, unless otherwise stated, supplied with 
a standard chow diet and water ad libitum.
6.2.3 Investigation of the effects of various, low molecular weight inhibitors on 
the biliary thioether metabolites of nevirapine and 12-OH NVP in the 
Wistar rat
Male Wistar rats (200-400 g) were terminally anaesthetised with urethane (1.4 g/ml 
in isotonic saline; 1.0 ml/kg i.p.) and cannulated via the trachea, femoral vein and the 
common bile duct. Bile was collected over 30 minutes before administration of 
nevirapine or 12-OH NVP. Nevirapine or 12-OH NVP (50 mg/kg in DMSO) was 
administered Lv. via the femoral vein over 5 minutes. Bile was then collected hourly 
for into micro centrifuge tubes. In inhibitor studies 1-aminobenzo triazole (50 mg/kg 
i.p.; ABT) and 2, 6-dichloro-4-nitrophenol (6.76 mg/kg i.p.; DCNP) were
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administered 3 horn's and 45 minutes prior to nevirapine/12-OH NVP dose, 
respectively. Bile was stored at -80°C until extraction and analysis.
6.2.4 Bile preparation by solid phase extraction for LC-MS/MS
Solid phase extraction was used to clean samples for LC-MS/MS analysis. An 
Oasis® HLB plate (30mg/30pm; Waters, Hertforshire, U.K.) was conditioned with 
200 pi MeOH and 200 pi 4% phosphoric acid. Samples and standards were then 
loaded with internal standards and pulled through by a vacuum. Wells were then 
washed with 1 ml df^O. Samples were eluted into a clean 96-well block with 500 pi 
100% ACN. Samples were dried under a steam of nitrogen and reconstituted in 200 
pi 10% ACN. The 96-well block was then centrifuged for 5 minutes to pellet any 
particulate.
6.2.5 Identification of nevirapine mercapturates in rat bile by LC-MS/MS
LC-MS/MS analyses were performed using a TSQ Quantum Access tandem 
quadrupole mass spectrometer (Thermo Fisher Scientific, San Jose, CA, U.S.A.; 
main working parameter described in table 6.1). Analytes were resolved on a Thermo 
Hypersil BDS Cl8 column (10 x 2.1 cm; Thermo Fisher Scientific, Runcorn, 
Cheshire, U.K.) at 0.3 ml/min with a gradient profile as described in Table 6.2. The 
mobile phase consisted of water + 0.05% formic acid (FA) and ACN. Nevirapine and 
metabolites were detected in the multiple-reaction monitoring (MRM) mode with the 
transitions described in Table 6.3.
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Parameters Selected Reaction Monitoring
Spray Voltage (kV) 4000
Vaporizer Temperature (°C) 200
Sheath Gas Pressure* 40
Ion Sweep Gas Pressure* 0
Aux Gas Pressure* 55
Capillary Temperature (°C) 277
Skimmer Offset (V) 0
Collision Pressure (Torr) 1.5
Table 6.1: The main working parameters for the TSQ Quantum Access tandem 
quadrupole mass spectrometer. * Arbitrary units
Time (min) % ACN % Water +0.05% FA
0.0 10 90
1 20 80
3 20 80
6 45 55
7 70 30
8 80 20
8.1 7 93
10 10 90
Table 6.2: Step-wise gradient program used for the separation of analytes.
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NVP/NVP 
Metabolite Parent Mass Product Mass Collision energy T Lens offset
NVP 267.00 227.00 17 83
12-OH NVP 283.00 144.500 30 83
M1 428.20 265.100 25 119
M2 428.210 299.500 17 119
NVP-GSH 572.0 265.00 25 119
Table 6.3: MRM transitions for nevirapine and nevirapine metabolites.
6.2.6 Quantification of nevirapine and nevirapine metabolites in rat bile using 
LC-MS/MS
Mass spectrometric analysis was carried out at the University of Liverpool (U.K.) 
and Pfizer, U.K. as described in section 5.2.15.
6.2.7 Statistical analysis
All results were expressed as mean + standard deviation. Data sets were analysed for 
normality using the Shapiro-Wilk test. For single comparisons of normal data an 
unpaired T~test was used. Where multiple comparisons were made and the data was 
normally distributed, one-way ANOVA was used with Bonferroni correction. Where 
multiple comparisons were made and the data was not normally distributed, a 
Kruskal-Wallis test, for all pair-wise comparisons, was used with either Conover- 
Inman or Dwass-Steel-Chritchlow-Fligner corrections for multiple comparisons. All 
statistical analysis was performed using the StatsDirect statistical software.
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6.3 RESULTS
6.3.1 Identification of mercapturate conjugates of 12-OH NVP
In order to assess whether 12-OH NVP is a precursor of a nevirapine mercapturate 
and therefore undergoes bioactivation, 12-OH NVP was directly administered to 
anaesthetised male Wistar rats. Bile from rats administered nevirapine or 12-OH 
NVP (50 mg/kg i.v. in DMSO) was analysed by LC-MS/MS to identify the minor 
(Ml) and/or major (M2) nevirapine mercapturates.
NVP-M2100 “I
NVP-M1
-O<
100-1
NVP-M1
Time (minutes)
Figure 6.2: Total MRM chromatograms of biliary nevirapine mercapturates 
following administration of nevirapine or 12-OH NVP to anaesthetised rats. Bile 
was collected following administration of 50 mg/kg (i.v. in DMSO) of either 
nevirapine (A) or 12-OH NVP (B) to anaesthetised male Wistar rats. Bile was 
analysed by LC-MS/MS using the TSQ Quantum Access tandem quadrupole mass 
spectrometer (Thermo Fisher Scientific, San Jose, CA, U.S.A.)
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Both Ml and M2 were identified in the bile from male Wistar rats following 
administration of nevirapine (Figure 6.2 A). However, after 12-OH NVP treatment 
only a single mercapturate could be seen at a retention time identical to Ml (Figure 
6.2 B). To confirm the identity of the mercapturate, bile from the 12-OH NVP dosed 
rat (93%) was mixed with that from the nevirapine dosed rat (7%). The mercapturate 
from the 12-OH NVP dosed rat co-eluted with Ml from the nevirapine dosed rat 
suggesting that they are identical (Figure 6.3 B).
NVP-M2100n
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Figure 6.3: Total IMRM chromatograms of mixed bile samples from nevirapine 
mercapturates following administration of nevirapine or 12-OH NVP to 
anaesthetised rats. Bile from anaesthetised male Wistar rats administered 
nevirapine (A; 50 mg/kg i.v. in DMSO) was mixed with bile from rats treated with 
12-OH NVP (B; 50 mg/kg i.v. in DMSO) in a 7:93 ratio. Bile was analysed by LC- 
MS/MS using the TSQ Quantum Access tandem quadrupole mass spectrometer 
(Thermo Fisher Scientific, San Jose, CA, U.S.A.)
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6.3.2 Investigation of inhibitors of nevirapine and 12-OH NVP bioactivation: 
1-AminobenzotriazoIe
A non-specific cytochrome P450 inhibitor, ABT, was used in an attempt to block the 
oxidative metabolism of nevirapine and 12-OH NVP in anaesthetised male Wistar 
rats. Reduction in Ml production suggests that bioactivation through the 12-OH 
NVP pathway has been inhibited. Pre-treatment with ABT resulted in a decrease in 
nevirapine (50 mg/kg i.v. in saline) metabolism to 12-OH NVP, Ml and M2 (Figure 
6.4) in rats. In the same experiment using 12-OH NVP, Ml levels were also reduced 
with the pre-treatment of ABT; however this reduction was not significant (Figure 
6.5 B).
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Figure 6.4: Effect of ABT pre-treatment on nevirapine metabolism in rats. Bile 
was collected from anaesthetized male Wistar rats which were pre-treated with ABT 
(50 mg/kg i.p.) 3 hours prior to administration of nevirapine (50 mg/kg i.v in 
DMSO). 1 hour biliary metabolites (nevirapine, 12-OH NVP and M2 are shown in 
the primary graph. Ml is shown in the insert) were quantified by LC-MS/MS. Data 
are presented as mean + standard deviation; n=3.
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Figure 6.5: Effect of ABT pre-treatment on 12-OH NVP metabolism in rats. Bile 
was collected from anaesthetized male Wistar rats which were pre-treated with ABT 
(50 mg/kg i.p.) 3 hours prior to administration of 12-OH NVP (50 mg/kg i.v in 
DMSO). 1 hour biliary was analysed and 12-OH NVP (A) and Ml (B) were 
quantified by LC-MS/MS. Data are presented as mean + standard deviation; n=3.
6.3.3 Investigation of low molecular weight inhibitors of nevirapine and 12- 
OH NVP bioactivation: 2, 6-dichloro-4-nitrophenol
2, 6-dichloro-4-nitrophenol (DCNP) was used as a sulphotransferase inhibitor 
(Mulder and Scholtens, 1977) in anaesthetized male Wistar rats to investigate the 
role of sulphation in nevirapine bioactivation. Reduction in Ml production would 
suggest that bioactivation through the 12-OH NVP pathway was inhibited. Pre­
treatment with DCNP (6.76 mg/kg i.p) did not significantly inhibit Ml formation 
when administered prior to nevirapine (50 mg/kg i.v. in saline) in rats (Figure 6.6). 
Ml levels were also unaffected when DCNP was administered prior to 12-OH NVP 
treatment (Figure 6.7 B).
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Treatment Groups
Figure 6.6: Effect of DCNP pre-treatment on nevirapine metabolism in rats.
Bile was collected from anaesthetized male Wistar rats which were pre-treated with 
DCNP (6.76 mg/kg i.p.) 45 minutes prior to administration of nevirapine (50 mg/kg 
i.v in DMSO). 1 hour biliary metabolites (nevirapine, 12-OH NVP and M2 are 
shown in the primary graph, Ml is shown in the insert) were quantified by LC- 
MS/MS. Data are presented as mean + standard deviation; n=3.
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Figure 6.7: Effect of DCNP pre-treatment on 12-OH NVP metabolism in rats.
Bile was collected from anaesthetized male Wistar rats which were pre-treated with 
DCNP (6.76 mg/kg i.p.) 45 minutes prior to administration of 12-OH NVP (50 
mg/kg /'.v in DMSO). 1 hour biliary was analysed and 12-OH NVP (A) and Ml (B) 
were quantified by LC-MS/MS. Data are presented as mean + standard deviation; 
n=3.
185
Chapter 6: Chemical inhibition of nevirapine bioactivation
6.4 DISCUSSION
Metabolism of nevirapine through the 12-OH NVP metabolic pathway has been 
implicated in development of nevirapine-induced skin rash in rats (Chen et al, 2008, 
Chen et al, 2009). It has previously been shown that 12-OH NVP is a substrate for 
sulphotransferase in rats (Chen et ah, 2008), and it has been proposed that the 
sulphate ester dissociates to form a reactive quinone methide intermediate in the skin 
(Chen et at., 2008, Uetrecht, 2006). However, some studies have provided evidence 
to contest this hypothesis. The investigations conducted in this chapter intended to 
characterise thioether metabolites of 12-OH NVP thereby providing evidence that it 
is a substrate for bioactivation.
Investigations conducted in our labs, have identified nevirapine mercapturates in 
human and rat urine following administration of nevirapine, using integrated mass 
spectrometry and NMR (nuclear magnetic resonance) techniques (Srivastava et at., 
2010). Male Wistar rats were used to conduct these metabolism studies initially as 
they are the strain with which we have the most experience, and given more time 
these studies would have been repeated in female Brown Norway rats. This work 
provided evidence of nevirapine bioactivation in humans and rats. Following 
administration of nevirapine to male Wistar rats, both mercapturates (Ml and M2) 
were identified in the bile. However, after 12-OH NVP treatment only a single peak 
could be seen at a retention time identical to Ml. The identity of the mercapturate 
was confirmed by co-elution of the peak with Ml from the bile from the nevirapine 
dosed rat.
In the previous chapter, investigations were conducted to find a correlation between 
the onset of skin rash and mercapturate levels in the female Brown Noiway rat. No 
such relationship was observed but the work may have provided a platform to 
develop future studies. In light of evidence to suggest that metabolism of nevirapine 
through the 12-OH NVP pathway is responsible for bioactivation, the use of enzyme 
inhibitors to block this pathway and inhibit bioactivation and toxicity was 
investigated.
ABT has been used previously to inhibit oxidative metabolism of nevirapine in rats 
(Chen et ah, 2008); authors found that urinary concentrations of all metabolites
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decreased, except 12-OH NVP. They also correlated this finding with an increase in 
incidence of skin rash from 0% to 100%. More relevant was the fact that following a 
50 mg/kg/day dosing regimen plus ABT, serum nevirapine concentrations increased 
to levels similar to those seen at a dose that was three times that (150 mg/kg/day), 
without ABT pre-treatment (Chen et aL, 2008). The work described here provides 
evidence that pre-treatment with ABT decreases 12-OH NVP and Ml formation and 
therefore does not support the finding described above; the discrepancy may be due 
to the use of p-glucuronidase treatment of samples prior to metabolite measurement 
in the work conducted by Chen, et al (2008). Using ABT pre-treatment in a chronic 
dosing experiment, similar to that described in Chapter 5, would likely provide 
evidence for the role of oxidative metabolism in development of nevirapine-induced 
skin rash in female Brown Norway rats.
A role of sulphation in bioactivation of nevirapine has been suggested; Antunes et ah 
(2009) demonstrated the reactivity of 12-sulphoxy nevirapine by formation of 
multiple DNA adducts in reactions with 12-mesyloxy nevirapine. 12-OH NVP was 
found to be a substrate for sulphotransferase in rats (Chen et al, 2008), and it has 
been proposed that the sulphate ester dissociates to form a reactive quinone methide 
intermediate (Chen et al., 2008, Uetrecht, 2006). However, preliminary studies 
indicate that the sulphate is not very reactive (Chen et al, 2008). In the present study 
2, 6-dichloro-4-nitrophenol (DCNP) was used to inhibit sulphation and observe the 
effect on bioactivation by measuring mercapturate levels in rats. Pre-treatment with 
DCNP (6.76 mg/kg i.p) did not significantly inhibit Ml formation when administered 
prior to nevirapine or 12-OH NVP (50 mg/kg i.v. in saline) in rats. This suggests 
sulphation is not a crucial step in nevirapine bio activation. The quinone methide 
could also be generated by enzymic oxidation (Wen et al, 2009) and nevirapine 
could also form one or more heteroarene epoxide metabolites in either of the pyridine 
rings
In summary, the evidence surrounding the role of 12-OH NVP in development of 
nevirapine-induced toxicity is controversial. Evidence has been provided in the work 
presented here that 12-OH NVP is a substrate for bioactivation. Although it is clear 
metabolism through this pathway is related to development of skin rash in female 
Brown Norway rats, the relationship to nevirapine toxicities in the clinic is not so
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clearly understood. In order to rigorously test the plausibility of using nevirapine 
mercapturates as urinary markers of nevirapine bioactivation and susceptibility to 
nevnapine-induced toxicities, a large clinical study would have to be conducted in 
for the test to be validated. A number of risk factors associated with nevirapine- 
induced toxicities have been identified (Kesselring et al, 2009, Sanne et al., 2005, 
Stern et al., 2003) and a major area of research has been into genetic polymorphisms 
that predispose patients to nevii-apine-induced skin rash and/or hepatotoxicity 
(Zanger et al, 2007, Penzak et al, 2007, Rotger et al, 2005, Haas et al., 2006, 
Martin et al, 2005b).
The G516T polymorphism in CYP2B6 has been shown to significantly increase 
plasma nevirapine levels in HIV-infected patients in Uganda (Penzak et al, 2007). 
The toxicological result of increased plasma nevirapine concentrations is not clear. 
Preliminary studies conducted in Spain found that a positive correlation exists 
between plasma nevirapine levels and the risk of liver toxicity; patients with plasma 
nevirapine concentrations above 6 j-ig/ml are thought to have a 92% risk of 
developing liver toxicity (Gonzalez De Requena et al., 2002, Gonzalez De Requena 
et al, 2005). The 3435C^T polymorphism in MDR1 was significantly associated 
with reduced risk of nevirapine-induced hepatotoxicity (Haas et al, 2006). P- 
glycoprotein is a multidrug efflux pump, encoded by MDR1; this membrane- 
associated protein is responsible for actively removing xenobiotics from the cell 
(Haas et al, 2006). It is believed it is possible that altered P-glycoprotein activity in 
the intestine associated with the MDR1 variants alters disposition of nevirapine 
and/or its metabolites that affect intracellular concentrations of nevirapine and 
toxicity in liver (Saitoh and Spector, 2008).
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7.1 INTRODUCTION
The work presented here has shown that the development of an assessment 
framework that encompasses all aspects of drug disposition and metabolism, and 
their relationship with bioactivation and toxicity, would be a valuable tool in drug 
development. The construction of a decision tree that can be populated with 
quantitative data could be used in the assessment of NCEs and highlight properties 
that require optimisation. Outcomes of changes or interventions to a new therapy 
could then be measured quantitatively and mechanisms defined. A caveat to this 
framework would stipulate that the model systems employed would have to be 
carefully selected to best represent the clinical situation. This work has highlighted 
that a better understanding of current systems for detecting potential human hazard is 
required. Development of translational biomarker panels that can monitor hazard 
posed by a drug, from the pre-clinical stage and into the clinic, would improve safety 
and also be used to reduce attrition in clinical studies.
Idiosyncratic ADRs are rare but can be fatal. Dose, drug accumulation and/or the 
formation of reactive metabolites have been implicated in many idiosyncratic ADRs 
(Park et al.,2Q\\). The dose of a drug will have a major impact on the toxicological 
outcome of therapy; there are no examples of drugs that are dosed below 10 mg/day 
that cause idiosyncratic ADRs (Uetrecht, 2003). The work of James and Elizabeth 
Miller provided the first evidence of drug metabolism leading to the formation of 
reactive metabolites, subsequent covalent binding to protein and ultimately resulting 
in toxicity (Miller, 1994, Miller, 1970). This concept is now well established, and 
there is a wealth of evidence to suggest that bioactivation to a reactive metabolite is 
the initiating step in a number of direct and immune mediated toxicities (Park et al., 
2005, Kalgutkar and Soglia, 2005). However, it is widely accepted that presentation 
of idiosyncratic ADRs largely depends on the individual, in terms of genetics, 
disease state and environmental factors etc.
Drug-induced liver injury accounts for more than half the cases of acute liver failure 
in the US (Ostapowicz et aL, 2002). The liver is the most frequently affected organ 
by idiosyncratic ADRs, but skin, kidney and blood are also common targets. 
Additionally, idiosyncratic ADRs can present as generalised hypersensitivity or 
anaphylaxis (Park et aL, 2011). It stands to reason that research into systems that can
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detect potential human hazard of NCEs has been of high priority, however, it remains 
that there are no accepted methods for the detection of hypersensitivity reactions in 
preclinincal or in vitro systems (Park et ah, 2005).
Identification of thioether adducts of drugs is one of two conventional methods for 
the detection of drug bio activation. These investigations can be carried out in a range 
of systems including hepatic microsomes, fresh hepatocyte suspensions, preclinical 
animal models and in the clinic (Park et al., 2011, Ma et a!., 2008). In in vitro 
systems trapping agents can be included in incubations to detect and provide 
structural information about the drag reactive metabolite(s). The identification of 
drug metabolite-GSH adducts in a preclinical setting is often treated as a hazard 
signal (Gan et al, 2009, Reese et al., 2010), however, it could be argued that 
detection of a GSH adduct is an indication of an effective detoxification system. 
Drug bioactivation can be detected through identification and/or quantification of 
thioether metabolites or some stable metabolites of drugs in human plasma and urine 
(Staack and Hopfgartner, 2007, Wen and Fitch, 2009, Srivastava et a!., 2010, Orhan 
and Vermeulen, 2011). Dihydrodiols are indicative of arene oxide intermediates 
(Forgue and Allen, 1982, Madden et al., 1996, Maggs et ah, 2000) and urinary 
mercapturates of several drugs have been used as markers of reactive metabolite 
exposure (Siegers et al, 1984, Veronese et al, 1985, Dieckhaus et al, 2002, Gopaul 
et al, 2003). Still, it remains that detection of a thioether conjugate or stable 
metabolite represents successfully biomactivated reactive metabolite.
The work presented in this thesis investigates the relationship between chemical 
stracture, bioactivation and toxicity, and examines the concept of thioether adduct 
detection and the information it can provide regarding the potential toxicity of a drag 
molecule. This was investigated in two ways;
(1) Using the model hepatotoxin, forosemide (FS), the pharmacological and 
toxicological consequence of substituting the toxicophore of FS (furan ring) 
and replacing it with a thiophene ring was investigated. Not only did this 
allow for the direct comparison of the two heterocycles, it also provided an 
opportunity to test the current systems used to identify a compounds 
propensity to be bio activated and investigate the downstream toxicity effects 
in vitro and in vivo.
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(2) Investigating whether mercapturates of NVP, a popular treatment for HIV in 
developing countries, could be used as markers of exposure to NVP reactive 
metabolites or whether they indicate successful bio/'/ractivation of reactive 
metabolites in an animal model. Idiosyncratic ADRs, associated with NVP 
treatment, have limited its clinical use.
ABC
Figure 7.1: Structures of FS (A), TPA (B) and NVP (C). Toxicophores are shown 
by a box.
7.2 SPECIES DIFFERENCES CAUSE A DISCONNECT IN DRUG 
SAFETY EVALUATION
Genetic differences between species can influence how a drug is tolerated, as they 
can manifest as differences in drug metabolising enzymes and drug transporters. This 
is important when using various animal models to predict the potential hazard of a 
drug to cause toxicity in humans. The importance of ADME properties and their 
effects on drug toxicity have been discussed throughout this thesis; it is obvious, 
therefore, that changes in these properties caused by genetic differences between 
species will ultimately effect the toxic outcome of drug administration. Species 
differences in glutathione S transferases (GST) provide a good example of this.
There are seven classes of mammalian cytosolic GST subunits, alpha, mu, pi, sigma, 
theta, omega and zeta; these exist as largely as homodimers and the alpha and mu 
subunits can form heterodimers. Different species will have different compositions of 
GST isoenzymes, as well as different levels of expression and activity (Hayes and 
Pulford 1995). Species differences in susceptibility to drug induced toxicity, 
mediated by reactive electrophilic intermediates or indeed by activation by GSH
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conjugation, can, for some drugs, be explained by differences in GSTs. Species 
differences in the toxicity of alfltoxin B1 exemplifies this.
Hepatotoxic effects of aflatoxin B1 (AFB1) have been observed in various 
experimental and farm animals. AFB1 has been shown to be metabolised to two 
isomers of AFB1-epoxide; the exo-8,9-epoxide is a highly reactive intermediate and 
the principle mediator of cellular injury. Both isomers of AFB1-epoxide can be 
conjugated with GSH by GST. It is thought that the formation of the exo-8,9-epoxide 
and its subsequent GSH conjugation are major determinants of the variation in 
species susceptibilities to AFB1. The rate of AFB1-GSH formation in the male 
Fischer rat was less then half of that of the ICR (imprinting control region) mouse 
and accordingly the rat was more susceptible to AFB1 induced toxicity compared to 
the mouse (Tulayakul et aL, 2005).
In the work presented here, FS was shown to induce hepatotoxicity in mice but not in 
rats. The reactive metabolite of FS covalently binds to murine hepatic protein; this 
does not occur in rats, instead the CRM is excreted in the form of a GSH conjugate, 
suggesting a possible safety mechanism exists in the rat to protect from FS-induced 
hepatotoxicity (Williams et al., 2007). In order to identify whether this was as a 
result of species differences in GSTs, an experiment, using mouse microsomes 
incubated with rat S9 and FS, was set up to see if a FS-GSH metabolite could be 
identified. Unfortunately, no metabolites could be observed Rom any microsomal 
incubation with FS and therefore no results where generated. As well as the species 
differences in the balance of bio activation and detoxification, the toxicokinetic 
studies conducted here also highlighted differences in the concentrations of FS in the 
liver of rats and mice. The liver exposure in the mouse was twice that in the rat, with 
free liver AUC values at 243 and 128 pg.h/ml respectively.
If the technology were available, pre-clinical safety evaluation packages would 
solely use human/humanised systems and models, and eliminate the need for 
translational research. One of the overall limitations of the work presented in this 
thesis is the lack of human safety and metabolic data generated with each of the 
compounds. This has resulted in an inability to relate the data generated in rodent 
models with a human system, and has limited the conclusions we can make in terms 
of the suitability of these models to predict human hazard. If human FS and TPA
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metabolites would have been identified, the conclusions drawn, regarding GSH 
conjugation and safety, might have been strengthened (or further exemplified species 
differences). Similarly with NVP, using patient samples to investigate NVP 
mercapturates as markers of exposure to a NVP reactive metabolite and toxicity, 
would have been more useful than using an animal model. The animal model was 
limited in that it only displayed a skin reaction (not hepatotoxicity) and the rash 
appeared to be caused by scratching. However, to generate such data for humans, and 
make it statistically powerful, a huge patient population would have been required.
As well as selecting the most appropriate species to conduct preclinical safety 
investigations, the system should also be carefully considered. Microsomes have 
been the system of choice to study covalent binding of drugs, however recent studies 
suggest that human hepatocytes might provide a more clinically relevant, 
metabolically complete system (Bauman et ah, 2009; Nakayama et ah, 2009). 18 
known hepatotoxic and non-hepatotoxic compounds were tested for levels of 
covalent binding in human liver microsomes (Obach et ah, 2008). Of the 18 
compounds tested, 14 demonstrated some extent of covalent binding; of the 4 that 
did not, 2 were hepatotoxins and 2 were non-hepatotoxins (Obach et al., 2008). 
Recently covalent binding studies conducted in human hepatocytes have provided a 
means of discriminating between hepatotoxins and non-hepatotoxins by 
incorporating factors such as daily dose and intrinsic clearance (Bauman et a!., 2009; 
Nakayama et ah, 2009).
7.3 BIO ACTIVATION IN DRUG SAFETY EVALUATION
Bioactivation of drugs to reactive metabolites is highly implicated as a causal factor 
in the development of drug-induced toxicities. Although bioactivation is not solely 
responsible for all drug toxicities, often, metabolism data is considered alone rather 
than in context with other aspects of ADME. Additionally, there are few methods of 
assessing the toxic consequences of drug administration, and therefore minimising 
the potential of bioactivation is the current approach for hazard reduction in drug 
discovery and development.
In ding development, structural liabilities are often identified in NCEs and, 
depending on the involvement of the moiety in the pharmacology; these liabilities
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can be modified or substituted in order to obtain a compound with reduced potential 
to be bioactivated, while retaining potency. The work conducted using FS and TPA 
aimed to assess the result of substituting a toxicophore (fiiran ring) for another 
structurally similar moiety, in terms of potency and hepatotoxicity in model systems. 
It was found that TPA was three times more potent towards the Na+/K+/Cf 
cotransporter than FS, and TPA had an improved safety profile in mice. The data 
generated during this study and previous data, suggested that both FS and TPA are 
bioactivated to reactive metabolites, however the reactive metabolite(s) of TPA 
(possibly the S'-oxide) could be biomactivated through GSH conjugation and 
therefore did not induce toxicity.
The data, generated from the studies with FS and TPA, show a link between GSH 
conjugate formation and an apparent lack of toxicity, and therefore question the 
paradigm of using GSH conjugates as markers of exposure to a reactive metabolite 
and ultimately risk of an ADR. Using mercapturates (breakdown products of GSH 
conjugates) as markers of reactive metabolite exposure has been demonstrated with 
several compounds, but as the data here suggests, each compound must be 
investigated on a case-by-case basis to assess whether a thioether metabolite implies 
risk or safety.
One of the limitations with the work presented here is that metabolite quantification 
was not completed. Having numerical values for each metabolite across all the 
systems tested might have strengthened the conclusions drawn with regards to the 
deferential metabolism between species, compounds and systems and the degree of 
toxicity observed. This applies not only to the thioether metabolites that were 
focused on in this study, but also to other metabolites that represent a non-toxic 
endpoint of metabolism (e.g. glucuronides).
In the case of NVP, the assumed toxicophore is incorporated into the structural 
scaffold of the molecule (Figure 7.1) and therefore would have been difficult to 
design out dining the development process (toxicophore = pharmacophore). 
Additionally, human hazard was not observed in pre-clinical studies (Table 7.1). 
NVP mercapturates had been identified prior to the initiation of the work conducted 
in this thesis; one of the hypotheses laid out was that NVP mercapturates could act as
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markers of exposure to NVP reactive metabolites in rats, and that exposure could be 
correlated to the development and severity of NVP-induced skin rash.
The animal model of NVP-induced skin rash, established by Uetrecht’s group, was 
selected as the system to address the hypothesis. This model was successfully 
replicated in Chapter 5; the time course of skin rash development was consistent with 
previous reports (Shenton et aL, 2003). After 3 weeks NVP treatment (~80 
mg/kg/day in food), NVP and its urinary metabolites were quantified by mass 
spectrometry on day 7, 14 and 21 of the study however, no time-dependent trend in 
any NVP metabolite was observed. It became clear that in order to use NVP 
mercapturates as markers of exposure to a reactive metabolite, more information 
regarding the bioactivation pathways of NVP was required. In Chapter 6 
investigations were designed to elucidate a metabolic pathway of NVP that resulted 
in the formation of mercapturates, and, by implication, reactive metabolites.
12-OH NVP has been implicated as an important metabolite in the metabolic 
pathway responsible of NVP-induced skin rash (Chen et aL, 2008, Uetrecht, 2006). 
The work conducted in Chapter 6 has shown that 12-OH NVP is a substrate for 
bioactivation; 12-OH NVP was administered directly to male Wistar rats and the 
minor mercapturate (Ml) only was identified in the bile. Following administration of 
NVP to male Wistar rats, both mercapturates (Ml and M2) were identified in the 
bile.
The role of sulphation in bioactivation of NVP has been suggested; Atunes et al. 
(2009) demonstrated the reactivity of 12-sulphoxy NVP by formation of multiple 
DNA adducts in reactions with 12-mesyloxy NVP. 12-OH NVP was found to be a 
substrate for sulphotransferase in rats (Chen et al., 2008), and it has been proposed 
that the sulphate ester dissociates to a form reactive quinone methide intermediate 
(Chen et ah, 2008, Uetrecht, 2006). In Chapter 6, 2, 6-dichloro-4-nitrophenol 
(DCNP) was used to inhibit sulphation; no inhibition of Ml formation was observed 
when DCNP was administered prior to NVP or 12-OH NVP (50 mg/kg z.v. in saline) 
in rats. This suggests that sulphation may not be involved in NVP bioactivation; 
however further studies, involving metabolite identification, would have to be 
conducted in order to confirm this.
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In contrast to previous studies, pre-treatment with ABT decreased 12-OH NVP and 
Ml formation (Chapter 6). Using ABT pre-treatment in a chronic dosing experiment, 
similar to that described in Chapter 5, would provide more information on the role of 
oxidative metabolism in development of NVP-induced skin rash in female Brown 
Norway rats. ABT has been used previously to inhibit oxidative metabolism of NVP 
in rats (Chen et al, 2008); authors found that urinary concentrations of all 
metabolites decreased, except 12-OH NVP. This finding was correlated with an 
increase in incidence of skin rash from 0% to 100% in female Brown Noiway rats. 
What was more significant in this work was the fact that following a 50 mg/kg/day 
dosing regimen plus ABT, serum NVP concentrations increased to levels similar to 
those seen at a dose that was three times that (150 mg/kg/day), without ABT pre­
treatment (Chen et al., 2008). Uetrecht and colleagues have shown that 12-OH NVP 
is unable to induce an immune response; lymph nodes were removed from Brown 
Norway rats treated with nevirapine or 12-OH NVP, and the response of 
lymphocytes to NVP and 12-OH NVP by cytokine production and proliferation was 
measured (Chen et al, 2009). Lymphocytes from animals re-challenged with NVP or 
12-OH NVP proliferated on treatment with NVP, but not with 12-OH NVP (Chen et 
al, 2009). Similarly, NVP-reactive T cells have been observed in a patient with 
early-onset hepatitis in the absence of any cutaneous manifestations. The patient’s T 
cells proliferated in vitro on exposure to NVP but not its stable metabolites 
(Drummond et al, 2006). This data suggest that NVP concentrations could be a 
primary determinant of whether NVP-induced skin rash is observed. Further studies 
analysing NVP metabolism following administration of ABT, and other inhibitors, 
would to provide answers to whether parent compound or a CRM(s) is responsible 
for NVP-induced ADRs.
7.4 IMPORTANCE OF COVALENT BINDING IN RISK ASSESSMENT
One of the few methods for looking at the downstream effects of bioactivation is 
measuring covalent binding. Covalent binding is known to be an important step in 
the development of drug-induced toxicity for some drugs. However, in some cases, a 
drug can be toxic without any evidence of covalent binding and covalent binding can 
occur without toxicity. Nevertheless, assessment of the degree of covalent binding to 
protein is frequently used in in vitro and in animal studies, as an indicator of a drug’s
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potential to cause toxicity. How informative covalent binding data is, in terms of 
predicting human hazard, depends on the systems and species employed to cany out 
the studies. This is referred to in section 7.2, where an example is given of the 
difference in retrospective predictivity between human microsomes and human 
hepatocytes in identifying hepatotoxic drugs from non-hepatotoxic drugs (Bauman et 
aL, 2009; Nakayama et ai, 2009; Obach et al, 2008).
In the work conducted using FS and TPA there was certainly a disconnect between 
different species and systems with regard to covalent binding and glutathione 
depletion. FS has previously been shown to undergo covalent binding to microsomal 
protein in NADPH supplemented mouse, rat and human micrcosomes and in freshly 
isolated rat and mouse hepatocytes (Williams et al, 2007). However, in vivo, hepatic 
covalent binding was only significant in mice; no covalent binding was observed in 
rats (Williams et al, 2007). Significant covalent binding of radiolabelled TPA to 
microsomal protein was observed in CD-I mouse and Wistar rat liver microsomes in 
the presence of NADPH. In mouse hepatocytes, TPA was shown to bind covalently 
to protein in a dose-dependent mannor, however, in rat hepatocytes covalent binding 
was not significant (although there was a non-significant increase). In vivo, TPA did 
not covalently bind to hepatic protein in either rats or mice (Butler, 2006).
The data from the experiments in microsomes and hepatocytes provide evidence that 
TPA can undergo bioactivation and that the reactive products of the process are able 
to bind covalently to hepatic protein. It was concluded, based on the metabolism data 
generated for TPA, that the reason for the lack of hepatotoxicity it induced in mice, 
compared to FS, was because of its conjugation with GSH.
In cases where covalent binding is observed but toxicity is not, a critical protein 
might not have been targeted by the drug reactive metabolite. This concept is best 
illustrated by APAP and its structural isomer 3-hydroxyacetanilide (A-acetyl-w- 
aminophenol, 3-acetamidophenol; AMAP), where AMAP at the same molar dose as 
APAP was found to covalently bind to cellular protein and yet did not result in 
toxicity. The RM of APAP and AMAP, a quinone imine (NAPQI) and a quinone 
respectively, are chemically similar species yet there is an intrinsic difference 
between them, which accounts for the difference in ability to cause hepatotoxicity 
(Rashed and Nelson, 1989). This introduced the concept of the critical protein
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hypothesis, delineating certain proteins as critical targets in hepatotoxicity (Park et 
al., 2005; Tirmenstein and Nelson, 1989). Supporting this, the reactive metabolite of 
APAP, NAPQI binds to a number of proteins. In mice, one of the major targets of 
NAPQI is urate oxidase, an enzyme lost during primate evolution. As a result it is 
thought unlikely that irreversible binding to urate oxidase represents a role in APAP- 
induced hepatotoxicity in mice, as both humans and mice develop centrilobular 
necrosis with similar per kg doses (Qiu et al., 1998).
Chemistry
▼
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Figure 7.2: An example of a potential assessment framework that would 
encompass all aspects of drug disposition and metabolism, and their relationship with 
bioactivation and toxicity. The framework can be populated with quantitative data 
and could be used in the assessment of NCEs and highlight drug properties that 
require optimisation
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7.5 CONSIDERATION FOR ADME IN RISK ASSESSMENT
Previous evidence has suggested that species differences in phase II metabolism is 
the reason for species differences observed in the hepatotoxicity of FS (Williams et 
ah, 2007). The reactive metabolite of FS covalently binds to murine hepatic protein; 
this does not occur in rats, instead the CRM is excreted in the form of a GSH 
conjugate, suggesting a possible safety mechanism exists in the rat to protect from 
FS-induced hepatotoxicity (Williams et ai, 2007). As well as the species differences 
in the balance of bio activation and detoxification, the toxicokinetic studies conducted 
here also highlighted differences in the concentrations of FS in the liver. The liver 
exposure in the mouse was twice that in the rat, with free liver AUC values at 243 
and 128 pg.h/ml respectively. It has previously been reported that with inhibition of 
biliary excretion of FS following a large dose of FS or pretreatment with 
sulfobromophthlein increases levels of covalent binding and development of liver 
necrosis in the mouse (Spitznagle et al., 1977). It was concluded that development of 
FS-induced hepatotoxicity in the mouse is a function of the chemistry of FS and 
species characteristics in terms of detoxification and excretion, which give rise to 
higher levels of reactive metabolite in the liver.
7.6 CONCLUDING SUMMARY
In terms of predictivity of current methods to detect CRM and/or potential hazard of 
drugs to humans, there is a disconnect between in vitro, pre-clinical and human 
systems; a greater understanding of the relevance of surrogate models to the clinical 
situation is crucial if any real extrapolations are to be made. The work conducted in 
Chapter 2 and previous studies demonstrates this point, as outcomes (GSH depletion, 
covalent binding and toxicity) vary in the different systems (rodent hepatocytes, pre- 
clinical animal models and humans). Research and development of models that more 
accurately represent the human physiological situation is much needed. As well as a 
drugs propensity to form a CRM, other factors, such as dose, ROA, etc, must also be 
taken into consideration when determining the overall human hazard (Figure 7.2). In 
Chapter 3 it was shown that dose and ROA were crucial in determining whether 
hepatotoxicity was observed; this resonates with the wider context of drug 
development. One also has to evaluate the detoxicification of drug CRM; in Chapter
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4 it was shown that, unlike FS, TP A forms several GSH adducts in rodent 
heptocytes; identification of GSH adducts in this setting suggests a successful 
detoxification system for CRMs of TPA highlighting the fact that identification of 
thioether conjugate should not be automatically assumed to be a hazard signal.
It is accepted that the probability that a drug will cause an ADR is a function of the 
chemistry of the drug and also a function of the biology of the individual The 
chemistry of FS was a major determinant in the development of hepatotoxicity; the 
TPA compound had a one-atom difference from FS yet failed to induce 
hepatotoxicity at all Although both compounds had the potential to undergo 
bioactivation to a reactive metabolite, the reactive metabolite of TPA was inferred to 
be a better substrate for GSH conjugation and therefore detoxification. The biology 
of the animals was shown to be an important factor, this was reflected in the species 
differences observed in then ability to detoxify the FS reactive metabolites and also 
in their ability to eliminate FS from the system. In the mouse, FS concentrations in 
the liver were twice that in the rat. The investigation conducted in this thesis 
regarding FS and TPA revealed that development of FS-induced hepatotoxicity in the 
mouse was a function of dose and ROA which was reflected in plasma and liver 
concentrations. The identification of drug metabolite-GSH adducts in a preclinical 
setting is often treated as a hazard signal (Gan et al, 2009, Reese et al, 2010), 
however, in the case presented here, it is clear that a GSH adduct is an indication of 
an effective detoxification system.
NVP has been shown to be bioactivated in vitro and in vivo, however, the biological 
implications of the products of bioactivation remain unknown. Despite evidence to 
suggest that the 12-OH NVP metabolic pathway gives rise to the reactive metabolite 
that causes skin rash in female Brown Norway rats, data in the same study point at 
parent compound plasma concentrations as a determinant of skin rash formation 
(Chen et al, 2008). The immunological studies into NVP-induced hypersensitivity 
have also negated the 12-OH NVP metabolite as being responsible for toxicity (Chen 
et al, 2009, Drummond et al, 2006). Based on current hypotheses on the 
mechanisms of ding-induced hypersensitivity reactions, the reactive metabolite or 
parent compound could still be the responsible species (Uetrecht, 2008). The work 
described here presents more evidence that 12-OH NVP is a substrate for 
bioactivation, and, although NVP mercapturates were detected in the urine of
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animals presenting rash, no mechanistic understanding could be drawn from the 
findings. Further investigations utilising enzyme inhibitors in the female Brown 
Norway rat model of NVP-induced skin rash would give more definitive answers to 
whether toxicity is induced by NVP itself or a reactive metabolite and whether 
pursuing NVP mercapturates as markers of exposure to bioactivation products is a 
valid endeavour.
The investigations using FS, TP A and NVP have highlighted a significant disconnect 
between in vitro, pre-clinical and human systems that make the extrapolation of data 
to the clinic difficult. A better understanding of current systems for detecting 
potential human hazard and development of improved animal models and surrogate 
end-points that more closely resemble the human physiological situation would 
improve the predictability of these systems. In a clinical setting, development of 
biomarker panels that can monitor hazard posed by a drug would improve safety and 
also be used to reduce attrition in clinical studies. Development of an assessment 
framework that encompasses all aspects of drug disposition and metabolism, and 
their relationship with bioactivation and toxicity, would be a valuable tool in drug 
development. Outcomes of changes or interventions to a new therapy could then be 
measured quantitatively and mechanisms defined.
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FS TPA NVP NVP
in
vivo
Toxic Liver Liver Skin Liver
Mouse S X X X
Rat X X ✓ X
Human X - V (idiosyncratic) V (idiosyncratic)
Covalent binding
Mouse ✓ X - X
Rat X X X
Thioether conjugate
Mouse X - - -
Rat ✓ ✓
Human - - s ✓
in
vitro
Toxic
Mouse - -
Rat - X
Human - - - -
Covalent binding
Mouse s S - -
Rat S - Y
Human S - - X
Thioether conjugate
Mouse S ✓ “ -
Rat s ✓
Human - - s ✓
Table 7.1: Summary of propensity of FS, TPA and NVP to cause toxicity, and 
systems in which evidence of bioactivation has been shown. Information has been 
compiled from data presented in this thesis, in Butler, 2006, PhD thesis, University 
of Liverpool and literature referenced throughout. * Covalent binding was observed 
in rat microsomes but not in rat hepatocytes.
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